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1.1 Anatomy of the human eye 
Visual pathway
The reflectance of light on objects makes those objects visible to the human eye. Reflected 
light waves enter the eye through the cornea, followed by the anterior chamber, lens and 
the vitreous to be finally focussed on and absorbed by the photosensitive cells of the retina: 
the photoreceptors (Figure 1). From here a cascade of processes - the phototransduction 
cascade - is initiated, finally resulting in an electrical signal. This electrical signal is conducted 
by the optic nerve via the optic chiasm and further converted to an image in the visual 
cortex. 
Figure 1. 
Anatomy of the human eye (http://www.eyesightresearch.org/background.htm)
Retina
During embryonic development, the eyes can be first recognized as optic vesicles as early as 
the 25th post-ovulary day.1, 2 During further development the retina arises from the region of 
the neural tube.1 The retina covers the inner lining of the eye, and is histologically composed 
of ten different cell layers (Figure 2).3 
The inner seven layers of the retina are referred to as neuroretina. These transparent layers 
are linked to each other by synaptic connections between axons and dendrites, and to the 
ganglion cells that are also part of the neuroretina.4 Until recently, two different kinds of 
photoreceptors were differentiated in the neuroretina: cones and rods. More recent, the 
ganglion cells have been identified as a third photosensitive cell in the retina.3 The 100 
million rods, that account for 95% of all photoreceptors, are responsible for vision at lower 
light intensities, and for sensing contrast. Rods are approximately 500 times more sensitive 
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1to light than cones. The cones are responsible for detailed vision and colour perception at 
bright light conditions. Three classes of cones exist: red, green and blue. These are maximally 
sensitive to 561, 530 and 430 nm light respectively. In contrast to the rods, which are more 
densely found in the peripheral retina, the 5 million cones are mostly concentrated in the 
macula. The macula provides the central vision with the highest visual acuity and colour 
vision as a result of the highest cone density in the centre of the macula, 
the fovea.5
    
Figure 2. 
Simplified schematic overview of the retinal and choroidal anatomy
The monolayer of retinal pigment epithelium (RPE) cells is the outermost part of the retina, 
located beneath the neuroretina. The RPE contains melanin granules that reduce the light 
scattering and block light absorption via the sclera, resulting in a better image received by 
the retina.1 Tight junctions, complex structures that are dynamically regulated,6 between 
adjacent RPE cells form the outer blood-retinal barrier.1, 6 The RPE actively regulates the 
movement of solutes between the underlying  permeable choriocapillaris and the overlying 
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photoreceptors.6 In addition, the RPE is involved in many other physiological processes, such 
as the phagocytosis of shed photoreceptor outer segments, the retinol metabolism (also 
known as the visual cycle), coordination of the immune response, and the maintenance of 
the extracellular matrix.1, 7 Especially the phagocytosis and processing of the outer segment 
discs of the photoreceptors, that are subject to constant renewal and replacement, requires 
a high energy supply. To provide this energy, the avascular outer retina is dependent on the 
support provided by the adjacent choroid.8
Choroid
At birth the choroid is approximately 329 ± 66 µm thick,9 but the mean choroidal thickness 
decreases gradually to about 80 µm by age 90.10 In addition, a correlation between the 
thickness of the choroid and the refractive error of eyes exists. Change in choroidal thickness 
can move the retina towards the plane of focus, therefore, it is thought that the choroid 
may play a role in the modulation of ocular elongation in response to defocus. In myopic 
individuals a thinner choroid, and in hyperopic individuals a thicker choroid is seen as 
compared to emmetropic individuals.11 The choroid consists of blood vessels, melanocytes, 
fibroblasts, resident immune competent cells and supporting tissue. With the highest rate 
of blood flow of all body tissues, the primary function of the choroid is to supply oxygen and 
nutrition to the outer retina and to eliminate waste products. In addition, the choroid has at 
least 2 other functions: thermoregulation, and secretion of growth factors.11 
The choroid runs from the borders of the optic nerve up to the pars plana, where it becomes 
the ciliary body. 11
Histologically, five different choroidal layers can be distinguished. Starting with innermost 
structure, underlying the RPE, is the Bruch’s membrane, followed by the choriocapillaris, 
two vascular layers, and the suprachoroid (Figure 2).11
The Bruch’s membrane is a thin (2 µm) layer that thickens slightly with age. This thin membrane 
is a pentalaminar structure consisting of the basement membrane of the RPE, an inner 
collagenous zone, an elastic layer, an outer collagenous zone, and the basement membrane 
of the choriocapillaris. Bruch’s membrane is involved in the exchange of biomolecules, 
oxygen, nutrients and waste products between the RPE and choriocapillaris.12 The age-
related thickening of Bruch’s membrane and built-up of material in the inner collagenous 
layer can result in a decreased permeability. In addition, changes in the integrity of Bruch’s 
membrane have been found in individuals with age-related macular degeneration (AMD) as 
compared to controls.13Underlying Bruch’s membrane is the highly anastomosed network 
of capillaries of the choriocapillaris, forming a thin vascular sheet. The choriocapillary 
thickness is about 7 µm in the periphery and increases up to 10 µm at the foveal region, 
which harbours the greatest density of capillaries. The fenestrated capillaries are relatively 
General introduction
15
Ch
ap
te
r 
1large in diameter (20-40 µm).
14 Unlike the other choroidal vasculature, the choriocapillaris is 
fenestrated and therefore permeable.
Two additional vascular layers of the choroid are the inner layer (Sattler’s layer) with medium 
and small arteries as well as arterioles that feed the capillary network, and an outer layer of 
larger blood vessels (Haller’s layer).11
The fifth and outermost layer of the choroid, the suprachoroid, forms the transitional zone 
between choroid and sclera. The suprachoroid contains collagen fibers, fibroblasts and 
melanocytes.
Similar to the retina, the composition of the choroid shows variability from the centre of 
the posterior pole towards the periphery. The maximal choroidal thickness is reached in 
the macula, and the choroid thins gradually towards the periphery. Simultaneously, the 
composition of the choriocapillary vasculature changes from a lobular pattern in the macular 
area, to a more ladder-like appearance in the periphery. This change in structure may also 
explain the difference in choroidal blood flow, being the highest beneath the macula, as the 
lobular structure provides a more efficient flow. 
Blood-retinal barrier and subretinal space
During embryonic development, the central neuro-ectoderm of the optic vesicle invaginates 
to finally form the sensory retina (Figure 3). Due to this invagination the neuroretina and 
the RPE become apposed, being separated by a potential subretinal space which can fill 
with fluid resulting in a detachment of the neuroretina.15 The RPE is among the most 
metabolically active tissues in the human body, and plays an important role in controlling 
the chemical environment of this subretinal space.6 
Similar to the blood-brain barrier, the retina is protected by a blood-retinal barrier with 
an inner and outer component. Both barriers consist of tight junctions, the inner barrier 
within the retinal blood vessels and the outer barrier being formed by the RPE layer. The 
blood-retinal barrier enables the highly selective diffusion of molecules and is essential 
for maintaining retinal homeostasis. Conditions of the surrounding tissue can influence 
autoregulation by local factors. For example, local autoregulation can be altered by changes 
in hydrostatic pressure, osmotic force, and capillary permeability, and in response to 
metabolic fluctuations. Interestingly, the choroidal circulation is strongly controlled by central 
sympathetic innervation, with little or no autoregulation, whereas the retinal circulation lacks 
sympathetic innervations and is dependent on autoregulation.8 In addition to forming the 
outer blood-retinal barrier the RPE provides active transport mechanisms, which maintain 
the finely balanced extracellular environment of the outer retina. Furthermore, the RPE 
possesses a pump function that actively dehydrates the subretinal space, thus maintaining 
the normal apposition of the neuroretina to the RPE. There is no firm attachment between 
the RPE and the photoreceptors. Therefore, the active pump function of the RPE is essential 
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to maintain this attachment. The retinal adhesive force across this subretinal space is 
energy-dependent and decreases within minutes in case of ischemia.8, 16
Figure 3. 
Embryological development of the eye. Illustration of the invagination in the optic cup and stalk resulting in the 
formation of the subretinal space between the neurosensory retina and retinal pigment epithelium (RPE).  
(http://www.oculist.net/downaton502/prof/ebook/duanes/pages/v7/v7c002.html#len)
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11.2 Retinal imaging  
Fluorescein angiography (FA) uses sodium fluorescein dye which can be given either 
intravenously or orally. The dye is transported by the bloodstream and consequently fills all 
vessels, including those of the retina. Light waves with a stimulating wavelength for sodium 
fluorescein (490 nm) are used to visualize the dye. In healthy eyes, the sodium fluorescein 
dye that diffuses from the large fenestrated choriocapillaris cannot pass the outer blood-
retinal barrier which is formed by tight junctions between RPE cells, and also remains inside 
the retinal blood vessels which form an inner blood-retinal barrier (Figure 4A).2 
Indocyanine green angiography (ICGA) is another dye-enhanced imaging technique, using 
relatively large ICG molecules of which 95% bind to blood albumin after intravenous 
injection. The ICG molecule normally does not pass the outer blood-retinal barrier due to 
its large molecular size and due to its lipophilic and hydrophilic properties it easily binds 
to proteins. It was thought that this protein-binding capacity limits the travel of ICG within 
the choroid vessel wall. However, it has been demonstrated that ICG diffuses through the 
choroidal stroma during angiography and accumulates within the RPE.1 In contrast to FA, 
ICGA uses a wavelength of 790-805 nm that penetrates the RPE,1 enabling imaging of the 
deeper choroidal vasculature (Figure 4B). 
Fundus autofluorescence (FAF) imaging provides non-invasive images by capturing the 
emission of light from endogenous fluorophores, after stimulation with 488 nm wavelength 
light.17 The phagocytosis and processing of outer photoreceptor segments through 
lysosome-derived organelles by the RPE results in degradation products. These products, 
that are stored and referred to as lipofuscin granules, are composed partially of bisretinoids, 
which have broad fluorescence absorption and emission spectra that can be detected by 
FAF. Lipofuscin accumulation is associated with increasing age, but is also found in various 
patterns in both acquired and inherited degenerative disease of the retina (Figure 4C).18, 19 
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Figure 4. 
Examples of fluorescein angiography (A), indocyanine green angiography (B) and fundus autofluorescence (C) 
images of the retina of the right eye in a healthy individual. 
Optical coherence tomography (OCT) is a non-invasive imaging technique that can provide 
high-resolution, cross-sectional images of the retina, retinal nerve fibre layer and the optic 
nerve head using low-coherence reflectrometry.20 In low-coherence reflectometry, the 
coherence property of light reflected from a sample provides information on the time-to-
flight delay from the reflective boundaries and backscattering internal microstructures in 
the eye.21 Multiple longitudinal scans are made, and the information gathered is used to 
create a two- or three-dimensional image (Figure 5).
Enhanced-depth imaging (EDI) and swept-source OCT imaging enable a better visualisation 
of the choroid. In EDI imaging the objective lens of the OCT-device is positioned closer to the 
eye, thereby approximating the choroid to the zero-delay line (the area where the resolution 
of the OCT is known to be sharpest). Consequently, more detailed images of the choroid can 
be obtained. The second method uses a higher scanning speed based on the swept-source 
technology. In addition, a longer wavelength is introduced that aids in preventing scattering 
by the RPE, resulting in a deeper penetration into the choroid (Figure 5).22-24
General introduction
19
Ch
ap
te
r 
1
Figure 5. 
Enhanced-depth optical coherence tomography of a right eye of a healthy individual illustrating the different layers 
of the retina and choroid.  
ELM: External limiting membrane, GCL: Ganglion cell layer, ILM: Internal limiting membrane, INL: Internal nuclear 
layer, IPL: Inner plexiform layer, NFL: Nerve fibre layer, ONL: Outer nuclear layer, OPL: Outer plexiform layer, , RPE: 
Retinal pigment epithelium.
Optical coherence tomography angiography (OCTA) is a novel non-invasive technique 
that uses motion contrast to visualize capillary blood flow, but without determination of 
the flow direction.25 Stationary tissue produces a nearly constant reflection or scattering 
whereas moving tissue produces OCT signals that change over time.26 OCTA is based on the 
oversimplified assumption that the only movement in the retina is the blood flow. Repeated 
scanning of the same region of tissue enables a comparison of OCT-pixels between different 
time points. Those pixels that show changes are displayed brightly, whereas pixels from 
areas with little or no change are displayed as black. For detection of motion contrast 
many different algorithms and/or methods exist. In addition, there are different statistical 
methods to assess changes. Essentially, all of these techniques use the detection of motion 
to visualize the retinal vasculature.26 As a result, OCTA is able to visualize the inner vascular 
plexus, the deep retinal vascular plexus, and the choriocapillaris separately (Figure 6).
Chapter 1
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Figure 6. 
Optical coherence tomography (OCT) angiography of a right eye of a healthy subject (25-year-old female). (A) The 
inner (“superficial”) vascular plexus. (B) The deep retinal vascular plexus. (C) The choriocapillaris. (D) Full-thickness 
OCT angiogram, a superposition of all previous layers. 
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11.3 Central serous chorioretinopathy 
Central serous chorioretinopathy (CSC) was first described in 1866 by the German 
ophthalmologist Von Graefe.27 Due to the diagnostic limitations, only limited phenotypical 
features of the disease could be noted and documented at that time. Therefore, Von Graefe 
was convinced of CSC being a retinal disturbance and described the pathology as ‘relapsing 
central luetic retinitis’.27 Other names for CSC in the earlier 20th century have included terms 
such as ‘capillarospastic central retinitis’ and ‘central angiospastic retinopathy’, illustrating 
the belief that vasospasm was underlying the pathophysiological mechanism.28 It took 
over 100 years after Von Graefe’s first description before Maumenee described FA findings 
in CSC, and discovered that the detachment of the macula resulted from leakage at the 
level of the RPE.29 The nomenclature at that time had already changed to ‘central serous 
retinopathy’. Gass introduced the term ‘idiopathic central serous choroidopathy’, which 
over time has been adjusted to ‘central serous chorioretinopathy’ based on the observation 
that underlying choroidal hyperpermeability is an important feature of CSC that ultimately 
affects the integrity of the RPE outer blood-retinal barrier, eventually causing a serous 
neuroretinal detachment.30, 31 This forms the basis of the current ideas concerning the 
etiology and definition of CSC.32 
CSC is an eye disease that generally only becomes symptomatic when it affects the central 
part of the retina. It is thought that especially the central part of the eye is more vulnerable 
to the disease, due to the different lobular structure and accompanying higher flow rate 
of the underlying choroid as compared to the peripheral area.33 With an estimated annual 
incidence of at least 9.9 cases per 100.000 men and 1.7 per 100.000 women,34 CSC is 
considered the fourth most common macular disease.35 Men are more frequently affected 
than women, with reported male-to-female ratios up to approximately 8:1,31 and the age at 
onset can range from 30 to 80 years.36 
Various risk factors have been described in CSC, of which the use of corticosteroids is 
the most prominent, with described odds ratios of up to 37 (Table 1).37 All forms of 
corticosteroid treatment have been described in association with CSC, ranging from systemic 
administration,38 nasal spray,37 eye drops,39 skin cream,40 inhalers,41 or illegal corticosteroid 
injection for professional body building.37, 40 In addition to exogenous corticosteroids, 
elevated levels of endogenous corticosteroids, as in patients with Cushing’s disease,42-44 
have also been described as risk factors for CSC.45 
Other potential risk factors that have been reported are cardiovascular disease and 
hypertension, type A personality,46 pregnancy,47, 48 stress,49 the use of sildenafil,50 and 
infection with Helicobacter pylori.51 
Furthermore, a hereditary predisposition may exist for CSC. Familial occurrence has been 
described, and racial differences in prevalence have been reported.52, 53 Relatively high rates 
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of CSC are seen in the Caucasian and Hispanic population, and even higher rates have been 
reported in the Asian population, whereas the incidence appears to be lower in African 
Americans. Recent studies have shown significant differences in the genetic profile of 
patients with chronic CSC as compared to healthy controls.54, 55
Table 1. Overview of reported risk factors for central serous chorioretinopathy 
Genetic predisposition Familial occurrence52, 53
Complement factor H gene54, 56
Cadherin 5 gene55 
Asian and Greek population
Significant in males
Cardiovascular disease Hypertension57 
Coronary hearts disease (CHD)58
Ischemic stroke59
Organic and psychogenic erectile 
dysfunction60
OR: 2.25
HR: 1.72
HR: 1.56; 95% CI, 1.11-2.18
HR: 2.14; 95% CI, 1.34-3.44
Corticosteroids Systemic37, 44, 57
Ocular61
Topical dermal62, 63
Intranasal64, 65
Intra-articular66, 67
Endocrine changes Pregnancy37
Cushing’s disease68, 69
OR: 7.1; 95% CI, 1.0-50.7
Psychopathology Type A personality70
Stress57 OR: 2.6; 95% CI, 1.33-9.23
Gastro-esophageal 
disorders
Gastro-esophageal reflux71
Peptic ulcer58
Helicobacter pylori infection72
OR: 6.05; 95% CI, 2.14-17.11
OR: 1.39; 95%CI, 1.14-1.70 
(Taiwan)
Elevated incidence in CSC
Drug-induced Adrenergic receptor antagonists73, 74
Phosphodiesterase-5 inhibitors50, 75
Sleep disturbances Obstructive sleep apnea76 Elevated incidence in CSC
CI: Confidence interval, HR: Hazord ratio, OR: Odds ratio
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1Acute versus chronic central serous chorioretinopathy
Two main subtypes of CSC can be distinguished: acute CSC and chronic CSC. A strict 
delineation between these subtypes can be difficult. In general, two main definitions have 
been proposed to differentiate acute CSC from chronic CSC. 
The first definition is purely based on the period of time during which subretinal fluid (SRF) 
is present. If the SRF resolves spontaneously within a few (generally 2-4) months,77 one can 
speak of acute CSC. In case the SRF is still present after 2-4 months (some authors propose 
6 months) the nomenclature used arbitrarily changes to chronic CSC.35, 78, 79 
However, this thesis adheres to literature that differentiates acute and chronic CSC not 
only based on the duration of the disease, but chiefly based on distinctive phenotypical 
characteristics that indicate chronicity. These phenotypical characteristics, which are 
discussed below, can be identified with multimodal imaging techniques.
Acute CSC
Patients suffering from acute CSC most commonly present with a sudden onset of central 
vision loss.80 Symptoms are usually confined to the central visual field, with or without a 
decline in best-corrected visual acuity. As a result of leakage of SRF in CSC, complaints such 
as metamorphopsia,81 micropsia and hypermetropisation may occur. In addition, patients 
can experience a relative scotoma, dyschromatopsia,82 and reduced contrast sensitivity. 35 
The male predisposition appears to be more prominent in acute CSC, and the age at onset 
usually ranges from 25-60 years.36 
 In acute CSC it is believed that a sudden focal disruption of the RPE leads to high-flow 
leakage beneath the overlying neurosensory retina. This focal leakage can be confirmed by 
FA imaging, which in some cases shows the typical sign of acute CSC, the smoke-stack leakage 
phenomenon (Figure 7I-J).35 ICGA reveals focal or sometimes more extensive alterations of the 
choroidal vasculature throughout the different angiographic phases (Figure 7F). During the 
early phase of ICGA, a delay in the filling of the choriocapillaris located at the sites of leakage, 
results in hypofluorescent areas.83, 84 Midphase ICGA shows dilation of the large choroidal 
vessels, and choroidal vascular hyperpermeability as evidenced by typical hyperfluorescent 
areas with blurred contours (Figure 7D).85-87 Punctate hyperfluorescent spots can also be seen 
in mid- and late-phase ICGA, in the macular area, outside the vascular arcade, or around the 
optic disc. These punctate spots seem to be located in the inner choroid, and often appear as 
clusters of small distinct spots. These hyperfluorescent spots on ICGA are present in 95% of 
eyes affected with CSC and 78% in unaffected fellow eyes.88 Late-phase ICGA is characterized 
by either persistence of hyperfluorescence, as seen in the midphase, wash-out of ICG dye, 
or centrifugal displacement of hyperfluorescence, forming hyperfluorescent rings.36, 88 
OCT in acute CSC shows the SRF accumulation in the macula, causing a neuroretinal 
detachment. OCT can also visualize RPE abnormalities such as associated RPE detachments.89-91 
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An overlap may exist between the location of the RPE detachment and the areas of dilated, 
large choroidal vessels and thickened choroid on OCT, and with hyperfluorescent area(s) of 
vascular hyperpermeability on ICGA.91, 92
In inactive disease, after the SRF is completely reabsorbed, the retinal anatomy often 
remains slightly abnormal. These abnormalities can range from very mild RPE changes or 
photoreceptor irregularities, to retinal atrophy. After resolution of SRF, with or without 
treatment, many patients with acute CSC show a gradual restoration of outer retinal 
structures on OCT, mostly on the outer photoreceptor level such as the external limiting 
membrane, ellipsoid, and the RPE. CSC patients typically have a thicker choroid as compared 
to healthy controls.91, 93-95 Such a thickened choroid is not only seen in eyes with active SRF 
leakage, but also in fellow eyes without SRF leakage.96, 97 In addition, an abnormally thin 
choriocapillary layer can be found in CSC patients on EDI-OCT.91
 Patients with acute CSC can show a spectrum of FAF abnormalities (Figure 7B). 
Typical early FAF findings in acute CSC consist of diffuse hypo-autofluorescent areas that 
often correspond with the leakage points as seen on FA, and hypo-autofluorescence 
corresponding to the areas of SRF accumulation possibly by blockage of RPE autofluorescence 
by the overlying SRF.98 After resolution of the episode of acute CSC, hypofluorescence with 
significant granular appearance corresponding to the areas of former retinal detachment 
can be observed. 98 
Chronic CSC
In contrast to acute CSC, chronic CSC patients often present at an older age, with a disease 
onset that is generally experienced as less sudden.99 Bilateral disease is more common in 
chronic CSC as compared to acute CSC.99 A history of acute CSC and/or an episode of acute 
vision loss compatible with acute CSC is present in only approximately 16% of chronic CSC 
patients.35, 77, 99 This indicates that there may be a pathogenetic distinction between acute and 
chronic CSC, although they may be similar disease expressions within a spectrum of CSC. 
 Abnormalities on FA and ICGA resemble those of acute CSC but are often more 
extensive in chronic CSC. In addition, more diffuse and sometimes multifocal leakage can 
be seen on FA and ICGA,  with irregularly distributed and more or less widespread RPE 
changes associated with varying degrees of low-grade leakage (Figure 7K-L). 28, 35, 77-79, 99-
103  In longstanding chronic CSC, a ‘gravitational tract’ can be seen on fundoscopy, fundus 
autofluorescence, and  fluorescein angiography (Figure 7M). This area of RPE atrophy 
from the macula is condidered to be the result of prolonged subretinal fluid accumulation 
extending inferiorly as a result of gravity.99 Abnormalities on ICGA in chronic CSC consist 
of more widespread, hyperfluorescent areas of hyperpermeability of the choroidal 
vasculature and congestion as compared to acute CSC (Figure 7D & 7L).35, 79, 83, 86, 88, 104 Besides 
choroidal leakage, choroidal venous dilation can also be seen. In active disease punctate 
hyperfluorescent spots, that appear to arise from the inner choroid/choriocapillaris, 
have been detected during mid- and late phase ICGA. These hyperfluorescent spots are 
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1associated with increased choroidal thickness and may be a manifestation of the increased 
choroidal hyperpermeability and intrachoroidal hydrostatic pressure36, 88 105 Interestingly, 
additional focal and diffuse areas of ICG hyperfluorescence are often found in areas that 
appear unaffected on FA.79, 104 The observation that choroidal changes on ICGA and EDI-OCT 
are often more extensive than retinal changes on FA and OCT may indicate that the primary 
inciting abnormality in CSC is situated in the choroid, which is discussed further in the next 
section (1.4 Pathogenesis).
 The SRF on OCT in chronic CSC is often more shallow as compared to acute CSC. 
In contrast to acute CSC the SRF tends to persist in chronic CSC, although it can wax and 
wane multiple times.28, 102, 103 Outer retinal changes are seen in longstanding neuroretinal 
detachments, and are thought to be abnormal outer segments of the photoreceptor layer. 
Due to the lack of apposition between the photoreceptors and the RPE, the photoreceptor 
outer segments cannot be properly phagocytosed. It is thought that these accumulating 
outer segments, which eventually contain precursors of the toxic hyperautofluorescent 
fluorophore N-retinylidene-N-retinylethanolamine, can gravitate downwards within the 
pocket of SRF accumulation.89, 106  These autofluorescent waste products in the subretinal 
space and RPE can be clearly seen on FAF (Figure 7J & 7M), also after resolution of the SRF. 
RPE detachments are invariably present in chronic CSC.36 In addition to more extensive RPE 
and outer photoreceptor abnormalities, variable degrees of photoreceptor and RPE atrophy 
can be present in longstanding chronic CSC. Also, intraretinal edema known as ‘posterior 
cystoid degeneration’ can been seen on OCT in longstanding chronic CSC, which can be 
difficult to distinguish from beginning choroidal neovascularisation (Figure 7P).107, 108
FAF in chronic CSC shows variably-shaped areas of speckled hyperautofluorescent and hypo-
autofluorescent spots (Figure 7J). These granules correspond to hyper-reflectivity at the 
outer photoreceptor layer and the RPE as confirmed on OCT.18, 98 A ‘descending tract’ is also 
frequently seen on FAF as a result of atrophic RPE changes due to prolonged SRF leakage 
that gravitates downward (Figure 7M).109 In addition, RPE atrophy can be seen characterised 
by a decreased autofluoresence.109-111 Generally, it is thought that the autofluorescence 
mainly arises from the lipofuscin in the RPE.18, 112 However, in CSC the hyperautofluorescent 
dots within the SRF pocket in active CSC may at least partly correspond to macrophages 
engorged with phagocytosed outer segments.18 This would be in accordance with the 
findings as seen on OCT.
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Figure 7. 
(A-P) An overview of clinical characteristics that can be seen in acute (A-H) and chronic (I-P) central serous 
chorioretinopathy (CSC). (A-D) The right eye of a 46-year old man with acute CSC. (A) Color fundus photograph 
(CFF) showing a well-demarcated round subretinal fluid (SRF) collection in the macula. (B) Fundus autofluorescence 
(FAF) with hyperfluorescent spots along the superior vascular arcade, and very mild hypofluoresence at the side 
of the SRF pocket (white arrow). (C) Fluorescein angiography (FA) with a single hyperfluorescent ‘hot spot’ of 
leakage at the level of the retinal pigment epithelium (RPE). (D) Indocyanine green angiography (ICGA) showing 
a larger hyperfluorescent spot as compared to FA. Also, central blockage of background fluorescence below the 
SRF pocket is seen. (E-F) An example of an early FA image with a single hot spot (E) that develops to a classical 
‘smoke stack’ appearance (F) in the later phase of FA. (G) Dome-shaped SRF accumulation on optical coherence 
tomography (OCT) during the active phase of an acute CSC patient. (H) Complete spontaneous resolution of SRF 
on OCT in the same patient. (I-L) The right eye of a 63-year old man with chronic CSC. (I) CFF with several areas of 
depigmentation of the retina, and a hyperpigmentation temporal superior of the fovea. (J) FAF showing a pattern 
of mottled hyper- and hypopigmentation. (K) Multiple hyperfluorescent ‘hot spots’ as well as diffuse leakage on FA, 
corresponding to diffuse hyperfluorescence and partial hypofluorescence on ICGA (L). A classic gravitational tract 
with hyper- and hypoflurescence on FAF (M). An example of ICGA (N) showing small punctiform hyperfluorescent 
areas in addition to diffuse hyperfluorescence. (O) OCT shows a shallow SRF accumulation and typical RPE 
detachments that can be seen in most chronic CSC cases. (P) OCT shows not only serous SRF, but also central 
posterior cystoid degeneration, indicative of long-standing disease.
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11.4 Pathogenesis of central serous chorioretinopathy 
The precise pathophysiological mechanisms of CSC are still largely unclear. Based on studies 
investigating the clinical characteristics in CSC with multimodal imaging, several theories 
have been proposed the past decades. Most of these theories are closely related and show 
an overlap that includes the choroid and the RPE as primarily abnormal structures, with a 
possible role for hormonal receptors and pathways.28 
Before the idea of choroidal involvement was introduced, the RPE was considered to be 
the primarily abnormal structure in CSC. The lesions that are seen on FA correspond to 
a disruption on the level of the RPE. The monolayer of RPE has an active pump function 
that regulates the transport of fluid and solutes from the retina to the choriocapillaris. It is 
thought that an impairment in the pump function of the RPE could result in a reverse fluid 
movement, causing an accumulation of SRF. 
Gass suggested that a focal increase in the permeability of the choriocapillaris is a pivotal 
and possibly primary event in the pathogenesis of CSC.30, 101 This hypothesis is supported by 
findings on OCT and ICGA. Multimodal imaging has not only shown a thickened choroid on 
EDI-OCT, but also extensive abnormalities of the choroid on ICGA clearly indicating choroidal 
involvement.83, 87 It is postulated that alterations in the choroidal circulation may result in 
ischemia.101, 113
Hyperpermeable choroidal vessels are thought to cause an increased hydrostatic pressure.28, 
36 This increase in choroidal hydrostatic pressure induces stress to the overlying RPE cells, 
which promotes the development of RPE detachments.28 Smaller or larger RPE detachments 
are seen in at least 45% of the patients with active CSC.35 When the RPE outer blood-retinal 
barrier is damaged and a small rupture in the RPE develops, the hydrostatic pressure from 
the choroid results in the typical leakage into the subretinal space.
Interestingly, studies have shown that choroidal abnormalities are not only found in the 
affected eyes, but are also often seen in the fellow eyes that seem unaffected by SRF 
leakage.96, 97 Furthermore, the clinical observation that the size of the leakage area and 
extent of hyperfluorescent abnormalities are often more pronounced on ICGA as compared 
to FA imaging, suggests an important and primary role for the choroid in CSC. Not only 
an increase in choroidal hyperpermeability may be found, but alterations in the choroidal 
circulation may also cause choroidal ischaemia.28, 101 
Therefore a combination of the choroidal and RPE dysfunction causing active SRF leakage 
in CSC may actually be the most plausible explanation, in which the increased hydrostatic 
pressure from the choroid overwhelms the RPE and results in a SRF accumulation through a 
dysfunctional outer blood-retinal barrier. It is possible that the RPE in these patients is more 
vulnerable and more easily damaged by the underlying choroidal abnormalities, resulting in 
further dysfunction. 
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Similar to the choroidal abnormalities, abnormalities of the RPE are not only seen in the 
symptomatic CSC eyes, but also in the fellow eyes.114 It is therefore possible that such 
changes of the RPE are rather early/subclinical signs of eyes at risk of active CSC than late 
sequelae of previous CSC. However, the question remains why changes appear to occur 
primarily in the choroid. A possible explanation may lie within the regulatory mechanisms 
of the choroid. Tittl et al. found that CSC patients may have an impaired subfoveal choroidal 
blood flow regulation in response to exercise that induces a considerable stimulation of the 
parasympathetic and sympathetic nervous system.115 This abnormal choroidal blood flow 
regulation may be an important pathogenetic factor, since abnormal sympathetic activity 
of the autonomic nervous system is compatible with the association of CSC and stress.115 
Finally, there are strong indications that there is an important role for hormonal factors in 
CSC pathogenesis. Two of the strongest associations reported thus far in CSC are the use 
of corticosteroids and male gender.37, 49 Interestingly, both risk factors exert physiological 
effects at the level of the hypothalamic-pituitary-adrenal axis (HPA-axis). The interconnected 
nature of the HPA-axis and the autonomic nervous system suggests a number of possible 
explanations involving influences on the choroid, Bruch’s membrane, and the RPE.28 Various 
relatively small studies have studied cortisol levels in chronic CSC patients. Although 24h 
urine samples showed elevated cortisol levels in chronic CSC patients in certain studies,116, 
117 these results were not observed in single serum measurements during set times in 
other studies.118, 119 These discrepancies could be explained by variable cortisol fluctuations 
between individuals during the day, and therefore changes in endogenous cortisol level 
cannot be ruled out as an important factor in chronic CSC. It is also possible that patients with 
chronic CSC generally have normal cortisol levels, but respond differently to stimulation of 
the HPA-axis. Stress, which also appears to be associated with chronic CSC,120, 121 stimulates 
the HPA-axis and could lead to temporarily elevated cortisol levels in patients as compared 
to healthy individuals. It is currently unclear how high levels of cortisol or corticosteroids can 
be linked to SRF accumulation. A study in rats suggested that the disease mechanism could 
be mediated by binding of corticosteroids to the mineralocorticoid receptor located in the 
choroidal vasculature.122 In that study, activation of the mineralocorticoid receptor caused 
vascular effects similar to those observed in chronic CSC.122 In addition, relative endogenous 
hypercortisolism can lead to an increased platelet aggregation, and consequently create the 
condition for increased microthrombus formation and increased blood viscosity.33 Caccavale 
et al. combined these events in a pathogenic model in which they postulate that a reduction 
of the vascular bed due to the vasoconstriction and capillary occlusion, combined with 
higher resistance and increased blood viscosity, results in a sectorial hypoperfusion and an 
increase in endoluminal pressure in the surrounding healthy vascular bed.33 Although this 
model is plausible and corresponds with the clinical findings, the exact underlying pathways 
still remain to be elucidated.
General introduction
29
Ch
ap
te
r 
11.5 Treatment options in central serous chorioretinopathy
There is no ‘gold standard’ treatment for acute and/or chronic CSC due to a remarkable 
lack of prospective randomized controlled trials. Therefore, a wide spectrum of treatments 
has been and is still being used. A significant problem in the interpretation of possible 
treatment effects in CSC is the observation that many cases of acute and, to a lesser degree, 
chronic CSC may resolve spontaneously. As a consequence, the observed ‘treatment effect’ 
in retrospective and/or uncontrolled treatment studies may actually be spontaneous 
resolution.
In acute CSC, SRF resolves without treatment within 2-3 months in most cases with minimal 
visual sequelae.36, 101, 123 Therefore, many ophthalmologists adopt a conservative approach 
in acute CSC cases.  However, treatments such as photodynamic therapy (PDT) with reduced 
settings, and other laser treatments such as selective retina therapy and micropulse laser 
treatment have been advocated.124-127 In steroid-associated cases, cessation of the steroids 
can also lead to spontaneous recovery.64
Many ophthalmologists would consider to treat chronic CSC cases in which persistent SRF 
leakage involves the fovea. However, there is considerable controversy on the optimal 
timing and treatment in chronic CSC. In chronic CSC cases in which SRF is present in the 
macula for more than 4 months, irreversible atrophic retinal changes may develop.128 
Therefore, many ophthalmologists would consider to treat chronic CSC within 4 months 
in an attempt to achieve resolution of SRF, and thereby reduce the likelihood of clinically 
significant irreversible damage to the retina due to chronic SRF leakage. A recent Cochrane 
review compared the relative effectiveness of interventions for CSC. The review concludes 
that of the interventions studied to date, PDT or micropulse laser treatment appear the 
most promising to pursue in further studies in chronic CSC.129 Nevertheless, a broad range 
of treatments has been and still is being used in CSC, which is discussed in the following 
section.
Conventional thermal laser treatment
The aim of conventional thermal laser treatment is to coagulate involved parts of the retinal 
tissue to achieve a therapeutic effect. This treatment depends on the selective absorption 
spectrum in specific tissues in the eye. Melanin is highly present in the RPE cells and has a 
high absorption coefficient in the spectral range of the conventional thermal laser.1
In CSC, conventional thermal laser treatment can be used to coagulate the hot spot(s) of 
leakage as seen on FA. The proposed treatment goal is resolution of SRF through the laser-
mediated formation of scar tissue which subsequently ‘plugs’ the RPE leak, restoring the 
RPE barrier and preventing further leakage. The healthy surrounding RPE cells are then able 
to pump the remaining SRF back into the choriocapillaris. However, Negi and Marmor have 
advocated that the SRF in CSC is not caused simply by a passive "leak" through the RPE barrier, 
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and the effects of photocoagulation in this disease cannot be explained simply as sealing 
such a leak.130 They demonstrated that focal RPE damage actually promotes the flow of SRF 
towards the choroid.130 Therefore the exact role of the RPE in CSC remains incompletely 
understood. Conventional laser treatment in CSC appears to have limited efficacy, and has 
several disadvantages. Most of the studies on conventional laser treatment in CSC have 
been carried out many years ago, before the advent of modern imaging techniques such 
as OCT, and these studies often did not clearly distinguish phenotypically between acute 
and chronic CSC. Although some studies suggest that conventional laser treatment reduces 
the duration of SRF accumulation, this treatment appeared to have no significant effect 
on the visual acuity.101, 131-133 The retinal tissue damage may result in a clinically significant 
scotoma when applied too centrally in the macula. Therefore, treatment of the (peri)foveal 
area should be avoided. This excludes thermal laser treatment as an option for patients with 
CSC who have a relatively central focus of SRF leakage. Conventional thermal laser is mainly 
effective in CSC phenotypes in which obvious focal leakage is observed on FA.101 Patients 
with chronic CSC can have multiple and/or large actively leaking areas in which case thermal 
laser treatment is also unwanted due to an increase of the possible side-effects. Side-effects 
that one should consider are the possibility of enlargement of the laser scar (creeping) with 
time and an increased risk of iatrogenic choroidal neovascularisation (CNV).36, 134, 135 Although 
conventional laser treatment has been used in CSC patients for decades, it is generally no 
longer the treatment of choice due to its limited efficacy and possible side-effects.100 
Photodynamic therapy
PDT is a laser technique that uses the light-sensitive substance verteporfin, which is 
intravenously administered and circulated during 10 minutes. The preferential concentration 
of verteporfin in the choroidal tissue is then reached after approximately 15 minutes. 
At this time point, the verteporfin is activated by a spot of laser light of a wavelength of 
689-693nm, which presumably results in a release of free radicals leading to endothelial 
vascular damage and vessel occlusion.36, 136 The precise mechanisms of the PDT-induced 
cell and tissue effects are complex and not fully understood.1 It is thought that selective 
damage, with minimal damage to the surrounding tissue, causes short-term choriocapillaris 
hypoperfusion and long-term choroidal restructuring, thus reducing choroidal congestion, 
hyperpermeability, and extravascular leakage in CSC.36, 137, 138 There is an ongoing debate 
about whether the area of PDT treatment should be guided by the abnormalities on FA 
and/or ICGA. The abnormalities on ICGA that often outweigh the abnormalities on FA 
suggest a strong involvement of the choroid. Therefore, choosing the laser spotsize of PDT 
based on the extent of the hyperfluorescent ICGA abnormalities is often considered a more 
appropriate approach then FA-guided treatment.
PDT was originally introduced and approved to treat certain subtypes of CNV in neovascular 
age-related macular degeneration (AMD). The original PDT settings in this disease used 
a verteporfin dose of 6 mg/m2, a laser fluency of 50 J/cm2, and a treatment time of 83 
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1seconds. A study using these settings in chronic CSC, found that the treatment appears to be 
safe and effective.139 A significant improvement of anatomy and visual acuity in the long-term 
(after 4-years follow-up) was seen, with no signs of laser-induced retinal atrophy or systemic 
adverse effects. However, in other studies in a minority of cases these unadjusted PDT settings 
showed long-term complications including choriocapillaris non-perfusion, secondary CNV 
and/or RPE atrophy and subsequent vision loss especially after repeated treatment.36, 140 To 
minimize the risk of such complications in CSC patients - who often still have a fairly good 
visual acuity - PDT settings were adjusted by reducing either the dose of the verteporfin (half-
dose: 3 mg/m2), the laser fluency (half-fluency: 25 J/cm2), or the treatment time (half-time: 
42 seconds).141-147 These approaches further reduced the risk of PDT-associated complications 
while still showing a similar effect on the resolution of SRF as compared to full-settings PDT 
as well in acute as in chronic CSC, with reported success rates of SRF resolution of 81-100%.94, 
141, 143, 144, 147-149  A further reduction of the verteporfin dose (to one third) may result in less 
efficacy in terms of SRF resolution.150 Ma et al. performed a meta-analysis of 9 studies with 
a total of 319 patients (63 acute CSC cases and 256 chronic CSC cases).151 The study design 
of these studies varied from retrospective comparative studies (3 studies), to prospective 
comparative studies (3 studies), nonrandomized controlled trial (1 study), and randomized 
controlled trials (2 studies).151 Ma et al. concluded that PDT was effective in the treatment of 
CSC with improving visual acuity, a decrease in central macular thickness, and resolution of 
SRF. They also demonstrated that PDT was superior in SRF absorption as compared to laser 
photocoagulation or intravitreal injection of anti-vascular endothelial growth factor (VEGF), 
which resulted in a promising trend towards the use of half-dose PDT.151 In addition, a study 
comparing half-dose PDT to half-fluency PDT found that half-dose PDT induced a more rapid 
SRF reabsorbtion that lasted longer as compared to the half-fluency group.148 However, 
another study comparing half-fluency PDT with half-dose PDT in chronic CSC patients did not 
find any significant differences in outcome when looking at the visual or anatomical results.152 
Although some advocate the use of half-dose PDT, it is currently unclear if one of the reduced-
settings protocols (half-dose, half-fluence, or half-time) is truly superior. Taken together, PDT 
treatment appears to be the most promising treatment for chronic CSC based on the currently 
available body of scientific evidence. However, there is a striking lack of large, multicenter 
prospective randomised controlled treatment trials in acute and chronic CSC, and there are 
no long-term follow-up and natural history studies evaluating the visual function, rate of 
recurrence and overall benefit of treatment in CSC.148, 152, 153  
High-density subthreshold micropulse laser treatment
High-density subthreshold micropulse laser treatment is a laser technique that targets the 
RPE, in contrast to PDT which targets the choroid. This laser technique uses a sequence of 
multiple ultrashort laser pulses with relative long intervals in between these laser pulses 
that allows the RPE to ‘cool down’ to avoid suprathreshold tissue-damaging thermal 
effects.127, 154-156 Using this technique, the level of photothermal effect on the RPE cells is 
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closely monitored, with no evident thermal tissue damage occurring in the retina, in 
contrast to conventional continuous-pulse thermal laser treatment. The mechanisms of 
action of micropulse laser treatment are largely unknown, but effects on the RPE have been 
postulated. It is hypothesized that the benefits may derive from altered regulation of factors 
mediated by the biological reaction of the RPE cells, for instance a therapeutic modulation 
of cytokine production. This is more likely to occur in RPE cells that have been only sub-
lethally treated by a lower thermal effect, than RPE cells that have been lethally treated at 
ophthalmoscopically visible end-points.156, 157 The aim of the treatment in CSC is to stimulate 
the RPE cell functions such as the pumping function, to accelerate the resolution of the 
SRF. A variety of wavelengths have been used for micropulse laser treatment, including 810 
nm,155 577nm, 158 and 527nm,154 and studies have shown a positive effect on the resolution 
of SRF ranging in 41% to 58% of the chronic CSC patients.127, 154, 156, 158-160  The laser settings for 
each wavelength to achieve non-damaging subthreshold yet clinically effective results are 
still subject of debate.
Anti (VEGF)-vascular endothelial growth factor treatment
Anti-VEGF agents are commonly used for intraocular diseases with intraretinal oedema and SRF 
accumulation related to the production of VEGF, such as diabetic macular oedema, exudative 
AMD, and retinal venous occlusions. Despite the fact that uncomplicated CSC does not show 
CNV, and the observation that VEGF levels are not significantly elevated in aqueous samples 
from patients with CSC,161, 162 the intravitreal injection of anti-VEGFs has been investigated 
as a treatment CSC in numerous small studies. It was hypothesized that hypoxic conditions 
in the choroid and/or RPE result in compartmentalized local VEGF expression, which is not 
detectable in the aqueous. Others have postulated that the effect of anti-VEGFs may be based 
on their anti-permeability properties that have been described previously.163-165 The scientific 
proof for a treatment effect of anti-VEGF medication in CSC remains poor, as the publications 
reporting favourable results regarding improvement of visual acuity and reduction of SRF are 
uncontrolled studies.36 The only randomized study comparing ranibizumab to observation in 
acute CSC showed no difference between both groups with regard to the visual acuity, central 
retinal thickness or duration of SRF.166 In addition, patients included in these studies often 
suffer from their first CSC episode with a mean duration of SRF presence of approximately 
4 months. Therefore, spontaneous resolution interpreted as a positive treatment effect is 
possible. A recent meta-analysis that include acute and chronic cases demonstrated that 
neither visual acuity nor central macular thickness were significantly improved 6 months after 
intravitreal bevacizumab as compared to observation, PDT or thermal laser therapy.163
Also, Koss et al. compared micropulse laser treatment to intravitreal injection with 
bevacizumab and observation.160 In the bevacizumab group persistent leakage was seen in 
60% compared to 12.5% in the micropulse laser group and 92% in the observational group.160
Bearing in mind that the precise pathogenetic mechanism of CSC remains unclear and does 
not seem to involve an important role for VEGF and neovascularisation, and the evidence 
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1from current studies results is weak, the use of intravitreal anti-VEGF medication is not 
considered as primary treatment in CSC.28 However, in CSC cases that become complicated 
by CNV167, intravitreal anti-VEGF injections have shown beneficial results. 168
Systemic treatment
Based on the different postulated pathophysiological pathways, a broad range of oral 
medication belonging to the following therapeutic classes has been evaluated in CSC: 
carbonic anhydrase inhibitors, beta-blockers, antibiotics and proton pump inhibitors for 
the treatment of Helicobacter pylori, glucocorticoid-receptor antagonists, anti-platelet 
aggregation medication,169 antimetabolites, 5α-reductase inhibitors, diarylheptanoids, 
and aldosteron/mineralocorticoid receptor antagonists.36, 170 In these therapeutic groups, 
when looking at a positive effect on the resolution of the SRF, promising result were 
reported for acetazolamide,171 antibiotic treatment in Helicobacter pylori infection,51, 172 
and mineralcorticoid receptor antagonist treatment.173, 174 As discussed above, especially 
the mineralcorticoid receptor antagonists could be of interest, as supported by several 
small studies. These studies showed a significant reduction in foveal SRF after 3 months 
as compared to baseline. This reduction in SRF corresponded with an increase of visual 
acuity.36, 173 However, the level of evidence to support the use of these systemic therapies 
is generally very low, mainly due to the inclusion of patients suffering from the acute form 
of CSC who are very likely to show spontaneous resolution anyway. Also, the number of 
included patients in these often retrospective and uncontrolled studies was low.28, 36 
For acetazolamide, a carbonic anhydrase inhibitor, it has been suggested to cause acidification 
of the subretinal space, a decrease in standing potential, and an increase in retinal 
adhesiveness.171 This acidification of the subretinal space may be responsible for increased 
fluid resorption from the RPE to the choroid. Also, an improvement of the polarization and 
the pump function of the RPE is thought to occur. Finally, an anti-inflammatory effect is 
observed that may aid to facilitate the adhesion by inhibition of γ-glutamyl transpeptidase 
activity in the ocular tissue.171 Positive findings were described in an acute CSC cohort, but 
the current scientific level of evidence is again very low.171
The eradication of a possible Helicobacter pylori infection has been investigated with 
variable results in acute CSC. Rahbani-Nobar et al. found a positive effect on SRF,51 but Dang 
et al. were not able to confirm these findings and only found a positive effect on the retinal 
sensitivity.172 It is thought that a Helicobacter pylori infection could lead to a low-grade 
inflammatory stimulus. It has been documented that anti-cagA antibodies may cross-react 
with vascular wall antigens, triggering an immunological cascade that damages vascular 
endothelial cells. Also, it has been suggested that an interaction between Helicobacter pylori 
infection and diseases with a vascular endothelial disorder is mediated by variations in serum 
interleukin levels.51 All of these mechanisms may be involved in the pathophysiological 
pathway of CSC, but none of them have been proven based on solid scientific evidence. 
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1.6 Differential diagnosis of central serous chorioretinopathy
Although several typical characteristics can be seen on multimodal imaging in CSC 
(Figure 7), there are no pathognomonic clinical findings.. For example, the presence of 
SRF is a hallmark feature of active CSC, but can also be seen in other macular diseases. 
Focal leakage through an RPE defect on FA associated with hyperfluorescent areas 
on ICGA is also a non-specific sign. Inactive and/or chronic CSC can be characterized 
by RPE alterations, which again are frequently seen in many other macular diseases. 
The most important differential diagnostic entities will be described below. 
Awareness of the most common differential diagnoses is of clinical relevance as a correct 
diagnosis determines the clinical prognosis and therapeutic decision-making. 
AMD is a multifactorial disease that is the leading cause of irreversible blindness in the 
elderly population in the Western world. Generally, two different phenotypes can be 
distinguished: an atrophic and neovascular form. In both forms the diagnosis of ‘typical’ 
AMD is thought to require the presence of drusen, or the assumption that drusen were 
present but have disappeared with the development of CNV or RPE atrophy.35 Drusen are 
focal subretinal deposits that consist of amorphous extracellular material between Bruch’s 
membrane and the RPE that appear like yellowish spots on the fundus.175 AMD should be 
considered especially in the differential diagnoses of chronic CSC because these patients 
are older and have more RPE changes than patients with acute CSC. Also, chronic CSC can 
be complicated by CNV and/or polypoidal choroidal vasculopathy,99, 176, 177 causing further 
clinical overlap with neovascular AMD. Compared to chronic CSC patients, neovascular AMD 
patients usually have an older age at onset and the prevalence of AMD is approximately 
equal in men and women. Drusen are not typically present in chronic CSC, and the presence 
of drusen in the (fellow) eye of an older patient with serous SRF should raise suspicion of 
AMD with (occult) CNV and/or polypoidal choroidal vasculopathy mimicking chronic CSC. 
Signs that can point clinicians towards the correct diagnosis, are the possible presence 
of hard exudates, grayish subretinal fibrosis or blood on fundoscopy, which are highly 
indicative for CNV. Most cases of CNV in AMD deteriorate quite rapidly, but some cases of 
small smouldering occult CNV and associated serous SRF in AMD can remain fairly stable 
for weeks to months. On OCT, signs indicative of (occult) CNV in AMD include: a relatively 
broad RPE detachment that is separated from the underlying Bruch’s membrane (‘double 
layer sign’) with a certain degree of hyperreflective sub-RPE changes; an irregular RPE 
defect due to neovascular subretinal ingrowth; and intraretinal edema different from 
posterior cystoid degeneration. In typical AMD, the macula in the fellow eye shows drusen 
if unaffected by CNV and/or profound RPE atrophy. On FA, signs indicative of neovascular 
AMD include indistinct leakage (no ‘hot spot’) and hyperfluorescent drusen. In the case of 
occult CNV in AMD, ICGA shows a well-circumscribed neovascular membrane (Figure 8A-D) 
of variable fluorescence, without the indistinct predominantly hyperfluorescent choroidal 
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178, 179 
Polypoidal choroidal vasculopathy (PCV) is a specific form of subretinal neovascularisation,180 
that can be seen as an isolated clinical picture, but also as a complication of other macular 
diseases such as drusenoid neovascular AMD and chronic CSC.181, 182 Although PCV and 
chronic CSC are two different entities, and chronic CSC can be complicated by PCV, cases of 
isolated PCV may present with similar clinical findings on OCT and FA, with smaller or larger 
RPE detachments and serous SRF accumulation. Polyps in PCV can be seen in fundoscopy as 
small or larger pink-colored subretinal structures, sometimes associated with haemorrhages, 
hard exudate leakage and/or subretinal fibrosis. Especially in the early phase of the disease 
and in Caucasian patients the polyp(s) in PCV may still be small and can be easily overlooked 
(Figure 8E-H). Like in occult CNV in neovascular AMD, PCV tends to deteriorate quite rapidly, 
but some cases of small smouldering polyps with or without small occult CNV can remain 
fairly stable for weeks to months. Yannuzzi et al. illustrated that ICGA is an important 
imaging modality to establish the correct diagnosis.180 One or more hyperfluorescent polyps, 
often surrounded by a hypofluorescent halo, and often associated with occult CNV, can be 
confirmed on early and midphase ICGA.180 Like in chronic CSC, ICGA in a subgroup of patients 
presenting primarily with PCV can reveal indistinct choroidal hyperpermeability besides the 
polypoidal lesion(s),36, 183 and distinctive hyperfluorescent punctate lesions.105 This indicates 
that a subgroup of PCV is part of the CSC/pachychoroid spectrum, which is also suggested 
by the finding of a thickened choroid in a subgroup of PCV patients.184 Furthermore, several 
OCT signs are indicative of a polypoidal process, such as a focal RPE detachment that often 
corresponds to the polypoidal lesions seen on ICGA. These lesions contain more highly 
reflective material on OCT compared to the adjacent RPE detachment (Figure 8H).185 PCV 
is more frequently associated with intraretinal cystoid edema, the presence of intraretinal 
lipid deposits, and hemorrhagic RPE detachments as compared to CSC.36, 186 Similar to 
some forms of occult CNV and some chronic CSC cases, a ‘double layer sign’ on OCT can be 
seen in PCV. In PCV the double layer sign is typically seen in the area of branching vascular 
network of the CNV, with an adjacent smaller or larger dome-shaped RPE detachment with 
underlying polyp, and may reflect a fluid accumulation together with neovascular and/or 
polypoidal tissue between the RPE en Bruch’s membrane.187
In contrast to half-dose PDT treatment, which is advocated for chronic CSC, for PCV a 
combination of full-dose PDT with or without intravitreal anti-VEGF injections are generally 
considered as first choice of treatment.188-190
The clinical spectrum of dome-shaped macula and tilted disc with inferior staphyloma 
presents mostly with a central SRF accumulation and an inward or anterior deviation of 
the macula (Figure 8P-S).191 This bulge affects the retina, the RPE, and the inner choroid. 
In contrast to classical chronic CSC, which is more commonly seen in hyperopic patients, 
dome-shaped macula is more common in (highly) myopic patients. Multimodal imaging 
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may reveal hyperfluorescent areas and spots on FA and ICGA. On OCT imaging small RPE 
detachments can be present, and a greater subfoveal choroidal thickness as compared to 
eyes without SRF can be seen on enhanced depth imaging.191 The presence of an inward 
or anterior deviation of the macula and myopia, is especially suggestive of dome-shaped 
macula. In the case of tilted disc with inferior staphyloma, a tilted optic disc with an oblique 
insertion into the globe, an inferonasal crescent of the optic disc, and in some cases situs 
inversus of the retinal vessels is seen.192 The inferior staphyloma is generally invisible on 
the horizontal OCT scan, and can best be recognized on a vertical OCT scan which shows 
an unusual convexity within the general concavity of the staphyloma (Figure 8S).193 
Macular serous SRF accumulation in the dome-shaped maculopathy and tilted disc/inferior 
staphyloma spectrum responds poorly to treatment such as PDT  and intravitreal anti-VEGF 
injections. Occasionally, SRF may resolve spontaneously.36, 194
Pachychoroid pigment epitheliopathy is a condition in which patients show an increased 
choroidal thickness on EDI-OCT, nonspecific pigment epithelial changes at the fovea, and 
RPE changes and/or small RPE detachments directly overlying localized areas of thickened 
choroid and/or dilated choroidal vessels that may be visible on fundoscopy.195, 196 Also, 
findings on FA and ICGA resemble milder variants of the hyperfluorescent patterns that 
can be found in chronic CSC patients. In contrast to chronic CSC, these patients do not have 
a history of vision loss due to SRF accumulation.195 However, due to the apparent clinical 
overlap, pachychoroid pigment epitheliopathy is thought to be a ‘forme fruste’ or precursor 
of CSC.195
Choroidal tumors can also be associated with serous SRF accumulation that may mimic 
CSC (Figure 8L-O). A benign vascular tumor such as circumscript choroidal hemangioma 
presents with a deep orange-red lesion on funduscopy, in contrast to chronic CSC. The 
tumor itself can appear fairly flat on retinal OCT, but increased vascular calibres may be 
present on enhanced depth or swept-source OCT imaging. During FA a similar pattern of 
hyperfluorescent RPE changes can be seen as in chronic CSC, although often without a clear 
‘hot spot’ of leakage. However, on ICGA the filling of intratumoral vessels is clearly seen 
during the arterial phase on the hypofluorescent background. During the venous phase 
the tumour shows maximum hyperfluorescence. During the late phase the ICGA shows a 
typical ‘wash-out’ image with residual hyperfluorescent caverns (Figure 8N).197 Therefore, 
ICGA helps to differentiate a choroidal hemangioma from chronic CSC. Ultrasonography 
enables additional distinction between a tumor and chronic CSC, identifying a high reflective 
choroidal swelling. Circumscribed choroidal hemangiomas generally respond favourably 
to full-dose PDT treatment.198 Choroidal naevi or melanoma may also be associated with 
serous SRF accumulation but are generally easy to distinguish from CSC on fundoscopy and 
ultrasonography. 
General introduction
37
Ch
ap
te
r 
1Optic disc pit is a developmental anomaly of the optic disc that can be associated with a 
serous retinal detachment in the macula, with or without associated schisis-like intraretinal 
edema, that can occur at any age, but most frequently in early adulthood. Signs of an optic 
pit on fundoscopy include a slightly larger than normal optic disc that contains a round or 
oval pit, usually gray, yellow, or black in appearance, of variable size (Figure 8I). The pit is 
usually located temporally in the optic disc.2 The fluid in optic disc pit can be localized under 
the neuroretina, causing a serous neuroretinal detachment, and/or between the inner and 
outer layers of the retina, producing a schisis-like appearance, thus mimicking (chronic) CSC. 
The origin of intra- and/or subretinal fluid in this condition is unclear. The optic disc pit can 
also be associated to peripapillary chorioretinal atrophy and RPE changes. In contrast to 
CSC, patients with an optic pit do not have hyperfluorescent areas with hot spots of leakage 
on FA and ICGA that are typical of CSC. OCT imaging of the optic disc can give additional 
diagnostic support for differentiation in addition to the characteristic fundoscopic aspect of 
an optic pit (Figure 8I-K).1, 199 As the natural course of SRF and intraretinal changes in optic 
disc pit is unfavourable, various types of surgical intervention have been proposed.200, 201
Serous retinopathy associated with mitogen-activated protein kinase kinase (MEK) inhibition, 
is a side effect described in patients treated with MEK inhibitors for metastatic neoplastic 
disease.202 Van Dijk et al. found that in this specific patient group a serous SRF accumulation 
can mimic CSC.203 However, additional imaging using FA hardly shows any hyperfluorescent 
leakage, and OCT does not show RPE changes or a thickened choroid in contrast to chronic 
CSC, and lesions are often multifocal. The SRF accumulation in this retinopathy was shown 
to be time-dependent and reversible. Resolution occurred either spontaneously or soon 
after cessation or dose tapering of the MEK inhibitor (Figure 8T-V).203
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Figure 8. 
(A-D) Images of an example of age-related macular degeneration (AMD). (A) Color fundus photograph (CFF) 
showing a few small yellowish drusen in the center of the macula. (B) Fluorescein angiography (FA) illustrates 
central punctiform staining without a clear ‘hot spot’ of leakage. On indocyanine green angiography (ICGA) (C) 
irregular hypofluorescence and hyperfluorescence are visible. On optical coherence tomography (OCT) (D) a 
shallow subretinal fluid (SRF) accumulation can be identified with a retinal pigment epithelium (RPE) detachment. 
Also, a relatively thin choroid is seen. (E-H) An example of a polypoidal choroidal vasulopathy (PCV), in combination 
with a branching vascular network of neovascularisation. (E) The CFF image shows a mild hypopigmentation of 
the macula area indicating the presence of SRF as evidenced on OCT (H) and a small pink polyp. FA (F) shows 
hyperfluorescent staining inferior of the foveal area, and superior of the foveal area a hyperfluorescent hot spot 
is seen with some diffuse leakage. On ICGA (G), a relatively wel-delineated hyperfluorescent branching vascular 
network is visible, with the hyperfluorescent polyp at the superotemporal edge of this neovascular network, 
surrounded by a hypofluorescent zone. The OCT-scan (H) demonstrates the SRF and an RPE detachment with 
some underlying hyperreflective changes that correspond to the neovascular polypoidal tissue. (I-K) CFF (I), 
late-phase ICGA (J), and OCT-scan of an optic pit. (I) The CFF image illustrates the slighly depigmented serous 
SRF collection in the macula. In addition, this patient had a microcoloboma below the optic disc. ICGA (J) did not 
show any hyperfluorescent zones, which is in contrast to CSC. (K) OCT-scan shows intraretinal fluid that bears 
resemblance to retinoschisis, especially between the fovea and the optic disc, in combination with SRF that 
seems to have a shallow connection to the optic disc. (L-O) Submacular choroidal haemangioma. The CFF (L) 
shows an orange circumscribed hemangioma with hyperpigmentation centrally in the macula. FA (M) reveals a 
hyperfluorescent structure without clear hot spots of leakage. This hyperfluorescent structure on FA corresponds 
to the hyperfluorescent choroidal abnormalities of the hemangioma on ICGA (N). On OCT (O), a choroidal mass 
with SRF and a small PED is seen. (P-S) Multimodal imaging of a patient with serous maculopathy associated with 
tilted disk/inferior staphyloma. The CFF (P) shows an optic disc tilted inferiorly. Hyperfluorescent abnormalities are 
seen on FA (Q) and ICGA (R), without clear ‘hot spots’ of leakage. A vertical OCT-scan (S) demonstrating the typical 
dome-shaped macula, with the serous SRF and RPE changes typically localized at the transition zone of thicker 
and thinner choroid of the inferior staphyloma. (T-V) A CFF, FA, and OCT-scan of a patient with serous retinopathy 
associated with mitogen-activated protein kinase kinase inhibitor treatment (in this case binimetinib) for metastatic 
cancer, in this case cutaneous melanoma. CFF (T) illustrates a almost invisible yellowish subfoveal lesion, and FA (U) 
shows hardly any abnormalities in contrast to CSC. A SRF collection in the macula is seen on OCT (V).
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1.7 Aims and outlines of this thesis
CSC often affects relatively young (middle-aged) patients who are still professionally active. 
Especially in chronic CSC, the prolonged disease course can have significant visual impact. 
Despite the fact that CSC is among the most common forms of maculopathy, relatively little 
is known about the pathogenesis, clinical characteristics, and optimal treatment of CSC. This 
thesis aims to provide new insights into the pathogenesis, clinical characteristics, long-term 
outcome, vision-related quality of life, and treatment of chronic CSC. Genetic influences 
are studied and possible pathophysiological mechanisms are discussed. Also, the overall 
clinical course and current clinical practice is evaluated, working towards a better treatment 
of chronic CSC through evidence-based treatment guidelines.
Chapter 2.1 describes one of the first genetic studies in a large chronic CSC cohort. A 
significant association was found between specific single nucleotide polymorphisms (SNPs) 
in the CFH gene, as well as a SNP in the ARMS2 gene. The frequencies of these SNPs are 
compared to an AMD population in which these SNPs were originally found to be important. 
Chapter 2.2 investigates the possible involvement of the complement system in the 
pathogenesis of CSC, through an analysis of the C4 gene. This gene plays an important role in 
the classic and the lectin pathway and was previously described in association with several 
autoimmune diseases with ocular involvement. 
Chapter 3.1 evaluates the long-term clinical outcome of patients with chronic CSC. In 
addition, the vision-related quality of life is assessed using a validated questionnaire. 
Chapter 3.2 describes the characteristics and variability of SRF in chronic CSC on spectral 
domain OCT, using a novel semi-automated analysis technique. Differences in these OCT 
characteristics may predict differences in treatment response of chronic CSC patients.
Chapter 3.3 describes the first results of a novel OCT imaging technique, OCT angiography, 
in chronic CSC patients. This technique visualizes the blood flow in the retina and the 
underlying choroid using a non-invasive OCT analysis technique. The findings are compared 
to the invasive imaging techniques that are currently used for evaluation of vascular 
abnormalities in chronic CSC: FA and ICGA.
Chapter 4.1 presents the results of a prospective treatment protocol in chronic CSC. Patients 
treated according to this protocol first received half-dose PDT treatment followed by high-
density subthreshold micropulse laser therapy if needed. 
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1Chapter 4.2 describes the response to PDT treatment in a specific subgroup of chronic CSC 
patients who developed the disease in association with corticosteroid use as a possible 
exogenic factor. We retrospectively evaluated if half-dose PDT shows similar efficacy as 
compared to a control group who had chronic CSC without associated corticosteroid use.
Chapter 4.3 presents the protocol of the first prospective, randomized controlled multicentre 
treatment trial for chronic CSC, the PLACE trial. In this study, half-dose PDT is compared to 
high-density subthreshold micropulse laser treatment in patients with chronic CSC. 
Chapter 4.4 reports a pilot study that tested the oral use of the mineralocortocoid antagonist 
eplerenone as a treatment option in patients with typical chronic CSC who did not respond 
to previous treatments that are commonly used, such as PDT and micropulse laser therapy.
Chapter 5 summarizes and integrates the major findings of this thesis, discussing their 
implications and future perspectives.
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Purpose: 
In this study, single nucleotide polymorphisms (SNPs) at 19 loci, previously associated with 
age-related macular degeneration (AMD), were systematically tested for association in 
patients with chronic central serous chorioretinopathy (CSC). In addition, we evaluated the 
effect of detailed phenotyping on these genetic associations.
Methods: 
A case-control study with 292 chronic CSC patients, 1147 AMD patients, and 1311 control 
individuals. SNPs at 19 AMD-associated loci and six additional SNPs at the Complement 
Factor H (CFH) locus were genotyped. Phenotyping of all patients was based on fundoscopy, 
spectral-domain optical coherence tomography, fluorescein angiography (FA) and 
indocyanine green angiography. 
Results: 
One SNP in ARMS2 (rs10490924) was significant after Bonferroni correction (P
unadjusted
 
= 0.002, OR = 0.64). SNPs at three other AMD loci (CFH, TNFRSF10A, ADAMTS9) showed 
a trend towards association with typical chronic CSC. Further analysis of the CFH locus 
identified two SNPs that significantly conferred increased risk for chronic CSC and one that 
was protective. The CFH-H3 haplotype was also found to be protective (P = 0.01, OR = 0.54). 
Using multimodal imaging, 197 patients were classified as typical chronic CSC, 52 patients 
had unilateral abnormalities on FA that were otherwise typical of chronic CSC, and 43 
patients had a clinical picture that could be compatible with chronic CSC, but with features 
that could also indicate other macular diseases. Significant differences of the minor allele 
frequencies of the tested SNPs were observed between these three phenotypic subgroups. 
Conclusions: 
Chronic CSC is associated with genetic variants in ARMS2 and CFH, indicating a genetic and 
pathophysiologic overlap between chronic CSC and AMD. Intriguingly, alleles in ARMS2 and 
CFH that confer risk of AMD may be protective for chronic CSC, while alleles in CFH that are 
protective for AMD confer risk for chronic CSC. Significant differences in allele frequencies 
were seen among the phenotypic subgroups for several SNPs, illustrating the importance of 
correct clinical classification. 
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1
Introduction
Central serous chorioretinopathy (CSC) is one of the most common forms of macular disease 
in the Western world.1, 2 It is characterized by a serous detachment of the neuroretina 
from the underlying retinal pigment epithelium (RPE) in the macula, due to fluid leakage 
through a dysfunctional RPE. Clinical evidence from multimodal imaging, such as choroidal 
congestion, thickening and hyperpermeability of the choroid, implies an important role for 
choroidal abnormalities as an underlying cause for RPE dysfunction and subretinal fluid 
leakage in CSC.1-3 
Two main subtypes of CSC can be distinguished. Patients with acute CSC present with 
sudden and marked central vision loss. Acute CSC is characterized by a focal leakage spot 
on fluorescein angiography (FA), beneath a macular neurosensory retinal detachment.1-9 
This so called ‘hot spot’ indicates leakage at the level of the RPE.1, 4, 10 The acute form of 
CSC generally has a favorable prognosis because the accumulated subretinal fluid often 
subsides spontaneously within 2-3 months, with (near-)normal recovery of vision (Figure 
1A-C).1 In contrast, chronic CSC is typically not self-limiting and subretinal fluid remains 
present longer than 3 months.2, 4, 10 Patients have more diffuse multifocal leakage on FA 
and indocyanine green (ICG) angiography, and often irregularly distributed widespread RPE 
changes associated with various degrees of low-grade leakage (Figure 1D-F).1-10 Because of 
persistent serous neuroretinal detachments with progressive and irreversible photoreceptor 
damage, chronic CSC has a poorer visual prognosis than acute CSC.2, 6, 11, 12 
Figure 1.
Examples of fluorescein angiography (FA), indocyanine green (ICG) angiography and spectral-domain optical 
coherence tomography (SD-OCT) in acute and chronic central serous chorioretinopathy (CSC). (A-C) The left eye 
of a patient with classical acute CSC, showing a small focal leak in the early phase of FA, and a typical smokestack 
fluorescein leak on late-phase FA (A-B) and the corresponding SD-OCT image showed a large central subretinal 
fluid (SRF) accumulation associated with a focal shallow retinal pigment epithelial (RPE) detachment(C). (D-E) The 
right eye of a patient with chronic CSC with more widespread leakage on FA (D), and diffuse hyperfluorescent areas 
on ICG angiography (E), as well as SRF and multiple RPE detachments on SD-OCT (F).
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Although the etiology of CSC is largely obscure, clinical observations point towards an 
association with the use of corticosteroids, hypercortisolism, stress and type A personality.1, 
10, 13 The incidence of CSC is approximately six times higher in men than in women,1 although 
this male-to-female proportion seems to be less pronounced in chronic CSC and steroid-
related CSC. 
Interracial differences in the prevalence of chronic CSC and the familial occurrence of 
chronic CSC suggest a strong genetic involvement.2, 14-16 However, only a limited number of 
possible genetic associations have been reported so far.17, 18 Certain phenotypic features of 
chronic CSC such as serous RPE detachments, neurosensory retinal detachment and patchy 
atrophy of the RPE are also observed in other macular diseases, like age-related macular 
degeneration (AMD) and polypoidal choroidal vasculopathy.19 This phenotypic overlap 
suggests that a genetic overlap may also exist. 
AMD is known to be a multifactorial and genetically complex disorder, and 19 genetic loci 
have been identified to be associated with the disease.20-22
In order to assess the degree of phenotypic and genotypic overlap between chronic CSC and 
AMD, this study used a combination of detailed phenotyping based on multimodal imaging 
and systematic analyses of SNPs at the known 19 AMD-associated loci in chronic CSC 
patients. Furthermore, a detailed analysis of CFH haplotypes in chronic CSC patients was 
performed. Finally, the effect of phenotypic differentiation on these genetic associations 
was evaluated. 
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Methods
Participants
In this study, we included 292 patients with chronic CSC who visited the outpatient clinic of 
the Department of Ophthalmology at the Radboud University Medical Center, Nijmegen, 
the Netherlands (Table 1). The diagnosis chronic CSC and phenotyping with multimodal 
imaging was based on an extensive ophthalmological examination including fundoscopy, 
spectral-domain optical coherence tomography (SD-OCT), FA and ICG angiography. The 
definition of chronic CSC used in this study was based on the currently available literature, 
taking the following characteristics into account that all had to be present: serous subretinal 
fluid on OCT, one or more areas of multifocal diffuse leakage on FA, and corresponding 
hyperfluorescence on ICG angiography in at least one eye.1-10 Patients suffering from acute 
CSC as recognized by a focal leakage spot or a smokestack pattern on FA, and patients with 
a disease period under three months, were excluded.1-10  A total of 1311 control subjects 
were recruited from the blood bank of the Radboud University Medical Center, Nijmegen, 
The Netherlands (n = 177), and the European Genetic Database (EUGENDA, www.eugenda.
org) (n = 1134). For control subjects recruited from EUGENDA ophthalmological grading 
was performed excluding signs of AMD. In addition, 1147 AMD patients from the European 
Genetic Database (EUGENDA, www.eugenda.org) were used for calculation of the minor 
allele frequencies of SNPs at AMD-associated loci (Table 1). The diagnosis of AMD was 
defined as described previously.23 Informed consent for the use of DNA for genetic studies 
was obtained from all subjects. The study adhered to the tenets of the Declaration of 
Helsinki. Institutional review board/ethics committee approval was obtained.
Table 1. Demographics of the study population
Subgroup 1 Subgroup 2 Subgroup 3 Controls AMD
Number of subjects 197 52 43 1311 1147
Sex (male/female) (154/43) (38/14) (26/17) (629/682) (448/699)
Mean age ± SD (years) 53 ± 10 55 ± 12 57 ± 13 66 ± 12 76 ± 9
Age range (years) 29-74 32-78 30-78 19-97 55-101
AMD = age-related macular degeneration; SD = standard deviation
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SNP genotyping 
Genomic DNA was extracted from peripheral blood samples using standard procedures. 
Nineteen SNPs at loci previously associated with AMD (rs10490924 (ARMS2), rs12144939 
(CFH), rs429608 (C2-CFB), rs2230199 (C3), rs9621532 (TIMP3), rs4420638 (APOE), rs3764261 
(CETP), rs943080 (VEGFA), rs13278062 (TNFRSF10A), rs493258 (LIPC), rs10033900 (CFI), 
rs3812111 (COL10A1), rs13081855 (COL8A1-FILIP1L), rs3130783 (IER3-DDR1), rs8135665 
(SLC16A8), rs334353 (TGFBR1), rs8017304 (RAD51B), rs6795735 (ADAMTS9)) and rs9542236 
(B3GALTL)) were genotyped in 292 chronic CSC patients and 1311 controls by outsourcing to 
the genotyping service of LGC genomics (©LGC Limited, United Kingdom).20-22 
Genotyping of six CFH SNPs (rs1061170, rs3753394, rs800292, rs2284664, rs1329428, 
rs1065489) was performed with KASP™ genotyping assays (LGC Genomics) in 292 chronic 
CSC patients and 881 controls. SNP-specific KASP primer mix and KASP master mix were 
added to 10ng DNA according to the manufacturer’s instructions. PCR amplification was 
performed (Veriti 384 thermal cycler, Applied Biosystems). Fluorescent FAM and HEX 
signals were read out with the 7900HT Fast Real-Time PCR System (Applied Biosystems) and 
converted to genotype information with the SDS program (version 2.3 Applied Biosystems). 
Statistical Analysis
Differences in allele frequencies were calculated using the Fisher’s Exact test (two sided for 
the 19 AMD-loci and one-sided for CFH SNPs based on previous reports), and a Bonferroni 
correction was performed. The individual tests for the 19 AMD-loci were considered 
significant for P-values less than 0.0026, corrected for 19 tests. The significance threshold 
for the six CFH variants was set at P<0.0083, correcting for six tests. 
Haplotypes were generated with R (version 3.0.2) and R Studio (version 0.98.501), using the 
haplo.stats package (version 1.6.8). For each SNP, information for both alleles was inserted 
into R and the haplo.cc command was used to determine associations between haplotype 
frequencies and chronic CSC. The most frequent haplotypes (frequency in controls > 
5%) were named H1-H5 according to the nomenclature described by Hageman et al. 24 
Haplotypes were considered to be significantly associated to CSC if P<0.01, correcting for 
five tests. Minor allele frequencies of significantly associated SNPs were compared between 
subgroups of CSC using a Fisher’s exact test, and were considered significant if P<0.0125, 
correcting for four test. 
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Results
Phenotyping and classification of chronic CSC patients
All chronic CSC patients were classified into three subgroups based on their phenotypic 
characteristics on multimodal imaging. Patients in phenotypic subgroup 1 (n = 197) showed 
the most typical clinical picture of chronic CSC. This typical picture was defined as the 
presence of chronic serous subretinal fluid in at least one eye on SD-OCT, bilateral irregular 
RPE window defects on FA with at least one “hot spot” of leakage in the affected eye(s), and 
corresponding hyperfluorescent zones on ICG angiography (Figure 2A-B). No evidence of 
choroidal neovascularization, polypoidal choroidal vasculopathy, or other atypical findings 
were seen in this subgroup.
Phenotypic subgroup 2 (n = 52) included patients with unilateral (instead of bilateral) 
abnormalities on FA that were otherwise typical for chronic CSC. Additionally, subgroup 2 
included patients with no clear “hot spot” and/or more focal leakage on FA, with an absence 
of subretinal fluid on SD-OCT but otherwise typical FA features of chronic CSC . Also, patients 
in whom ICG angiography imaging did not show clear hyperfluorescence corresponding to 
FA abnormalities were included in subgroup 2 (Figure 2C-D). Furthermore, these patients 
showed no evidence of choroidal neovascularization, polypoidal choroidal vasculopathy, or 
other atypical findings.
For patients in phenotypic subgroup 3 (n = 43), the clinical picture was primarily compatible 
with chronic CSC, but with more atypical features suggestive of other macular diseases, 
or possibly constituted a combination of chronic CSC and another diagnosis. For instance, 
atypical clinical features in patients in subgroup 3 included evidence of choroidal 
neovascularisation, the presence of drusen, or (highly) myopic fundus changes (Figure 2E-F).
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Figure 2. 
Examples of fluorescein angiography (FA; of right eyes (RE): column I, of left eyes (LE): column III), indocyanine 
green angiography (ICG angiography of RE: column II, of LE: column IV) and spectral-domain optical coherence 
tomography (SD-OCT; of RE: upper images of column V, of LE: lower images of column V) imaging of each 
phenotypic subgroup. (A-B) The RE and LE of two patients representing subgroup 1, demonstrating diffuse areas 
of leakage on FA and ICG angiography (A/I-II, B/III-IV) and subretinal fluid (SRF) beneath the fovea (A/V (upper 
image), B/V (lower image)), illustrative for typical active chronic central serous chorioretinopathy (chronic CSC). 
(A/I) A classic example of a gravitational tract on FA in chronic CSC. The fellow eyes of these patients did not have 
SRF on SD-OCT (A/V (lower image), B/V (upper image)), but had clear hyperfluorescent areas on FA and ICG 
angiography indicating chronic CSC without active leakage (A/III-IV, B/I-II). (C-D) Imaging of two patients belonging 
to subgroup 2 with unilateral, more localized leakage on FA and ICG angiography (C/III-IV, D/III-IV) and central SRF 
on SD-OCT (C/V (lower image), D/V (lower image)). (E-F) The RE and LE of two patients as an example of subgroup 
3. In the first patient an irregular hyperfluorescent pattern was seen on FA and ICG angiography of the right 
eye (E/I-II). SD-OCT showed a large retinal pigment epithelium detachment in association with serous SRF (E/V 
(upper image)). In the fellow eye central mild hyperfluorescence was seen on FA with hypofluorescence on ICG 
angiography (E/III-IV). Also, minimal central SRF was present on SD-OCT (E/V (lower image)). The second patient 
had diffuse leakage on FA and ICG angiography (F/I-II) accompanied by SRF on SD-OCT (F/V (upper image)) in the 
right eye. Imaging of the left eye showed multifocal areas of atrophy on FA and ICG angiography (F/III-IV) and 
retinal atrophy on SD-OCT (F/V). Both eyes had choroidal folds on FA and ICG angiography (F/I-IV).
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Association of SNPs at AMD loci with chronic CSC
To investigate the extent to which chronic CSC and AMD overlap genetically, the association 
of 19 SNPs at previously described AMD loci was tested in 197 typical chronic CSC patients 
(subgroup1) versus 1311 controls (Table 2).
Of these 19 loci, only rs10490924 in ARMS2 remained significant (P = 0.002, OR = 0.64) after 
correcting for multiple testing (Table 2). 
Association of CFH SNPs and haplotypes with chronic CSC
To investigate the CFH locus in more detail, we tested six additional SNPs for association in 197 
typical chronic CSC patients (subgroup 1), and 881 controls (Table 3). 
After correction for multiple testing two CFH SNPs conferred an increased risk for chronic 
CSC (rs800292, P = 7.5 x 10-4, OR = 1.50 and rs1329428, P = 4.6 x 10-4, OR = 1.47) and one SNP 
was protective (rs1065489, P = 0.003, OR = 0.63) (Table 3). 
Out of the five observed CFH haplotypes, H3 (TGTCCT) was significantly associated (P = 0.01) 
with chronic CSC. The H3 haplotype was protective for the development of chronic CSC (OR 
= 0.54), being present in 15.7% of the control population and in 9% of chronic CSC patients. 
The H2 haplotype (CATTTG) showed a trend towards association (P = 0.072), conferring risk 
for chronic CSC (OR = 1.33) and being present in 20.8% of control individuals and in 25.8% 
of chronic CSC patients (Table 4). 
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Differences in minor allele frequencies of tested SNPs and haplotypes among phenotypic 
subgroups of chronic CSC
To investigate whether classifying chronic CSC into three distinct phenotypic subgroups 
had an effect on the underlying genetic associations, the minor allele frequencies of the 
significantly associated SNPs (rs10490924 (ARMS2), rs800292 (CFH), rs1329428 (CFH) and 
rs1065489 (CFH)) were compared between subgroups 1, 2 and 3 (Table 5).
When comparing chronic CSC subgroups 1 and 2, none of the SNPs showed a significant 
difference in frequency, suggesting that these subgroups are genetically similar. When the 
atypical patients (subgroup 3) were compared to subgroup 1, rs10490924 in ARMS2 (P = 
0.002) and rs800292 in CFH (P = 0.002) showed a significant difference in allele frequencies 
between these clinical subgroups, suggesting that subgroup 1 and 3 are genetically different 
(Table 5). 
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Table 2. Analysis of 19 age-related macular degeneration loci in chronic central serous chorioretinopathy
SNP (locus)
Alleles 
(Major/
Minor)
MAF 
subgroup 
1 (n=197)
MAF 
controls 
(n=1311)
 
Unadjusted 
Allelic  
P- value
Allelic 
Odds Ratio  
(95% CI)
rs10490924 (ARMS2) G/T 0.17 0.24 0.002 0.64 (0.49-0.85)
rs12144939 (CFH) G/T 0.25 0.20 0.031 1.33 (1.03-1.70)
rs429608 (C2-CFB) G/A 0.16 0.13 0.133 1.25 (0.94-1.68)
rs2230199 (C3) G/C 0.19 0.17 0.393 1.16(0.83-1.61)
rs9621532 (TIMP3) A/C 0.05 0.05 0.807 1.05 (0.65-1.68)
rs4420638 (APOE) A/G 0.16 0.17 0.470 0.89 (0.66-1.19)
rs3764261 (CETP) G/T 0.30 0.32 0.484 0.92 (0.73-1.16)
rs943080 (VEGFA) T/C 0.44 0.48 0.211 0.87 (0.70-1.08)
rs13278062 (TNFRSF10A) T/G 0.40 0.48 0.004 0.73 (0.59-0.90)
rs493258 (LIPC) C/T 0.49 0.46 0.064 1.23 (0.99-1.52)
rs10033900 (CFI) C/T 0.50 0.48 0.514 1.08 (0.87-1.34)
rs3812111 (COL10A1) A/T 0.34 0.36 0.498 0.92 (0.74-1.15)
rs13081855 (COL8A1-FILIP1L) G/T 0.12 0.09 0.074 1.38 (0.98-1.93)
rs3130783 (IER3-DDR1) A/G 0.20 0.19 0.836 1.03 (0.78-1.34)
rs8135665 (SLC16A8) C/T 0.21 0.22 0.600 0.92 (0.71-1.20)
rs334353 (TGFBR1) T/G 0.26 0.25 0.662 1.06 (0.83-1.35)
rs8017304 (RAD51B) A/G 0.36 0.38 0.467 0.92 (0.73-1.14)
rs6795735 (ADAMTS9) C/T 0.46 0.41 0.047 1.25 (1.01-1.54)
rs9542236 (B3GALTL) T/C 0.44 0.44 1.000 1.01 (0.81-1.25)
SNP = single nucleotide polymorphism; MAF = minor allele frequency; CI = confidence interval
For the analysis displayed in this table two sided P-values < 0.0026 were considered to be significant
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Table 3. Complement factor H locus in chronic central serous chorioretinopathy.
SNP Location
Alleles 
(Major/
Minor)
MAF 
subgroup 1 
(n=197)
MAF 
controls 
(n=881)
Unadjusted 
Allelic 
P-value
 
Allelic Odds 
Ratio (95% CI)
rs3753394
Promotor C/T 0.245 0.295 0.027 0.78 (0.60-1.00)
rs800292 
(I62V) Exon 2 G/A 0.315 0.235 7.5 x 10-4 1.50 (1.18-1.90)
rs1061170 
(Y402H) Exon 9 T/C 0.310 0.350 0.065 0.83 (0.66-1.05)
rs2284664
Intron 15 C/T 0.276 0.218 0.009 1.37 (1.07-1.76)
rs1329428
Intron 15 C/T 0.526 0.431 4.6 x 10-4 1.47 (1.17-1.83)
rs1065489 
(D936E)
Exon 18 G/T 0.118 0.176 0.003 0.63 (0.45-0.87)
SNP = single nucleotide polymorphism; MAF = minor allele frequency; CI = confidence interval
For the analysis displayed in this table one sided P-values < 0.0083 were considered to be significant
Table 4. Complement factor H haplotypes in chronic central serous chorioretinopathy.
SNP
HF
Subgroup 
1 (n=197)
HF
Controls 
(n=881)
Unadjusted
P-value
Odds ratio 
(95% CI)
  r
s3
75
33
94
  r
s8
00
29
2
  r
s1
06
11
70
  r
s2
28
46
64
  r
s1
32
94
28
  r
s1
06
54
89
H1 C G C C C G 0.291 0.328 0.164 0.83 (0.59-1.17)
H2 C A T T T G 0.258 0.208 0.072 1.33 (0.93-1.90)
H3 T G T C C T 0.090 0.157 0.010 0.54 (0.32-0.91)
H4 C G T C T G 0.125 0.132 0.480 0.96 (0.60-1.52)
H5 T G T C T G 0.102 0.076 0.150 1.37 (0.81-2.32)
SNP = single nucleotide polymorphism; HF = haplotype frequency; CI = confidence interval
For the analysis displayed in this table one sided P-values < 0.01 were considered to be significant
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Discussion
Both risk-conferring and protective associations of polymorphisms in the ARMS2 and 
CFH genes with chronic CSC were identified in this study. Moreover, by introducing a 
subclassification of chronic CSC our data demonstrate clear differences as well as a certain 
degree of phenotypic and genetic overlap between chronic CSC and AMD. 
Chronic CSC is a heterogeneous disease that sometimes shows a clinical overlap with 
other macular diseases such as polypoidal choroidal vasculopathy and AMD. With detailed 
phenotyping based on SD-OCT, FA and ICG angiography, we defined three clinically 
distinctive subgroups, including typical chronic CSC (subgroup 1), slightly atypical chronic 
CSC (subgroup 2), and a third more atypical phenotypic subgroup of chronic CSC patients 
that had evidence of an overlap with other macular diseases (subgroup 3).
Out of an analysis of 19 SNPs at known AMD loci,20-22 one SNP in ARMS2 remained significant 
after correction for multiple testing, and three SNPs at other AMD loci (CFH, TNFRSF10A, 
ADAMTS9) showed a trend towards association with typical chronic CSC (subgroup 
1). The association of these SNPs with chronic CSC was not exactly in concordance with 
the strength of the association previously reported in AMD.20 Indeed, the effect sizes for 
ARMS2 (rs10490924) and CFH (rs1061170 Y402H) are larger in AMD (ORs = 2.76 and 2.25, 
respectively),20, 24 while an inverse and weaker effect was observed in chronic CSC (ORs = 
0.64 and 0.83, respectively). A protective effect was observed for TNFRSF10A (rs13278062) 
in chronic CSC (OR = 0.73), while an opposite and weaker effect was previously detected 
in AMD (OR = 1.15).20 ADAMTS9 (rs6795735) conferred increased risk for both diseases, 
but with a less strong effect in AMD (OR = 1.10) compared to chronic CSC (OR = 1.37).20 
For some of these associations the effect was mainly carried by the males (Supplementary 
Table 2). However, since chronic CSC is predominantly found in males, the low number of 
female patients present in our cohort made the interpretation of sex-specific associations 
unreliable. Genotyping of more female chronic CSC patients can shed light on the occurrence 
of a gender-specific effect, and on potential differences in disease etiology.
 
It is well known that AMD is a multifactorial disease, in which a number of subcellular systems 
and pathways are involved such as the complement system, angiogenesis, lipid metabolism 
and the extracellular matrix.20 Our current findings suggest a partial pathophysiologic 
overlap of chronic CSC with AMD, that could be connected with one or more of these 
associated pathways
 
In both AMD and chronic CSC the reported association with ARMS2 (rs10490924) has the 
strongest effect compared to other disease-associated SNPs (OR = 2.76 for AMD and OR = 
0.64 for chronic CSC).20 Interestingly, the association of ARMS2 (rs10490924) with chronic 
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CSC is protective, whereas the previously reported association with AMD is risk-conferring.20, 
25 The potential protective effect of ARMS2 (rs10490924) in chronic CSC was not reported 
before. However, an association of ARMS2 (rs10490924) with a lower incidence of serous 
retinal detachments has been reported in polypoidal choroidal vasculopathy, a disease that 
shows clinical overlap with chronic CSC.26 Intriguingly, a history of CSC is more prevalent in 
patients with polypoidal choroidal vasculopathy and choroidal hyperpermeability,27 and CSC 
in combination with a type 1 neovascularization or polypoidal choroidal vasculopathy has 
also been described.28, 29 The protective effect of ARMS2 (rs10490924) in both conditions may 
suggest a functional involvement of ARMS2 at the level of the RPE and/or choroid. Although 
the exact role of the ARMS2 protein product is unknown, a recent study demonstrated 
that ARMS2 interacts with components of the extracellular matrix.30 Disturbances in the 
extracellular matrix at the level of the RPE and/or choroid could result in an increased 
susceptibility for cellular detachments, which may indicate a possible link between the 
supposed molecular function of ARMS2 and the clinical phenotype of chronic CSC. 
Our data also suggest involvement of other extracellular matrix molecules. Although these 
results did not remain significant after correction for multiple testing, and would require 
replication in other cohorts for confirmation, it is worthwhile to consider their association. 
ADAMTS9 (rs6795735, P = 0.045) encodes a metalloproteinase that cleaves large aggregated 
proteoglycans, has thrombospondin domains, and is an inhibitor of angiogenesis.31 COL8A1 
(rs13081855, P = 0.074) encodes a collagen type VIII which is expressed in the endothelium 
of blood vessels and is involved in endothelial cell and vascular smooth muscle proliferation 
and migration.32, 33 TNFRSF10A (rs13278062, P = 0.004) is part of the tumor necrosis factor 
alpha receptor superfamily and acts as a death receptor after binding its cytokine ligand 
TNFSF10/TRAIL, known to play an important role in the induction of apoptosis,34 vascular 
smooth muscle proliferation, and regulation of angiogenic responses in the brain after 
stroke.35, 36 These potential associations suggest that the extracellular environment as well as 
angiogenic processes may be involved in chronic CSC. 
We also found a significant association with several SNPs in the CFH gene (rs800292, 
rs1329428, and rs1065489) but the effect sizes were slightly smaller than those recently 
reported in a Japanese CSC cohort (e.g OR = 1.47 for rs1329428 reported in the current cohort 
versus 1.79 reported by Miki et al).17 This may partially be explained by genetic differences 
in the frequency of the minor alleles for the tested SNPs at the CFH locus that exist between 
the Japanese and Western European populations (hapmap.org) (Supplementary Table 1), 
as well as differences in phenotyping. Similar to our observation for ARMS2, CFH SNPs that 
confer risk for chronic CSC were previously found to be protective for AMD, whereas SNPs 
that were found to be protective for chronic CSC were previously found to increase risk for 
AMD.24 The H2 haplotype, previously found to be protective for AMD (OR = 0.54),24 was 
found to increase risk for chronic CSC (OR = 1.33). Conversely, the H3 haplotype that was 
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previously not found to be significantly associated with AMD was found to be protective for 
chronic CSC (OR = 0.54).24 The observation that CFH SNPs have opposite effects in CSC versus 
AMD was also recently reported by Miki et al,17 but the underlying mechanisms that could 
explain these observations are unclear.
The functional implications of the associated CFH SNPs in the present chronic CSC cohort 
and their possible significance for the pathogenesis of chronic CSC are unknown, but there 
appears to be an important role for the CFH protein in the RPE and choroid. CFH is an 
inhibitor of the alternative complement pathway (AP), and choroidal cells play a central 
role in complement AP activity in the eye. C3, an acute phase protein and the central player 
in complement activation, is most highly expressed in the choroid.37, 38 The CFH protein is 
the predominant cell surface-associated complement inhibitor in the RPE-choroid complex, 
where it down-regulates the complement AP activation via inhibition of C3 activity.39
The choroid seems to play a pivotal role in the pathogenesis of CSC, as choroidal thickening, 
congestion, and hyperpermeability seem to be the most pronounced and extensive 
abnormalities in chronic CSC patients.40 Additionally, patients with CSC show an increased 
choroidal blood flow compared to controls during exercise.41 Homozygosity for the CFH 
rs1061170 (Y402H) risk allele was shown to be associated with an increased choroidal blood 
flow and ocular perfusion pressure during exercise using Doppler flowmetry,42 a process that 
may be linked to the CFH-binding partner adrenomedullin via (steroid-)hormone-dependent 
nitric oxide bioactivity in vascular endothelial cells.39, 43, 44 Altered complement AP activity, 
extravasation of complement-related proteins, and deposition of terminal complement 
membrane attack complexes may lead to RPE damage and dysfunction. Damage to the RPE 
cell layer, further destabilized by changes in the extracellular matrix and under stress from 
increasing pressure from the thickened choroid, could eventually result in subretinal fluid 
leakage.43, 44
Three distinct phenotypic subgroups within our analyzed chronic CSC patient population were 
identified based on multimodal imaging, ranging from typical to less typical phenotypes. The 
minor allele frequencies of the SNPs (rs10490924, rs800292, rs1329428, and rs1065489) that 
were significantly associated with typical chronic CSC (subgroup 1), differed from the minor 
allele frequencies observed in the other subgroups. Subgroup 2 differs only slightly from the 
most typical subgroup (subgroup 1), suggesting that considerable genetic overlap exists. In 
fact, the major distinction in the reported phenotypic criteria are bilateral versus unilateral 
occurrence. The atypical subgroup (subgroup 3) differs significantly from subgroup 1 for 
ARMS2 (rs10490924, P = 0.002) and CFH (rs800292, P = 0.002) minor allele frequencies, 
which suggests that subgroup 3 is genetically different from the typical chronic CSC group. 
Based on the phenotypic criteria, subgroup 3 shows overlap with other maculopathies such 
as AMD, highly myopic macular changes and polypoidal choroidal vasculopathy. The minor 
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allele frequencies of these two SNPs in subgroup 3 were even similar to those normally 
observed in AMD, with the same direction of effect seen in AMD opposed to typical chronic 
CSC. Our results demonstrate that detailed phenotyping in chronic CSC patients is important 
to obtain reliable genetic results.
In conclusion, we show that genetic variants in ARMS2 and CFH are associated with chronic 
CSC. Detailed phenotyping and classification of chronic CSC is important to establish 
such genetic associations. Our findings indicate that complement dysregulation in the 
RPE/choroid, and potentially dysregulation of genes involved in extracellular matrix and 
angiogenesis factors, are involved in the pathogenesis of chronic CSC. Further genetic and 
phenotypic analysis of chronic CSC, as well as genotype-phenotype correlation analyses, can 
provide important clues on the genetic background and pathogenesis of chronic CSC, and 
may lead to the identification of possible new preventive and therapeutic targets.
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Supplementary tables
Supplementary Table 1. 
Minor allele frequencies of CFH SNPs in European (CEU) and Japanese (JPT) population.
SNP
MA  
(HapMap-CEU)
MA frequency 
HapMap-CEU
MA frequency 
HapMap-JPT
CFH rs3753394 T 0.279 0.509
CFH rs800292 A 0.217 0.416
CFH rs2284664 T 0.195 0.406
CFH rs1329428 T 0.424 0.473
CFH rs1065489 T 0.161 0.469
CFH = complement factor H; SNP = single nucleotide polymorphism; MA = minor allele  
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Supplementary Table 2. 
Analysis of 19 age-related macular degeneration loci in chronic central serous chorioretinopathy split based on 
gender
SNP (locus)
Alleles 
(Major/
Minor)
Gender
MAF
subgroup 1 
(M=154/
F=43)
MAF
controls 
(M=629/
F=682)
Unadjusted 
Allelic  
P- value
Allelic Odds Ratio  
(95% CI)
rs10490924 
(ARMS2)
G/T M 0.15 0.22 0.006 0.63 (0.45-0.88)
F 0.21 0.25 0.601 0.83 (0.49-1.42)
rs12144939 
(CFH)
G/T M 0.27 0.20 0.006 1.51 (1.13-2.01)
F 0.18 0.21 0.675 0.86 (0.49-1.54)
rs429608 
(C2-CFB)
G/A M 0.17 0.14 0.277 1.22 (0.87-1.71)
F 0.14 0.13 0.615 1.15 (0.61-2.17)
rs2230199 
(C3)
G/C M 0.18 0.16 0.355 1.21 (0.81-1.82)
F 0.21 0.19 0.630 1.16 (0.63-2.17)
rs9621532 
(TIMP3)
A/C M 0.05 0.05 0.883 0.93 (0.51-1.69)
F 0.08 0.05 0.224 1.60 (0.71-3.60)
rs4420638 
(APOE)
A/G M 0.15 0.19 0.181 0.78 (0.55-1.10)
F 0.18 0.16 0.649 1.13 (0.63-2.01)
rs3764261 
(CETP)
G/T M 0.31 0.32 0.681 0.94 (0.72-1.23)
F 0.27 0.32 0.468 0.81 (0.50-1.33)
rs943080 
(VEGFA)
T/C M 0.44 0.48 0.337 0.88 (0.68-1.13)
F 0.44 0.48 0.501 0.85 (0.55-1.33)
rs13278062 
(TNFRSF10A)
T/G M 0.41 0.50 0.005 0.69 (0.54-0.89)
F 0.38 0.46 0.139 0.71 (0.45-1.12)
rs493258 
(LIPC)
C/T M 0.49 0.45 0.140 1.22 (0.95-1.56)
F 0.48 0.47 1.000 1.02 (0.65-1.58)
rs10033900 
(CFI)
C/T M 0.50 0.48 0.443 1.11 (0.86-1.42)
F 0.49 0.48 0.911 1.03 (0.66-1.60)
rs3812111 
(COL10A1)
A/T M 0.35 0.35 1.000 1.00 (0.77-1.30)
F 0.31 0.37 0.295 0.76 (0.48-1.23)
rs13081855 
(COL8A1-FILIP1L)
G/T M 0.12 0.09 0.049 1.49 (1.01-2.21)
F 0.10 0.09 0.844 1.07 (0.50-2.26)
rs3130783 
(IER3-DDR1)
A/G M 0.22 0.20 0.579 1.10 (0.81-1.49)
F 0.12 0.18 0.184 0.62 (0.31-1.21)
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rs8135665 
(SLC16A8)
C/T M 0.21 0.24 0.408 0.84 (0.65-1.18)
F 0.18 0.20 0.675 0.85 (0.48-1.51)
rs334353 
(TGFBR1)
T/G M 0.27 0.25 0.513 1.10 (0.83-1.46)
F 0.21 0.25 0.601 0.84 (0.49-1.43)
rs8017304 
(RAD51B)
A/G M 0.36 0.37 0.742 0.95 (0.73-1.23)
F 0.35 0.38 0.563 0.85 (0.54-1.35)
rs6795735 
(ADAMTS9)
C/T M 0.47 0.41 0.052 1.29 (1.00-1.66)
F 0.44 0.41 0.570 1.14 (0.73-1.77)
rs9542236
(B3GALTL)
T/C M 0.43 0.44 0.748 0.96 (0.74-1.23)
F 0.48 0.44 0.498 1.18 (0.76-1.83)
SNP = single nucleotide polymorphism; M = male; F= female; MAF = minor allele frequency; CI = 
confidence interval
For the analysis displayed in this table two sided P-values < 0.0026 were considered to be significant

Myrte B. Breukink*, Rosa L. Schellevis*, Camiel J.F. Boon, Sascha Fauser, Carel B. Hoyng, 
Anneke I. den Hollander & Eiko K. de Jong
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Purpose: 
Chronic central serous chorioretinopathy (CSC) has recently been associated to variants in 
the complement factor H gene. To further investigate the role of the complement system 
in chronic CSC, the genomic copy number variations in the complement component 4 (C4) 
gene were studied.
Methods: 
C4A and C4B copy numbers were analyzed in 197 chronic CSC patients and 303 healthy 
controls using a Taqman® copy number determination assay. Copy numbers of C4A, C4B 
and the total C4 load were compared between cases and controls, using a Fisher Exact test. 
For this analysis Bonferroni correction was performed for three tests, and p-values <0.017 
were considered to be significant. A logistic regression model was constructed to calculate 
the odds ratios (OR) of each of the C4B copy numbers, using two copies as a reference. For 
this model p-values <0.05 were considered to be significant.
Results: 
C4B genomic copy numbers differed significantly between chronic CSC patients and healthy 
controls (p=0.0018). Absence of C4B significantly conferred risk of chronic CSC (p=0.039, 
OR=2.61 [95% confidence interval (CI)=1.05–6.52]), whereas three copies of C4B significantly 
decreased the risk of chronic CSC (p=0.014, OR=0.45 [95%CI=0.23–0.85]). The C4A genomic 
copy numbers and total C4 load did not significantly differ between cases and controls. 
Conclusions:
This study shows that copy numbers of C4B are significantly associated with chronic CSC. 
Carrying no copies of C4B significantly increases the risk of chronic CSC, whereas carrying 
three C4B copies is protective. These findings reinforce the hypothesis of a possible 
involvement of the complement system in the pathogenesis of chronic CSC. 
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Introduction 
Chronic central serous chorioretinopathy (CSC) is characterized by fluid accumulation 
under the neuroretina. It has been postulated that this serous fluid derives from the 
choroid, and that it leaks through a dysfunctional retinal pigment epithelium (RPE) causing 
a detachment of the neuroretina.1-4 Classically, chronic CSC patients are relatively young 
(middle-aged) men who are still professionally active.5 Besides male gender, also the use 
of corticosteroids, type A personality and stress have been associated with chronic CSC.4-6 
Although the exact pathophysiological mechanism of the disease remains unknown, we and 
others have previously suggested involvement of the complement system, and in particular 
the complement factor H (CFH) gene in chronic CSC.7, 8 Interestingly, CFH variants that confer 
increased risk in chronic CSC have previously been described to be protective in age-related 
macular degeneration (AMD), and vice versa.8-10
The complement system consists of three major pathways; the classical, the lectin, and 
the alternative pathway.11 CFH is involved in the alternative pathway and can influence 
C3b production by blocking one of the two C3-convertases (C3bBb). The classical and 
lectin pathways also play an important role in C3b production mediated by the other C3-
convertase (C4b2a), of which the complement component 4 (C4) protein is a key factor.12 
Copy number variations of the C4 gene have been associated with several eye diseases and 
autoimmune disorders (e.g. Vogt- Koyanagi-Harada and Beçhet’s disease).13-15 In addition, 
Banlaki et al. found that the genomic copy number of C4B is associated with cortisol release 
after adrenocorticotropic hormone (ACTH) stimulation.16 This is of particular interest 
considering that stress, which appears to be associated with chronic CSC,4 has a strong 
influence on the hypothalamic-pituitary-adrenal (HPA)-axis and increases ACTH release.17 
Because of its role in the complement system, and its association with the HPA-axis, we 
hypothesized that copy number variation in the C4 gene may be associated with chronic 
CSC. In this study we assessed the copy number variations of the C4 gene in a chronic CSC 
cohort. 
Chapter 2.2
82
Materials and Methods
Subjects
In this study, 197 patients diagnosed with chronic CSC who visited the outpatient clinic of 
the department of Ophthalmology at the Radboud University Medical Center, Nijmegen, the 
Netherlands were included (Table 1). The diagnosis chronic CSC was based on an extensive 
ophthalmological examination including fundoscopy, spectral-domain optical coherence 
tomography, fluorescein angiography and indocyanine green angiography. The definition 
of typical chronic CSC used in this study was based on the previously published subgroups 
by de Jong et al.,8 and patients in this study were phenotypes by an experienced retina 
specialist (CJFB) (Figure 1). Additionally, a total of 303 control subjects were recruited from 
the blood bank of the Radboud University Medical Center, Nijmegen, the Netherlands (n = 
154), and the European Genetic Database (EUGENDA, www.eugenda.org) (n = 149) (Table 
1). For this last group fundus photographs were graded to rule out any ophthalmological 
abnormalities at the moment of inclusion. Informed consent for the use of DNA for genetic 
studies was obtained from all subjects. This study followed the guidelines of the Declaration 
of Helsinki and was approved by the local ethics committee.
Figure 1. 
Example of fluorescein angiography (FA) of a right eye (RE): A, and a left eye (LE): C, indocyanine green (ICG) 
angiography of a RE: B, and a LE: D and spectral-domain optical coherence tomography (SD-OCT) of a RE: E, and a 
LE: F imaging of the phenotypic characteristics of the chronic central serous chorioretinopathy (CSC) cohort used 
for this study. (A-F) The RE and LE of a patient demonstrate diffuse hyperfluorescent areas of leakage on FA and 
ICG angiography (A-D) and subretinal fluid beneath the fovea (E), illustrative for typical chronic CSC. 
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Table 1. Demographics of the study population
cCSC 
patients
Controls p-value
No. of subjects 197 303 NA
Sex (male/female) 154/43 226/77 0.392
Mean age ±SD (years) 53 (±10) 53 (±11) 0.755
Age range (years) 29-74 29-77 NA
cCSC; chronic central serous chorioretinopathy, 
SD; standard deviation
Copy number determination
DNA was isolated from peripheral blood using standard procedures. C4A and C4B copy 
numbers were determined by real-time PCR using Taqman® genotyping assays (Applied 
Biosystems, Thermo Fisher Scientific, Waltham, USA). The FAM-labeled C4A (Hs07226349_
cn) or C4B (Hs07226350_cn) Taqman® copy number assay was combined together with the 
VIC-labeled Ribonuclease P (RNaseP) reference assay (Catalog nr. 4403326), and Taqman 
genotyping mastermix (Catalog nr. 4381656). All samples were tested in duplicate for C4A 
and C4B on 384-wells plates using 10 ng of DNA in a total reaction volume of 10 μl. 
Samples with known copy numbers for either C4A (0-4) or C4B (0-3) were kindly provided 
by Dr. C. Yung Yu.18 These samples were included as a reference on each plate to facilitate 
accurate copy number determination, using the method described previously.18 In each 
run the amplification efficiencies of the C4A/C4B and RNaseP probes were calculated using 
a serial dilution (50 ng-1.56 ng) of a sample with two C4A and C4B copies. The primer 
efficiencies of the probes were compared, and deemed similar if they differed <2%, this was 
the case in all runs. Therefore, the efficiencies were not incorporated into the calculations 
of the copy numbers. PCR was performed with a 7900HT thermocycler (Applied Biosystems, 
Thermo Fisher Scientific, Waltham, USA) using the following program: 2 min at 50°C, 10 
min at 95°C, and 40 cycles of 15 sec at 95°C and 60 sec at 60°C. Data was analyzed with 
the Copycaller software (V2.0) (Applied Biosystems, Thermo Fisher Scientific, Waltham, 
USA). Copy numbers determined by the Copycaller software were corrected using the trend 
line based on the reference samples, as described before.18 If the results were inconsistent 
between the Copycaller output and the values corrected with the trend line, samples were 
retested on a new plate in triplicate.
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Statistics
The comparison of C4A, C4B and total C4 copy number distribution between chronic CSC 
patients and controls was performed by means of a Fisher Exact test using SPSS Statistics 
(V20)(IBM Corp., Armonk, USA). Bonferroni correction for multiple testing was performed 
for three tests and p-values < 0.017 were considered to be statistically significant. A logistic 
regression model was constructed to determine the odds ratios for the various copy numbers 
of C4B. According to previously published studies, two genomic copy numbers of C4B are 
considered to be most common in the healthy population.15, 19 We were able to confirm this 
in our cohort, and therefore this copy number was set as reference. In this model, p-values 
<0.05 were considered to be significant. Graphs were generated using Graphpad Prism (V5) 
(Graphpad Software, San Diego, USA).
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Results
The copy numbers of C4A and C4B were successfully determined in 197 chronic CSC cases and 
303 controls. No significant difference was observed between cases and controls for the C4A 
genomic copy number (range: 0-6, p=0.649, Figure 2A). The C4B distribution was significantly 
different between chronic CSC patients and controls (range: 0-4, p=0.0018, Figure 2B). Overall, 
cases carried lower copy numbers of C4B than the control population. The total C4 genomic copy 
number was not different in cases compared to controls (p=0.148, Figure 2C). Age and gender were 
not associated with either C4A, C4B, or total C4 genomic copy number (Table 2, data for C4A and 
total C4 not shown). 
To assess the effect size of the different copy numbers of C4B on development of chronic 
CSC, a logistic regression was performed (Table 2). The logistic regression model based on the 
distribution of C4B between cases and controls was significant (p=0.0035, Table 2). Carrying 
no copies of C4B conferred increased risk of chronic CSC (p=0.039, odds ratio (OR)=2.61, 95% 
CI [1.05-6.52]). A similar trend was observed for carriers of one copy of C4B, but the results 
were not significant (p=0.080, OR=1.47, 95% CI [0.96-2.26]). Carrying three C4B copies was 
associated with a significantly decreased risk of chronic CSC (p=0.014, OR=0.45, 95% CI [0.24-
0.85]), whereas no significant association with chronic CSC was observed in individuals carrying 
four copies of C4B (p=0.81). 
Figure 2. 
Distribution of the genomic copy numbers of C4A (A), C4B (B), and totalC4 (C) in patients with chronic central 
sereous chorioretinopathy (cCSC) and controls. Displayed p-values were generated with a Fisher Exact test. To 
correct for multiple testing, p-values <0.017 were considered to be significant.
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Table 2. Logistic regression model for C4B load
Overall significance model   P=0.0035
C4B copy nr. cCSC 
patients 
(n)
Controls 
(n)
p-value OR 95% CI
Age 197 303 0.605 NA NA
Gender 197 303 0.346 NA NA
0 13 8 0.039 2.613 1.048-6.518
1 58 63 0.080 1.469 0.956-2.259
2 110 179 Ref. 1 NA
3 14 49 0.014 0.445 0.234-0.849
4 2 4 0.808 0.809 0.145-4.503
cCSC; chronic central serous chorioretinopathy 
OR; Odds Ratio
CI; Confidence Interval
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Discussion
Our study results demonstrate that chronic CSC patients have a significantly different C4B 
load as compared to healthy controls (p=0.0018). Carrying no copies of C4B was associated 
with an increased risk of chronic CSC (OR=2.61, 95% CI [1.05-6.52]), whereas carrying three 
C4B copies was associated with a decreased risk of chronic CSC (OR=0.45, 95% CI [0.23-
0.85]). No association with chronic CSC was observed in individuals carrying four C4B copies, 
which is likely due to the limited sample size of this group (cases, n=4, controls, n=2). No 
significant differences were observed between cases and controls for C4A and total C4 load. 
The C4 gene lies within the RP-C4-CYP21-TNX (RCCX) locus located in the major 
histocompatability complex (MHC) region III on chromosome 6 of the human genome.19 The 
MHC region contains an elevated level of genomic copy number variations that are presumably 
present to increase immunological diversity.20 Duplications and deletions in the region have 
led to the formation of haplotypes containing variable copies of the RCCX locus in the human 
population (Figure 3B).20-22 Haplotypes containing two or more duplications of the RCCX locus 
show extensive variability in their gene content, generally with complete duplications of the 
C4 gene (Figure 3B).21, 23 The C4 gene encodes for the C4 protein, of which two variants have 
been described (C4A/C4B), differing in only four amino acids encoded by exon 26 (Figure 3A).24
Figure 3. 
A schematic illustration of the RCCX-locus. A, a display of the two variants of the C4 gene, differing in 4 amino acids 
in exon 26. B, an example of the structure of the RCCX-locus with a single copy (upper panel) and two copies (lower 
panel) of the C4 gene. In case of duplication, a complete C4A or C4B gene and the CYP21 gene are duplicated while 
the RP and TNX genes are only partially duplicated. The dotted lines indicate the approximate site were during 
recombination the duplication has occurred in the past. (Figure based on Banlaki et al. 2013)22
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Copy number variations of either C4A or C4B, have been associated with several systemic 
diseases with ocular involvement, such as Vogt-Koyanagi-Harada disease, Behçet’s disease, 
and systemic lupus erythematosus (SLE).13-15 Hou et al. showed that a lower copy number 
of C4A and C4B increased the risk of Vogt-Koyanagi-Harada, an autoimmune disorder 
characterized by bilateral granulomatous panuveitis.13 The same group also demonstrated 
that higher copy numbers of C4A conferred risk of Behcet’s disease, an auto-inflammatory 
disease, which presents with acute anterior uveitis.14 Several studies have shown an 
association between low copy numbers of C4 and an increased risk for SLE, an auto-immune 
disease that is typically mediated by immune complexes.15, 25, 26 In the past, CSC has been 
described in SLE patients,27, 28 but it remains unclear whether this is a primary manifestation 
of SLE, or whether it is a consequence of corticosteroid treatment for SLE.29, 30 Several 
studies have reported a positive linear correlation between serum C4 and C4 genomic copy 
number,31-33 suggesting that the lower number of C4B copies in chronic CSC patients leads to 
lower systemic C4B levels. This may indicate that an overall lower activity of the complement 
system might be present in chronic CSC patients. 
Recently, low copy numbers of C4B have been described to be associated with hyperreactivity 
of the HPA axis.16 Banlaki et al. showed that in patients with adrenal incidentaloma and low 
(<2 copies) C4B genomic copy number, baseline ACTH was significantly reduced compared 
to high (≥2 copies) genomic copy number of C4B.16 Moreover, a significantly higher cortisol 
response was observed after ACTH stimulation in the patients with low C4B genomic copy 
number.16 
These results are of interest in the context of chronic CSC because of the described clinical 
associations with stress and the use of corticosteroids that both exert physiological effects 
at the level of the HPA axis.17 Various relatively small studies have studied cortisol levels 
in chronic CSC patients. Although 24h urine samples showed elevated cortisol levels in 
chronic CSC patients in certain studies,34, 35 these results were not observed in single serum 
measurements during set times in other studies.36, 37 These discrepancies could be explained 
by variable cortisol fluctuations between individuals during the day, and therefore changes 
in endogenous cortisol levels cannot be ruled out as a hallmark of chronic CSC. It is possible 
that patients with chronic CSC generally have normal cortisol levels, but respond differently 
to stimulation of the HPA axis. Stress, which also appears to be associated with chronic CSC,2, 
38 stimulates the HPA axis and could lead to temporarily elevated cortisol levels in patients 
as compared to healthy individuals. How high levels of cortisol can lead to subretinal fluid 
accumulation is currently unknown. A study in rats suggested that the disease mechanism 
could be mediated by binding of corticosteroids to the mineralocorticoid receptor.39 In this 
study, activation of the mineralocorticoid receptor caused vascular effects similar to those 
observed in chronic CSC,39 but the underlying pathways still remain to be elucidated.
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The mechanism through which low copy numbers of C4B may lead to hyperresponsiveness 
of the HPA axis is unclear. It has been hypothesized that it is not the C4B gene, but rather 
the neighboring CYP21A2 gene that mediates this effect.16 The CYP21A2 gene encodes the 
enzyme 21-hydroxylase, which plays an important role in the steroid metabolism pathway by 
converting progesterone and 17-alpha-hydroxyprogesterone to 11-deoxycorticosterone and 
11-deoxycortisol, respectively. Because of the genomic structure of the RCCX locus, variation 
in the CYP21A2 gene is in high linkage disequilibrium with variation in the neighboring C4 
gene (C4A or C4B, respectively).16 Therefore, further exploration of the precise structure and 
specific variations present in the RCCX locus may reveal new insights into the pathogenesis 
of chronic CSC.
The current study and previous studies identified an association between complement genes 
and chronic CSC,7, 8 suggesting that the complement system may be dysregulated in chronic 
CSC. Taken together, these findings may indicate that the immune system, influenced by 
environmental factors, such as stress, could play a pivotal role in the pathophysiology of 
chronic CSC.  Further studies are necessary to determine the physiological effects of genetic 
variation at the C4 gene and the RCCX locus in chronic CSC. 
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Chronic central serous chorioreti nopathy: 
follow-up and vision-related quality of life 
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Purpose:
To describe the clinical findings and long-term outcome of patients with chronic central 
serous chorioretinopathy (CSC). 
Methods:
Retrospective case series in 52 eyes of 36 patients with a follow-up period of at least one 
year.  Extensive ophthalmic examination, and a validated questionnaire concerning vision-
related quality of life (NEI-VFQ-39) were analyzed.
Results:
The mean visual acuity (VA) showed a significant decline over time of 0.16 LogMAR 
(range:-0.22-1.30 LogMAR, P =0.009) after a mean follow-up period of 10.6 years. Also, 
patients reported a lower vision-related quality of life based on the NEI-VFQ-39 for almost 
all categories compared to healthy controls. Macular atrophy was diagnosed more often 
on optical coherence tomography (OCT)  as compared to other diagnostic entities. Retinal 
pigment epithelium (RPE) detachments in the macula were documented on OCT in 56% 
of the patients. We measured a significant thinning of the foveal thickness over time as 
compared to non affected fellow eyes (P=0.002). On long-term follow-up, 13 eyes (37%) 
showed an increase of the number of hot spots on fluorescein angiography.
Conclusions:
This study indicates that chronic CSC is a progressive disease in many patients, causing a 
progressive decline in VA, accompanied by a lower reported vision-related quality of life. In 
deciding whether or not to treat, the progressive nature of chronic CSC should be taken into 
account in this relatively young and often still professionally active patient group. 
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Introduction
Central serous chorioretinopathy (CSC) is characterized by a fluid accumulation between the 
neuroretina and the retinal pigment epithelium (RPE).1,2 It often affects the macula, leading 
to central vision loss, scotoma, metamorphopsia and/or micropsia.1,2 The accumulation of 
subretinal fluid (SRF) results from leakage through a dysfunctional RPE with a disrupted outer 
blood-retinal barrier. Dilation, congestion and hyperpermeability of the choriocapillaris and 
larger choroidal vessels appear to play a pivotal role in the pathogenesis of CSC.3,4,5 
The etiology of CSC is unknown. Risk factors for CSC include the use of corticosteroids, 
Cushing’s disease, pregnancy, and male gender.2,6 Recent studies have also found genetic 
associations.7,8
There are two main subtypes of CSC. Acute CSC is characterized by sudden vision loss due 
to fluid leakage through a focal pinpoint leak in the RPE, often in association with a small 
RPE detachment.1,2 In most acute CSC patients the SRF resolves spontaneously within 2-3 
months.1 The visual acuity (VA) in these patients generally returns to (near-)normal levels.1 
In the other main subtype, chronic CSC, patients have more widespread atrophic RPE 
abnormalities, as well as more extensive choroidal changes on fluorescein angiography 
(FA) and indocyanine green angiography (ICGA).1,2 In contrast to acute CSC, most patients 
with chronic CSC have a more pronounced central vision loss, and often do not show a 
spontaneous resolution of SRF.2
Although chronic CSC is one of the most common forms of macular degeneration,1 relatively 
little is known about the long-term visual consequences in these patients. The aim of this 
study was evaluate the clinical outcome of patients with chronic CSC, and assess the vision-
related quality of life to provide a more accurate prognosis to patients. 
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Materials and Methods 
Participants
Patients with chronic CSC and a follow-up time of at least one year were included in 
this retrospective observational study. Subjects were recruited from the Department of 
Ophthalmology of the Radboud University Medical Center (Nijmegen, the Netherlands), 
and at the Oxford Eye Hospital (Oxford, United Kingdom). The diagnosis chronic CSC was 
defined as the presence of SRF longer than 3 months in at least 1 eye on optical coherence 
tomography (OCT), RPE window defects on FA with at least 1 “hot spot”, defined as 
indistinct hyperfluorescent area of leakage, and/or diffuse leakage in the affected eye(s), 
and corresponding hyperfluorescent zones on ICGA when available. Patients with evidence 
of other retinal diagnoses at the first visit, were excluded. This study adhered to the tenets 
of the Declaration of Helsinki, and approval for the study was obtained from the local 
institutional review board in Oxford, United Kingdom and waived by the local institutional 
board in Nijmegen, The Netherlands. 
The following parameters, when available, were collected from the medical records: visual 
acuity (VA), disease activity, duration of visual symptoms, the (prior) use of corticosteroids, 
number of treatments, colour fundus photography, OCT, FA, and ICGA. Only visits for which 
VA and information about the disease activity, defined as subfoveal fluid on OCT or - when 
OCT was not available - as stated by the ophthalmologist in the medical records, were 
included.
Additionally, patients were asked to complete a validated questionnaire (Visual Function 
Questionnaire (VFQ-39)).9 For all Dutch patients a validated Dutch translation of this 
questionnaire was used.10 
Clinical evaluation
Submacular RPE detachments, subfoveal SRF, change in submacular SRF accumulation 
and retinal atrophy were scored on OCT. The number of hot spots, defined as indistinct 
hyperfluorescent areas of leakage, seen on FA and ICGA were registered. Evidence of 
atrophy was assessed on FA and colour fundus photography. 
Central foveal thickness (CFT), defined as the distance between the outer part of the internal 
limiting membrane and the outer part of the external limiting membrane at the central fovea, 
of the first and the last available OCT scans was measured by two independent graders. Only 
patients who had follow-up imaging with spectral domain OCT (OCT, Spectralis™, Heidelberg 
Engineering, Heidelberg, Germany) were included in CFT measurements. The mean of the 
measurements of both graders was used for further analysis, after no significant difference 
between the graders was confirmed by a student’s independent t-test (p-value > 0.05). In 
selected patients, the non-affected fellow eyes, defined as eyes in which no central lesions 
suspect for chronic CSC were present, were included. The difference in CFT over time was 
compared between the affected and non-affected eyes using a student’s independent t-test. 
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Visual acuity
The VA of all first visits was compared to the VA of all last known visits using an independent 
samples t-test. For the VA of the last visits, only patients with inactive disease, defined 
as absence of SRF on OCT, were included. Additionally, a Pearson correlation test was 
performed to determine if the number of episodes of active disease or the number of 
treatments affected the overall change in VA when comparing the first visit to the last visit. 
Vision-related quality of life 
The scores of every individual subcategory of the VFQ-39 questionnaire were compared 
to the reference group, which was used for the assessment in the original validation of 
the VFQ-39,9 using the independent samples t-test. The original validation of the VFQ-39 
analysed the data of the reference group as being normally distributed, therefore this article 
also chose this approach. A Pearson correlation test was performed to analyse if VA at the 
end of follow-up was associated with the score on the VFQ-39 questionnaire.
A p-value < 0.05 was considered statistically significant for all tests. 
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Results 
Demographics
The demographic information is presented in Table 1. The mean number of episodes of 
active disease per eye was 1.7 (range 0-6). Each episode was defined as a presence of 
documented SRF followed by a period of OCT-proven absence of SRF.
Table 1. Demographics of the study population
Parameters Nijmegen Oxford Total
Patients 
(affected eyes)
22 (33) 14 (19) 36 (52)
Sex 
(male/female)
13/9 8/6 21/15
Mean age 
(years)
56.9 
(range 42 - 72 years)
56.3 
(range 39 - 81 years)
56.7 
(range 39 - 81 years)
Bilateral disease 
(patients)
11 (50%) 5 (36%) 16 (44%)
Reported steroid use 
(patients)
6 (27%) 4 (29%) 10 (28%)
Mean follow-up 
(years)
9.8 
(range 1 - 24 years)
3.8 
(range 1 - 11 years)
7.4 
(range 1 - 24 years)
Mean number of  
treatments per eye
3.2 (range 0 - 8) 0.1 (range 0 – 1) 2.1 (range 0 – 8)
Clinical course
When comparing the VA of the first and last visit, excluding the 21 eyes (40%) with persistent 
subfoveal SRF at the final visit, a mean decline of 0.16 LogMAR (range -0.22-1.30, p = 0.009) 
was found after a mean follow-up period of 10.6 years (range 1.5-24). In the 21 eyes (40%) 
with persistent subfoveal SRF at the final visit, a mean decline of 0.22 LogMAR (range -0.35-
0.66 , p = 0.003) with a mean follow-up period of 4.5 years (range 1-11 years) was seen. In 
11 of these 21 eyes (52%) the SRF was continuously present during follow-up. The number 
of episodes of active disease, and number of treatments did not have a significant effect on 
the overall change of VA.
Optical coherence tomography
An overview of the findings on OCT is displayed in Table 2 and Figure 1A-C. In the 13 eyes with 
a decrease of SRF, 8 eyes (62%) had received treatment. The 7 eyes with an increase of SRF, 
had not received treatment. In the eyes showing fluctuating SRF accumulation, 18 eyes (82%) 
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had received treatment. The following treatments were performed: 41 micropulse therapy 
(MP), 23 photodynamic therapy (PDT), 1 Argon laser treatment, 1 Retaane® (anecortave 
acetate) treatment and 9 anti-vascular endothelial growth factor (VEGF) treatments. 
In 14 eyes (24%) SRF was continuously present on OCT until the last follow-up. 
In this group this was also the case in 5 eyes (36%) despite receiving treatment 
(including MP (52%), PDT (29%), anti-VEGF (14%), and argon laser treatment (5%)). 
Posterior cystoid retinal degeneration as described previously by Piccolino et al was seen in 
7 eyes of 4 patients (8%) (Figure 1 F-G).11 In 3 of these 7 eyes a lesion which was suspected 
to be a choroidal neovascularisation developed during follow-up. In 3 of 7 eyes the 
posterior cystoid retinal degeneration disappeared completely during follow-up, in 2 eyes 
this resolution occurred spontaneously and in 1 eye after PDT (Figure 1H,I). The onset of 
posterior cystoid retinal degeneration was respectively 2, 10 and 16 years after the reported 
start of the chronic CSC in 3 of the 4 patients in whom this was recorded (Figure 1D-G). 
In 21 eyes (41%) with SRF and 6 eyes without SRF a spectral domain OCT was available for 
evaluation of CFT on follow-up. The CFT showed a mean decrease of 15.1 μm (standard 
deviation: 17.7 μm) in the eyes with SRF, whereas no significant change was seen in the eyes 
without SRF. This difference in CFT was statistically significant (p = 0.002).
Fluorescein angiography, indocyanine green angiography and colour fundus photography 
Characteristics of hot spots of leakage on FA on follow-up are shown in Table 2. Of the 9 
eyes that showed a decrease in the number of hot spots during follow-up, in 7 eyes the 
original hot spots disappeared after treatment, whereas the number of hot spots decreased 
spontaneously in the remaining 2 eyes. Overall the mean number of hot spots at the first 
visit was 1.0 (range 0-4) compared to 1.7 (range 0-7) at the last visit (Figure 2A,B). An 
increase of atrophic RPE changes on FA was seen in 14 eyes (41%) during a mean follow-up 
of 9.7 years (range 2-24 years).
A classic “gravitational tract” was seen in 8 eyes (15%), and was already present at the 
first visit in 5 eyes (Figure 2C-D). The other 3 eyes developed the gravitational tract after 
approximately 2, 4 and 8 years, respectively. 
When ICGA was available (in 28 (54%) eyes), we were able to compare hot spots and 
hyperfluorescent areas on ICGA in 27 eyes (96%) with characteristics on FA that was 
performed on the same date. The overall hyperfluorescent area was larger on ICGA in 8 (30%) 
eyes, in 11 (41%) eyes the hyperfluorescent area had a comparable size, in 1 (4%) eye the 
hyperfluorescent area was smaller on ICGA, and in 8 eyes (30%) no clear hyperfluorescence 
was seen on ICGA to be compared (Figure 2E,F). In 11 eyes (39%) ICGA showed multiple 
small punctate hyperfluorescent spots, without clear evidence of a leaking hot spot focus 
(Figure 2G-H).
Colour fundus photography was available at baseline in 42 eyes (81%), and mild RPE atrophy 
in the macula was seen in 18 eyes (43%). Follow-up images were available for 31 (74%) eyes 
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with a mean follow-up of 45 months (range 1.5-87 months), and evidence of development 
and/or progression of RPE atrophy was present in 14 (45%) eyes.
Table 2. An overview of the findings on optical coherence tomography and fluorescein angiography
Optical coherence tomography Fluorescein angiography
No. RPE detachments                    
   0  = 23 eyes (44%)
   ≥ 1 = 29 eyes (56%)
Subfoveal SRF   
   yes = 40 eyes (77%)
   no = 12 eyes (23%)
Outer photoreceptor layer atrophy           
   yes = 24 eyes (49%)
   no = 28 eyes (51%)
Change of height of SRF accumulation (N=49) 
   decrease = 13 (27%)
   increase = 7 (14%)
   no change = 3 (6%)
   fluctuation = 26 (53%)
No. hot spots at first visit (N=45)
   1 =13 eyes (29%)  
   2 = 7 eyes (16%)
   ≥ 3 = 3eyes (7%)    
   diffuse leakage = 7 eyes (16%)  
   no clear leakage = 15 eyes (33%)
Change in no. of hot spots (N=35)      
   increase = 13 eyes 37%)
   decrease = 9 eyes (26%)
   no change = 2 eyes (6%)
   new hot spot*1,2  = 2 eyes (6%) 
   no clear hot spot*3 = 9 eyes (26%)
RPE; retinal pigment epithelium, SRF; subretinal fluid 
1 Hot spot defined as indistinct hyperfluorescent area of leakage  
2 Disappearance of the original hot spot and appearance of a new hot spot 
3 No distinct hot spot at first visit
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Figure 1. 
Imaging of two chronic central serous chorioretinopathy (CSC) patients demonstrating characteristic findings in 
long-standing chronic CSC on optical coherence tomography (OCT) and fluorescein angiography (FA). Images A-C  
illustrate a fluctuating subretinal fluid (SRF) accumulation on OCT in the right eye of a patient, and typical subfoveal 
retinal pigment epithelium detachments. The time between scan A and B is 1 month, in which a clear decrease 
of SRF occurs, and between scan B and C another 2 weeks elapsed, showing a spontaneous increase of SRF. No 
therapeutic interventions had been performed between these visits. Images D-G represent the FA and OCT of 
the right and left eye of a chronic CSC patient suffering from bilateral extensive chronic CSC. On FA a large area 
of hyperfluorescence can be seen indicating advanced disease (D-E). OCT shows not only serous SRF in the right 
eye, but also bilateral central posterior cystoid degeneration, indicative of long-standing disease (F-G). This central 
posterior cystoid degeneration resolved spontaneously after a period of approximately 6 months (H-I).
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Figure 2. 
Abnormalities on fluorescein angiography (FA), indocyanine green (ICG) angiography and fundus autofluorescence 
(FAF) in chronic central serous chorioretinopathy (chronic CSC). A-B, The appearance of ‘new’ hot spots, 
highlighted by two arrows, on FA during 4 years of follow-up. On image C and D the development of a gravitational 
tract was observed originating from the initial leakage area after 6 years of follow-up. E-F, Example of differences 
seen in the extent of the hyperfluorescence areas between FA (E) and ICGA (F). The area depicted by the arrow 
shows clear hyperfluorescence on ICGA, but is not evident on the mid-phase FA. G-H, ICGA (H) shows small 
punctiform hyperfluorescent areas in addition to diffuse hyperfluorescence. The corresponding FA (G) of the same 
patient shows an area of hyperfluorescence that is significantly smaller than the area seen on ICGA.
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Quality of life
Patients of this chronic CSC cohort scored significantly less on the VFQ-39 questionnaire as 
compared to the reference group on 8 of the 12 subcategories (Table 3).
Patients with a lower last recorded VA scored significantly lower on the following categories 
of the VFQ-39: general vision, near activities, distance activities, social functioning, mental 
health, role difficulties, dependency and driving (Table 3).
Table 3.  VFQ-39 questionnaire scores of the study population and controls, and Pearson correlation with last 
visual acuity
Chronic CSC patients Controls Pearson correlation
Last visual acuity
VFQ-39 item Subjects Mean SD Subjects Mean SD Pearson 
correlation
P-value
General Health 36 65 17 122 75 17 -0.146 0.396
General Vision 36 62 18 122 81 13 -0.360 0.031
Ocular Pain 36 85 17 122 90 15 -0.044 0.800
Near Activities 36 72 23 122 93 10 -0.435 0.008
Distance Activities 36 79 20 122 95 8 -0.475 0.003
Social Functioning 36 90 17 122 99 3 -0.416 0.012
Mental Health 36 72 22 122 91 11 -0.509 0.002
Role difficulties 36 74 22 122 96 6 -0.628 <0.001
Dependency 36 91 18 122 99 5 -0.408 0.013
Driving 31 70 29 122 89 14 -0.584 0.001
Colour Vision 36 94 19 122 98 8 -0.109 0.527
Peripheral Vision 36 80 26 122 97 10 -0.178 0.299
CSC = central serous chorioretinopathy; SD = Standard Deviation ; VFQ = Visual Function 
Questionnaire. 
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Discussion
This study shows that chronic CSC is a progressive chorioretinopathy with a significant 
impact on VA and vision-related quality of life. 
Patients in this study cohort generally showed a progressive decline in VA as well as a 
gradual decrease in CFT on OCT. Wang et al previously demonstrated in the pre-OCT era that 
persistence of SRF for more than 4 months can result in foveal atrophy.12 This permanent 
damage to photoreceptors and RPE can explain the often persistent visual complaints 
even after resolution of SRF. The progressive nature of chronic CSC is demonstrated on FA, 
characterized by an increase of hyperfluorescent atrophic RPE changes and an increased 
number of hot spots during follow-up.
An interesting finding in our study were the small punctate hyperfluorescent spots on ICGA 
(Figure 2H). Similar lesions have been described previously by Tsujikawa and co-workers.13 
This group described small clusters, which were located within the center of the focal 
hyperfluorescent area on ICGA and were therefore thought to be very small leakage spots. In 
our study, no clear abnormalities corresponding to these lesions on ICGA could be identified 
on OCT. However, Lehmann et al identified similar hyperfluorescent lesions on ICGA that 
correlated with vascular dilations on en face enhanced-depth OCT .14 In contrast to the 
lesion seen in this study, the lesions were always located under an area of SRF accumulation 
and/or RPE detachment. Additionally, a clinical and pathogenetic overlap between CSC and 
polypoidal choroidal vasculopathy may exist. Punctate hyperfluorescent spots on ICGA have 
also been identified in polypoidal choroidal vasculopathy, in which these lesions correlated 
with a thicker choroid.15 We therefore hypothesize that these lesions may be focal vascular 
dilations in the choriocapillaris that fill on ICGA.
The blood flow in the choroid is among the highest in the human body, and the macular 
choriocapillaris is thicker, has a distinct lobular architecture and higher blood flow as compared 
to the peripheral choroid.16,17 These anatomical and functional choroidal differences, as well 
as anatomical differences between central and peripheral RPE and Bruch’s membrane,18,19 
probably explain why CSC principally affects the posterior pole. However, it is currently unclear 
why some individuals develop active CSC in the case of a dysfunctional thickened choroid 
(“pachychoroid”) unlike others,20 and why in the same individual the disease can remain 
subclinical in the fellow eye despite the presence of similar choroidal abnormalities.5 It is likely 
that additional factors play a role in determining an individual’s likelihood to develop CSC, for 
instance patient-specific differences in genetic background,7,8 local differences in RPE outer 
blood-retinal function, and possibly the interphotoreceptor matrix.21
Our data show a marked decrease in reported vision-related quality of life in this chronic 
CSC cohort when compared to healthy individuals. Nevertheless, the impact of chronic 
CSC on vision-related quality of life seems to be less pronounced than in other common 
maculopathies such as neovascular age-related macula degeneration and diabetic 
retinopathy.22,23 In our chronic CSC cohort, social functioning and dependency seemed 
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to be most affected. Differences between the vision-related quality of life impact of the 
different diseases may not only be due to the variable effects on macular anatomy and 
visual function, but may also be partly explained by the difference in the mean age of the 
different study populations during which the VFQ-39 questionnaire was taken (present study 
55 years, neovascular age-related macular degeneration 77 years, diabetic retinopathy 68 
years, and diabetic macular oedema 62 years).23 Also, the mean years since diagnosis was far 
shorter in the neovascular age-related macular degeneration studies compared to our study 
(respectively 0.6 and 7.4 years). A possible explanation could also be that younger individuals 
are more flexible and more capable to cope with newly developed visual impairment than 
older individuals.24 Also, the negative impact on the reported vision-related quality of life 
appears to be higher when evaluated closer to the onset of visual impairment.
Surprisingly, we did not find a significant difference in the reported quality of colour vision, 
although impaired colour vision has been previously reported in CSC.25 It is still possible that 
a disturbed colour vision exists in this cohort, but that it remains subclinical for instance due 
to a better-seeing fellow eye and does not interfere with the daily activities.
In conclusion, chronic CSC is a progressive chorioretinopathy with many chronic CSC patients 
experiencing significant vision loss, a lower vision-related quality of life, and a lower rating 
for overall health as compared to healthy individuals. Despite these observations, it is not 
uncommon for ophthalmologists to adopt a conservative approach in these patients who 
are often relatively young. Our findings demonstrate that the possible impact of chronic 
CSC should not be underestimated, and therefore an active treatment approach may be 
advocated. However, few high-quality randomized controlled treatment trials have been 
reported in chronic CSC, with a current lack of a gold standard for treatment of chronic CSC. 
We are currently performing a multicentre prospective randomized controlled treatment 
trial, comparing half-dose photodynamic therapy with high-density subthreshold micropulse 
laser treatment in chronic CSC [EudraCT number 2012-004555-36, NCT01797861] in an 
attempt to identify the most suitable treatment strategy in chronic CSC.
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Purpose:
To analyse if characteristics of the subretinal fluid pocket in chronic central serous 
chorioretinopathy (CSC) on spectral-domain optical coherence tomography (SD-OCT) 
correlate with response to half-dose photodynamic therapy (PDT) treatment.
Methods:
Forty-eight eyes of 48 treatment-naive chronic CSC patients who underwent half-dose PDT 
for active chronic CSC as the first treatment were included. Clinical information including 
visual acuity, SD-OCT, fluorescein angiography, and indocyanine green angiography was 
retrospectively collected. The SRF collection seen on SD-OCT imaging was analysed by a 
a machine-learning algorithm, specifically designed for this purpose. SRF volume and 
morphology, as well as SRF reflectivity characteristics were computed and correlated to 
response to half-dose PDT treatment (persistent or absent SRF on SD-OCT after treatment). 
Results:
A complete resolution of SRF was seen in 24 eyes (51%). In a total of 47 SD-OCT scans 
(98%) the SRF accumulation could be segmented as a whole and SRF volume, and pixel 
information analyzed. The median intensity of the SRF accumulation was lower in the group 
with complete absence of SRF after treatment. Also, the skewness of the histogram of the 
pixel intensity values was significantly higher in this group. No significant difference was 
seen when comparing the total SRF volume before treatment between the groups.
Conclusions:
Characteristics of SRF on SD-OCT are significantly different  between chronic CSC patients 
who do or do not respond well to half-dose PDT treatment. Using the described semi-
automated segmentation program to analyse these imaging characteristics may help to 
predict response to half-dose PDT in chronic CSC patients.
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Introduction
Central serous chorioretinopathy (CSC) is a relatively common early-onset eye disease, 
characterized by an accumulation of leaked serous subretinal fluid (SRF) causing a 
detachment of the neuroretina. This leakage of SRF results from dysfunction of the retinal 
pigment epithelium (RPE) outer blood-retinal barrier, caused by choroidal congestion and 
thickening and hyperpermeability of the choroid.1-4 Although the etiology of CSC is largely 
unknown, previous studies have described the male gender, the use of corticosteroids, 
hypercortisolism, stress, and possibly type A personality as risk factors.1, 5, 6 Genetic 
predisposition also appears to play a role, as single nucleotide polymorphisms in the 
Complement Factor H and ARMS2 have recently been found in association with sporadic 
chronic CSC,7, 8 and familial CSC cases have been described.9, 10 
In contrast to acute CSC, chronic CSC is usually not self-limiting, with persisting SRF on 
OCT. Persistent serous neuroretinal detachments can cause progressive and irreversible 
photoreceptor damage, resulting in a lower visual prognosis of chronic CSC as compared 
to acute CSC.2, 11, 12 Therefore, patients with chronic CSC who are affected by fluid leakage 
in the macula are often treated. A broad spectrum of treatment modalities has been used 
in chronic CSC, such as Argon or micropulse laser treatment of the leaking “hot spot” on 
fluorescein angiography (FA), intravitreal injections with anti-vascular endothelial growth 
factor or systemic drug treatments (e.g. spironolactone and eplerenone).2, 13-17 Currently, 
photodynamic therapy (PDT) is among the more frequently used treatments, that is effective 
in reducing SRF, with studies describing improvement of retinal anatomy and visual acuity 
(VA) in 70-100%.18-22 It is not precisely known why some patients respond well to PDT, and 
others respond poorly to therapy. 
Inoue et al. found a correlation between the degree of hyperpemeability on indocyanine 
green angiography (ICGA) and the efficacy of PDT in CSC patient. In addition, Kim et al. 
demonstrated that patients that respond well to intravitreal injections with anti-vascular 
endothelial growth factor have a significant thicker subfoveal choroidal thickness on 
enhanced depth optical coherence tomography (OCT). OCT, which is a non-invasive imaging 
technique, gives high-resolution, cross-sectional images of the retina and choroid,23 and 
can provide 3-dimensional information about the SRF accumulation, that can be used to 
monitor the disease activity over the time. Using retinal OCT-scans, correlations that have 
been found to be of importance in the prediction of the visual outcome are outer nuclear 
layer thickness in spontaneous resolved CSC,24 and foveal thickness after resolution of SRF 
partially after photocoagulation.25 In addition, Landa et al. also found a correlation between 
the thickness of the subfoveal deposits that are sometimes present in CSC and the BCVA and 
the time of spontaneous CSC resolution.26  
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Recently, differences in the optical density ratio of the SRF accumulation in serous 
neuroretinal detachment were demonstrated to be a valuable tool to differentiate chronic 
CSC from polypodial choroidal vasculopathy, two entities that may be strikingly similar and 
may partly have overlapping pathophysiology.27-29 In addition, Ahlers et al. found that the 
optical density ratio in the SRF correlates well with the functional outcome of an anti-vascular 
endothelial growth factor therapy in patients with age-related macular degeneration.30 
Also, in longer lasting SRF detachments, subretinal hyperreflective material on SD-OCT in 
chronic CSC can appear and may become increasingly prominent.31 Therefore, parameters 
obtained from SD-OCT in chronic CSC, which cannot be visualized with funduscopy or other 
imaging methods, could not only provide important information on the prognosis, but may 
also help in predicting the treatment outcome after half-dose PDT. The purpose of this 
explorative study was to identify possible biomarkers from the SRF accumulation on SD-OCT 
that can predict the treatment response to half-dose PDT in chronic CSC patients.
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Methods
Patients
The patients enrolled for this retrospective case series were seen at the outpatient clinics 
of the Department of Ophthalmology of the Radboud University Medical Center, Nijmegen, 
the Netherlands between March 2012 and October 2014. The medical records of all patients 
who had been diagnosed with chronic CSC were retrospectively reviewed. Only treatment-
naive patients who received half-dose PDT as first therapy were considered for this study. 
The diagnosis chronic CSC was based on characteristic features as seen on multimodal 
imaging consisting of SD-OCT, FA and ICGA (according to previously described criteria).7 
These criteria were defined as the presence of chronic serous SRF in at least one eye on 
SD-OCT, bilateral irregular RPE window defects on FA with at least one “hot spot” of leakage 
in the affected eye(s), and corresponding hyperfluorescent zones on ICGA. Patients who 
showed evidence of other diagnoses that could explain SRF accumulation, such as choroidal 
neovascularization, polypoidal choroidal vasculopathy, were excluded for this study.
Approval for this study was obtained by the local institutional review boards, and the study 
adhered to the Declaration of Helsinki. 
At the visit prior to the half-dose PDT therapy, and the first evaluation visit after therapy 
the following parameters were collected, if available: VA (LogMAR), onset of complaints, 
presence of SRF on SD-OCT, spot size and number of spots used for half-dose PDT treatment. 
Only patients who underwent an SD-OCT scan prior to half-dose PDT treatment and at the 
first evaluation visit after therapy were eligible for inclusion. 
Half-dose photodynamic therapy
Pupils of the patients were dilated with 1.0% tropicamide and 2.5% phenylephrine. 
Verteporfin (Visudyne®) was intravenously administered at half dosage (3 mg/m2) as 
compared to the original protocol for neovascular age-related macular degeneration, with 
an infusion time of 10 minutes. At 15 minutes after the start of the infusion, an anesthetic 
eye drop was given (oxybuprocaine 0.4% or equivalent), a contact glass (a Volk ® PDT lens) 
was positioned on the affected eye, and a laser beam was focused on the area to treat 
based on mid-phase (approximately 10 minutes) ICGA. PDT treatment was performed with 
standard 50 J/cm2 fluency, a PDT laser wavelength of 689nm, and a standard treatment 
duration of 83 seconds.
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Semi-automatic SRF segmentation 
All SD-OCT images used in this study were made with the Spectralis HRA+OCT (Heidelberg 
Engineering, Heidelberg, Germany) at a wavelength of 870 nm,  a horizontal resolution ≤ 15 
µm and an axial resolution of up to 5 µm. The number of slices varied from 18 to 60 B-scans 
per volume with 512 to 1536 A-scans per B-scan. 
An image analysis algorithm was developed to automatically segment the 3-dimensional 
shape of the SRF from an arbitrarily selected seed point inside the SRF.  The method applies 
a smart opening based region growing algorithm which uses intensity based similarity to 
determine if a pixel is part of the SRF or not. Therefore, the system performs the following 
steps:
i. A seed point s
0
 is manually placed in the SRF
ii.  s
0
 is added to the set S called seeds 
iii. For each seed point si in S
a. Neighboring points pn of si are identified
b. If the intensity of pn is lower than a threshold T of the intensity 
of si, then pn is added to S
c. Remove si from S
iv. Repeat step iii until no seed points 
After the segmentation of the SRF was obtained, a set of image biomarkers was extracted 
from the segmentation in order to capture the various characteristics of the SRF. These 
characteristics can be separated in two distinct groups, i.e., spatial characteristics, capturing 
the three-dimensional shape information, and reflectivity characteristics, which disregards 
the shape, and capture the pixel intensity characteristics of the fluid content. 
The spatial characteristics were described using the following parameters: total volume (TV) 
in µl. 
The reflectivity characteristics were described using the following parameters extracted 
from the raw pixel intensity values (greyscale range between 0 and 255): mean intensity 
(MI), median intensity (MedI), standard deviation of the intensity values (stdI), the kurtosis 
(KI), a measure for the "peakedness" of the histogram of pixel intensity values, and the 
skewness (SI), a measure for the symmetry of the histogram of pixel intensity values. 
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Definition of the outcomes
Efficacy of half-dose PDT was based on the anatomical result on SD-OCT, and defined 
absence of SRF as complete success. The outcome of half-dose PDT was compared 
with the following three variables analyzed on SD-OCT prior to the treatment: total 
volume of the SRF accumulation, MI and MedI of the fluid accumulation, and KI and SI. 
Statistical analysis
MS-Excel version 2010 was used for data management. Statistical analyses were performed 
using IBM SPSS software for Windows version 20. For comparison of continuous numerical 
data in SD-OCT characteristics and study outcome (presence or absence of SRF on SD-
OCT) we performed Mann-Whitney U test. Bonferroni correction for multiple testing was 
performed for three tests and p-values < 0.017 were considered to be statistically significant. 
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Results
Forty-six eyes of 46 chronic CSC patients (41 male, 5 female) with a mean age of 49 years 
(range: 29-67 years) were included in this study. For 42 eyes a date for the start of the 
complaints was reported, and in these eyes the mean time between start of the complaints 
and the SD-OCT scan was 82 weeks (range: 4 – 1037 weeks). The mean time between half-
dose PDT and the first control visit was 8.6 weeks (range 4.9 – 20.3 weeks). In 24 eyes (51%) 
the PDT treatment resulted in a complete absence of SRF on SD-OCT.
In all eyes we were able to delineate the central SRF fluid pocket(s). In 1 eye (2%) the SRF 
fluid accumulation could not be computed as a whole, due to disruption by either debris 
or an RPE detachment. This eye was not included for the further analyses. In 7 eyes (15%) 
2 separate SRF collections were detected. In these eyes the most central SRF accumulation 
was included for further analysis. 
Skewness was significantly higher in the patients who had a complete absence of SRF after 
treatment (group 1) compared to those with persistent SRF on SD-OCT (group 2) (mean 
skewness ‘group 1’; 1.09, SD: 0.38, range: 0.39 – 1.77 versus ‘group 2’; 0.76, SD: 0.42, range: 
0.12 – 1.72; p=0.013). 
Comparison of the complete SRF volume before treatment between the patients in ‘group 
1’ and ‘group 2’, did not show a significant difference (mean volume of SRF pocket in group 
1’; 0.635 µl, standard deviation (SD): 1.47, range: 0.01 – 7.09 µl, versus a mean volume in 
group 2 of 0.383 µl, SD: 0.73, range: 0.01 – 3.33 µl, p=0.476). 
When looking at the MI pixel intensity values of the SRF inside the fluid accumulation on 
SD-OCT, a  possibly lower but statistically non-significant MI was seen in group 1 (mean 
intensity ‘group 1’; 28.7 SD: 6.5, range: 17.09 – 41.51 versus group 2; 31.9, SD: 6.2, range: 
15.58 – 41.01 p=0.094). Also, the median intensity appeared lower in this group (median 
intensity ‘group 1’; 24.8, SD: 8.0, range: 12.00 – 41.00 versus ‘group 2’; 29.8, SD: 7.2, range: 
11.00 – 39.00 p=0.038). However, this difference was also not statistically significant after 
Bonferroni correction for multiple testing. 
Finally, the correlation between the kurtosis and skewness of the histogram of the pixel 
intensity values between both groups was assessed. The kurtosis being appeared to be 
higher, although not statistically significant, in the ‘group 1’ (mean kurtosis ‘group 1’; 1.50, 
SD: 1.33, range: -0.47 – 3.71 versus ‘group 2’; 0.78, SD: 1.22, range: -0.96 – 3.14 p=0.065).
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Discussion
In this study we analyzed the characteristics of the SRF accumulation on SD-OCT in 
chronic CSC. We were able to find significant differences in the characteristics of the SRF 
accumulation of SD-OCT between chronic CSC patients who respond well to half-dose PDT 
treatment, with a complete absence of SRF after treatment, and those who have persistent 
SRF. Assessment of the histogram of the intensity of the pixels inside the SRF accumulation 
on SD-OCT, showed a significantly higher skewness in the patients that respond well to half-
dose PDT (p=0.013). The same may hold true for the median intensity, although significance 
was lost after Bonferroni correction (p=0.038). The total volume of the SRF accumulation did 
not show any significant correlation to the treatment outcome (p=0.476).
OCT is a non-invasive imaging technique that gives high-resolution, cross-sectional images 
of the retina and choroid,23 and can provide 3-dimensional information about the SRF 
accumulation, which can be used to monitor the disease activity over the time. Several 
studies have shown correlations between the findings on OCT and the clinical outcome of 
patients with chronic CSC.24, 25, 32 These studies mainly focused on the anatomical changes 
located in the foveal neuroretina. Correlations found to be of importance in the prediction 
of the visual outcome are outer nuclear layer thickness in spontaneous resolved CSC,24 and 
foveal thickness after resolution of SRF partially after photocoagulation.25 Landa et al. also 
found a correlation between the thickness of the subfoveal deposits that are sometimes 
present in CSC and the BCVA and the time of spontaneous CSC resolution.26  In longer lasting 
SRF detachments, subretinal hyperreflective material on SD-OCT in chronic CSC can appear 
and may become increasingly prominent,31 possibly due to progressive photoreceptor outer 
segment debris accumulation, in association with less efficient phagocystosis of this debris 
by a diseased RPE and/or SRF leakage that is less pronounced in the chronic stage of the 
disease. 
Serous SRF accumulation is not an exclusive feature of CSC, and may also be seen for instance 
in diseases such as polypoidal choroidal vasculopathy, choroidal neovascularisation in age-
related macular degeneration, and Best vitelliform macular dystrophy. 
Differences in the optical density ratio of the SRF accumulation in serous neuroretinal 
detachment were recently demonstrated to be a valuable tool to differentiate chronic CSC 
from polypodial choroidal vasculopathy, two entities that may be strikingly similar and may 
partly have overlapping pathophysiology.27-29 In addition, Ahlers et al. found that the optical 
density ratio in the SRF correlates well with the functional outcome of an anti-vascular 
endothelial growth factor therapy in patients with age-related macular degeneration.30 
These SD-OCT parameters in chronic CSC, which cannot be visualized with fundoscopy 
or other imaging methods, can therefore not only provide important information on the 
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prognosis, but also seem to correlate with treatment outcome after half-dose PDT. In this 
study we describe a semi-automatic segmentation program for SD-OCT data, which can 
facilitate the reliable analysis of such SD-OCT parameters.
Numerous treatment options have been tried in chronic CSC patients over the past decades.2, 
13-15  However, there is no international consensus on the optimal treatment of chronic CSC to 
date. In this study, we chose for half-dose PDT , which is the most frequently used treatment 
described in current literature.20-22  Our findings suggest that a higher pixel intensity of the 
SRF accumulation exists in the patients that do not respond with a complete reduction of 
the SRF after PDT. The rationale of half-dose PDT is to reduce the fluid leakage from the 
hyperpermeable choroid by inducing remodeling of the choroidal vasculature, supposedly 
through selective vascular occlusion due to damage to choroidal endothelial cells and 
subsequent thrombotic events of the choriocapillaris.33, 34 Our findings suggest that chronic 
CSC patients with a higher pixel intensity on SD-OCT are less likely to achieve complete SRF 
resolution after half-dose PDT. A possible explanation may be that this higher intensity is a 
reflection of increased subretinal debris such as photoreceptor outer segments, that are 
less efficiently phagocytosed by an dysfunctional RPE due to longstanding, more inactive 
disease. In these less active cases, targeting the choroid with PDT may be too late to achieve 
optimal effect.  It is currently unknown if persistence of SRF after half-dose PDT also resulted 
in a worse final visual outcome in this subgroup of chronic CSC patients. 
Another limitation to this study was the relatively low sample size, which was due to the fact 
that only treatment-naive patients could be included.
In conclusion, this study shows that characteristics of SRF accumulation in chronic CSC 
patients correlates with the treatment outcome after half-dose PDT, using a new semi-
automatic method of SD-OCT image analysis. Prospective studies in larger patient cohorts, 
such as the randomized controlled treatment trial that we are currently performing (EudraCT 
number 2012-004555-36, NCT01797861), are required to confirm the present findings. 
These findings may aid in achieving a more personalised healthcare approach in chronic 
CSC, in which patients can be identified who would have a higher likelihood to benefit from 
PDT treatment, or those who would require a different approach. 
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Purpose:
Abnormal choroidal blood flow is considered important in the pathogenesis of chronic 
central serous chorioretinopathy (CSC). Optical coherence tomography (OCT) angiography 
can image ocular blood cell flow and could thus provide novel insights in disease mechanisms 
of CSC. We evaluated depth resolved flow in chronic CSC by OCT angiography compared to 
fluorescein angiography (FA) and indocyanine green angiography (ICGA).
Method:
Eighteen eyes with chronic CSC, and 6 healthy controls, were included. Two human 
observers annotated areas of staining, hypofluorescence and hot spots on FA and ICGA, and 
areas of abnormal flow on OCT angiography. Inter-observer agreement in annotating OCT 
angiography and FA/ICGA was measured by Jaccard indices (JIs). We assessed co-location of 
flow abnormalities and subretinal fluid visible on OCT, and the distance between hot spots 
on ICGA from flow abnormalities.
Results:
Abnormal areas were most frequently annotated in late-phase ICGA and choriocapillary 
OCT angiography, with moderately high (median JI, 0.74) and moderate (median JI, 0.52) 
inter-observer agreement, respectively. Abnormalities on late-phase ICGA and FA co-located 
with those on OCT angiography. Aberrant choriocapillary OCT angiography presented as foci 
of reduced flow surrounded by hyperperfused areas. Hot spots on ICGA were located near 
hypoperfused spots on OCT angiography (mean distance, 168 µm). Areas with current or 
former subretinal fluid were co-located with flow abnormalities.
Conclusions: 
On OCT angiography, chronic CSC showed irregular choriocapillary flow patterns, 
corresponding to ICGA abnormalities. These results suggest focal choriocapillary ischemia 
with surrounding hyperperfusion that may lead to subretinal fluid leakage.
OCTA compared to FA and ICGA in chronic CSC
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Introduction
Central serous chorioretinopathy (CSC) is characterized by a serous retinal detachment, 
sometimes accompanied by a detachment of the retinal pigment epithelium (RPE).1-4 The 
leakage of fluid through the RPE often occurs at the macula, resulting in central vision loss, 
disturbed color vision, (para-) central scotoma, metamorphopsia and/or micropsia.2, 4-6 
Patients with CSC are typically male (male/female ratio 6:1), with an average age of 45 to 51 
years.1, 3 Besides the male gender, the most consistent risk factor appears to be the use of 
corticosteroids, as well as circumstances where corticosteroid levels are increased, such as 
Cushing disease and pregnancy. In addition, a type A personality and certain genetic factors 
may increase the risk for CSC.1, 7, 8 Although the precise pathophysiological mechanism is still 
unclear, multimodal imaging indicates that subretinal fluid (SRF) accumulation in CSC results 
from a thickened, congested, hyperpermeable choroid leaking fluid through a dysfunctional 
RPE.9-12 
Two main forms of CSC can be distinguished: the acute and chronic form.1, 3, 4, 11 Patients with 
acute CSC usually present with sudden and marked central vision loss, caused by SRF leakage 
at the macula due to a focal leak in the RPE that is visible on fluorescein angiography (FA).1, 2, 
13 The prognosis is favorable in this type and spontaneous recovery is often seen within 2-3 
months.1 In contrast to acute CSC, chronic CSC is typically not self-limiting and SRF persists for 
more than 3 months. Patients with chronic CSC have more diffuse multifocal leakage on FA 
and indocyanine green angiography (ICGA), as well as irregularly distributed widespread RPE 
changes associated with various degrees of low-grade, more distinct leakage on angiography: 
diffuse retinal pigment epitheliopathy (DRPE). Such persistent serous neuroretinal detachments 
may cause progressive and irreversible photoreceptor damage, resulting in a far worse visual 
prognosis of chronic CSC as compared to the acute form.2, 14, 15
Previous studies have examined blood flow in CSC by use of FA/ICGA imaging, and observed 
choriocapillary congestion.10 In an ultrastructural study of a cynomolgus monkey model of 
CSC, damage of choriocapillary endothelial cells underneath damaged RPE cells that were 
covered by fibrin platelet clots was observed, which led to the suggestion that choriocapillary 
hyperpermeability occurs in CSC.16, 17 Blood flow in CSC has also been examined using other 
optical imaging modalities. For instance, choroidal hypoperfusion was demonstrated with 
laser Doppler flowmetry.18 
Spectral-domain optical coherence tomography (SD-OCT) is a noninvasive, high-speed, 
high-resolution, three dimensional imaging technique frequently applied in patients with 
CSC to evaluate SRF and photoreceptor damage.19 SD-OCT may also be used to perform 
angiography in a non-invasive manner. Split-spectrum amplitude decorrelation angiography 
(SSADA) is a clinically feasible, commercialized technique which can visualize capillary 
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blood flow, but without determination of the flow direction.20 In contrast to dye assisted 
FA and ICGA imaging, OCT angiography detects movements of blood cells, instead of serum 
extravasation or staining of vessel walls and tissue. SSADA has been used recently in the 
examination of abnormal vascular structures in macular telangiectasia type 2,21 and of 
choroidal neovascularization in age-related macular degeneration, 22, 23 as well as chronic 
CSC.24 Hence, OCT angiography could provide additional information on the blood supply in 
CSC, and it could therefore help to better understand the underlying pathophysiology of the 
disease. In our current study we compared OCT angiography in chronic CSC to established 
angiographic imaging modalities like FA and ICGA.
OCTA compared to FA and ICGA in chronic CSC
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Methods
We studied 18 eyes of 11 consecutive patients (6 male, 5 female) with chronic CSC seen 
at the outpatient clinic of the Department of Ophthalmology of the Radboud University 
Medical Center (Nijmegen, the Netherlands) from November, 2014 to January 2015. All study 
participants gave oral informed consent for OCT based angiography imaging. In addition, 6 
healthy volunteers (3 male, 3 female) with no medical history of ocular or cardiovascular 
diseases and/or diabetes mellitus served as controls. Ethical approval for retrospective 
analysis of this observational case series was granted by the institutional review board at the 
Radboud University Medical Center and the study adhered to the tenets of the Declaration of 
Helsinki. The diagnosis of chronic CSC was based on a history with persistent fluid of at least 
3 months, as well as RPE damage due to longstanding SRF. Active chronic CSC was defined by 
active leakage of fluid under the neuroretina confirmed by SD-OCT and by hyperfluorescent 
spots on ICGA and/or at least one ill-defined leakage spot on FA. Patients were included if OCT 
angiography, FA and ICGA were performed on the same day to maximize the comparability 
of the angiographic techniques. Patients with other ocular disorders commonly associated 
with serous SRF, such as choroidal neovascularization, polypoidal choroidal vasculopathy, 
diabetic retinopathy, retinal vascular occlusion, and myopia > 6 diopters were not eligible.
 
For SD-OCT, fundus autofluorescence (AF), FA and ICGA imaging, we used the Spectralis™ 
HRA+OCT device (Heidelberg Engineering, Heidelberg, Germany). Simultaneous FA and 
ICGA imaging were performed after patients were given a 2.5 ml intravenous injection of 
25% fluorescein solution mixed with 12.5 mg indocyanine green (ICG-Pulsion® 25 mg). FA 
and accompanying ICGA images were selected from the early phase (30 to 60 seconds post-
injection) and the late phase (6 to 8 minutes post-injection) of the dye transit. Following 
ICGA/FA imaging, the presence of sub-macular fluid deposits was evaluated based on SD-
OCT. 
OCT Angiography
We used a newly developed SD-OCT device (OptoVue RTVue XR Avanti™ AngioVue™, 
Optovue Inc, Fremont, CA) to obtain SSADA images. This instrument has an A-scan rate of 70 
kHz and an axial resolution in tissue of 5 µm, using a light source with a center wavelength 
of 840 nm and a spectral bandwidth of 45 nm. Two consecutive B-scans (M-B frames) of 
304 A-scans each along the fast scanning axis were recorded at each of the 304 positions 
along the slow scanning axis. According to this protocol, horizontal priority fast transverse 
(x-fast) scans and vertical priority fast transverse (y-fast) scans were obtained consecutively 
to record a 3-dimensional data cube. The M-B frames were analyzed for highly decorrelated 
pixels, which are co-located with moving blood cells in retinal and choroidal vessels. 
These data were used to reconstruct three-dimensional blood flow images as described 
previously.20  Scans with insufficient quality due to blinking (appearing as straight, black 
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stripes), or fixation loss were excluded. After selecting the best scans, residual axial and 
saccadic motion artifacts were corrected using the contained software (ReVue™, Optovue 
Inc.). OCT angiography images of four vascular layers (inner vascular plexus, deep retinal 
vascular plexus, outer retina, and choriocapillaris), and a full thickness OCT angiogram 
including all retinal layers and the choriocapillaris, were then exported. Examples of these 
images in a healthy control subject and a patient with chronic CSC are depicted in Figure 1.
Figure 1. 
OCT angiography of a healthy subject and of a patient with chronic CSC. A-D, Right eye of a healthy 25 year-old 
female, E-H, Left eye of a patient with chronic CSC (patient 4, see Table 1). A and E, The inner vascular plexus 
(‘Superficial’). B and F, The deep retinal vascular plexus (‘Deep’). C and G, Choriocapillaris (‘Choroid cap’). The 
choriocapillaris was defined as a 20 µm band below the RPE-Bruch’s membrane complex. It was segmented by 
the ReVue software and, if needed, corrected for significant segmentation errors. D and H, Full-thickness OCT 
angiogram. Outer retina not shown.
OCTA compared to FA and ICGA in chronic CSC
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Image Readings and Annotations
OCT angiography images and FA/ ICGA images were aligned using a semi-automatic 
registration tool, developed in MeVisLab (version 2.5a, MeVis Medical Solutions AG, Bremen, 
Germany), that translates, rotates, and rescales the target image to accurately match three 
user specified landmark locations on both the source (FA) and target (OCT angiography of 
the superficial layer) images.25 The same transformation matrix was applied to ICGA images 
for co-registration. 
All image readings were performed at NANOREAD (Nijmegen Angio OCT Reading Center) by 
experienced and masked observers, and were done separately on the same computer. Each 
observer (M.B., T.T.) annotated areas showing leakage and hypofluorescence in the FA and 
ICGA images and regions in the OCT angiography images with visually evident deviations 
from the normal appearance. In Figure 2, the image registration and annotation processes 
are depicted in a flow chart together with illustrative examples. A representative example of 
registered images is shown in Figure 3. OCT angiography images of five healthy volunteers, 
who were not part of the study, served as a reference. Images of patients and controls were 
anonymized and randomized, by replacing filenames with unique random numbers and 
subsequent sequential rearrangement according to consecutive numbering. The region-of-
interest (ROI) function of ImageJ (version 1.46r, National Institutes of Health, Bethesda, MD) 
was used for annotation purposes. 
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Figure 2. 
Flow chart of the image registration and annotation procedures. Original images, i.e. superficial retinal OCT 
angiography and FA images, were registered by an observer, using a variety of image overlay options (Step 1). 
Simultaneously acquired ICGA images were transformed identically to the FA image (Step 2). The final display 
image, with a standard layout, was then created, which included the original FA/ICGA image containing contextual 
information (Step 3). Annotations were made by human observers (Step 4), after which the overlap of annotations 
was calculated by Jaccard’s index (Step 5). See text for details.
OCTA compared to FA and ICGA in chronic CSC
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Figure 3. 
Example of image registration. Overlay of an early-phase FA image (red) registered to a superficial OCT angiography 
image (green), with overlapping vessels indicated in yellow. 
Image Analysis
To determine the inter-observer agreement of image annotations, the number of images 
annotated by both observers was determined. In case both observers annotated the image, 
we calculated the spatial overlap of the annotations by the Jaccard index (JI) as:
Indices were calculated separately for each observer’s set of annotations, and were then 
pooled together. The spatial correspondence of abnormalities visible in OCT angiography 
images with FA/ICGA was firstly determined by the frequency of annotations on both 
modalities. In those cases, we calculated JIs to determine the extent of their overlap. We 
tested if the overlap of each combination of OCT angiography images and FA/ICGA images 
was different from all other combinations with the Mann-Whitney U-test. We also tested if 
this overlap, in terms of JIs, was correlated between both eyes of a patient. P-values < 0.05 
were considered statistically significant. 
Image analysis was performed to determine the correspondence between hot spots or 
profound hypofluorescence in late-phase ICGA images, and focal areas of decreased flow 
in the choriocapillary lamina on OCT angiography images, in terms of the distance between 
their centers. These centers were determined by the center of mass of the annotated areas. 
In case adjacent foci appeared confluent on ICGA images, they were often amalgamated in 
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a single ROI as ‘beads on a string’. A watershed algorithm was applied to split these ROI’s 
to facilitate the distinction of different foci. Subsequently, the shortest distances between 
leakage hot spots or hypofluorescent foci in ICGA images and dark spots in OCT angiography 
images with a visually evident correspondence were calculated (Figure 4). 
Figure 4. 
Annotation and quantitative analysis of hyperfluorescent areas on ICGA and aberrant flow on OCT angiography. 
Left image, late-phase ICGA image of a patient with chronic CSC with location of the registered image (yellow 
frame). Middle image, detail of abnormalities in the registered ICGA image. Right image, the aberrant flow pattern 
on OCT angiography of the choriocapillaris is co-located with the annotated region on late-phase ICGA; the darkest 
region corresponds with a hypofluorescent spot on ICGA, bordered by increased flow co-located to the leakage hot 
spot and late staining. The annotated region is depicted by the yellow line.
Fundus autofluorescence
To determine whether the results of OCT angiography of the choriocapillaris were affected 
by light-absorbing chromophores of the RPE, we compared OCT angiography images to AF 
images that were recorded on the same day. AF images were registered to OCT angiography 
images as described earlier. We considered OCT angiography signals above or below the 
mean +/- 2 standard deviations of apparently uninvolved areas, respectively, as abnormal 
choriocapillary flow. Uninvolved areas were determined by a lack of annotations, absence 
of large vessel shadows, and in the near vicinity of the image border, as irregular flow at 
the image borders was common even in healthy subjects. Thresholded pixels of increased 
or decreased flow were overlaid on the registered AF images. Finally, two observers 
(M.T., T.T.) evaluated whether there was any co-location of focally changed AF signals and 
choriocapillary flow. 
OCTA compared to FA and ICGA in chronic CSC
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Results
Patient demographics are depicted in Table 1. 
Table 1. Clinical characteristics of the patients included in this study
ID/Gender 
/Age, y
Eye(s) Included Signs of Chronic CSC 
on FA, ICGA and OCT 
Active Chronic CSC 
on FA, ICGA and OCT 
Previous 
Treatment(s)
P1/F/55 OD yes yes 1 x MP
P2/M/58 OD yes yes NA
P3/F/64 OD yes yes NA
OS yes yes NA
P4/M/40 OD yes no NA
OS yes yes NA
P5/M/71 OD yes no 2 x PDT
P6/F/56 OD yes yes NA
P7/F/38 OD yes no NA
OS yes yes 1 x PDT
P8/F/56 OD yes no 1 x MP
OS yes yes NA
P9/M/59 OD yes yes 2 x MP, 1 x PDT
OS no no NA
P10/M/62 OD no no NA
OS yes yes NA
P11/M/47 OD yes yes NA
OS yes no 2 x MP, 1 x PDT
CSC: central serous chorioretinopathy; FA: fluorescein Angiography; F: female; ICGA: indocyanine 
green angiography; M: male; MP: micropulse laser therapy; NA: not applicable; OCT: optical 
coherence tomography; OD: right eye; OS: left eye; PDT: half-dose photodynamic therapy. 
Inter-observer Agreement
A total of 255 images were analyzed, including 100 FA and ICGA-images of patients, and 
125 and 30 OCT angiography images of patients and healthy subjects, respectively. In 132 
images (52%), abnormalities were annotated by both observers (83 FA/ICGA images and 49 
OCT angiography images). An example of image annotations by both observers is shown 
in Figure 5. The corresponding JIs as indicators of inter-observer agreement and numbers 
of annotated images are summarized in Table 2. FA and ICGA images were annotated with 
moderate agreement (median JIs, 0.43-0.67). Of the various OCT angiography images, 
choriocapillary flow images were most frequently annotated by both observers (80% of 
the patient images, 17% of the control images) with moderate inter-observer agreement 
(median JI, 0.52). OCT angiography images of retinal layers were annotated less often 
than choriocapillary flow images. The inter-observer agreement in annotating abnormal 
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choriocapillary flow was similar to FA and ICGA, both in terms of the frequency of annotations 
and the agreement scores.
Figure 5. 
Examples of image annotations. 
A and B, late-phase ICGA images 
(left eye of patient 8, 6x6 
mm). C and D, superficial OCT 
angiography images. E and F, 
deep OCT angiography images. 
G and H, choriocapillary OCT 
angiography images. Left column, 
annotations by observer 1; right 
column, annotations by observer 
2. The Jaccard indices (JIs) of 
overlap between late-phase ICGA 
and superficial- and deep- OCT 
angiography were 0.006 and 
0.022, respectively (observer 
2). The JIs of overlap of late-
phase ICGA with choriocapillary 
OCT angiography were 0.43 
and 0.55 for observers 1 and 2, 
respectively.
OCTA compared to FA and ICGA in chronic CSC
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Table 2. Inter-observer agreement of annotated vascular abnormalities in FA, ICGA and OCT angiography images
JI Annotations Made by Observers
FA/ICGA Mean (SD) Median Both Either None
FA (early phase) 0.46 (0.29) 0.35 19 1 5
FA (late phase) 0.59 (0.23) 0.58 20 2 3
ICGA (early phase) 0.43 (0.29) 0.47 22 1 2
ICGA (late phase) 0.67 (0.15) 0.74 22 2 1
OCT Angiography 
Superficial 0.28 (0.22) 0.28 4 9 18
Deep 0.27 (0.19) 0.26 11 10 10
Outer retina 0.47 (0.17) 0.40 7 16 8
Choroid cap 0.49 (0.22) 0.52 21 5 5
FT-OCTA 0.5 (0.2) 0.53 6 11 14
JI: Jaccard index; FA: fluorescein angiography; ICGA: indocyanine green angiography; FT-OCTA: full 
thickness OCT angiogram; OCT: optical coherence tomography; SD: standard deviation. 
General Correspondence between OCT Angiography and FA/ICGA
Table 3 summarizes the overlap of annotated abnormal areas observed with various 
angiographic imaging modalities expressed in JIs. Choriocapillary flow images and late-
phase FA/ICGA images corresponded best in determining abnormality with moderately 
low overlap of the annotated areas (median JI of both FA and ICGA vs. choriocapillary, 
0.41). In general, there was a poor overlap between annotated changes on FA and OCT 
angiography images, with median JIs ranging from 0 to 0.05. The correspondence between 
aberrant choriocapillary flow and abnormalities on late-phase FA/ICGA was higher than the 
correspondence of abnormalities in early or late FA images and abnormalities in retinal OCT 
angiography images (p < 0.001). In general, the JIs showed a significant correlation between 
both eyes (Spearman’s ρ = 0.59, p = 4.5·10-7). 
The annotated choriocapillary flow patterns had a highly variable appearance. In some 
cases, we observed mottled flow patterns with patches of increased and decreased flow. 
Mostly, however, we observed irregular patterns with large and semi-confluent patches of 
decreased flow adjacent to similar patches with increased flow. A small number of patches 
with decreased choriocapillary flow corresponded with RPE-detachments visible on SD-OCT. 
Several other patches corresponded with focal areas of a thickened RPE below a SRF pocket, 
which appeared to produce shadow artifacts on late phase ICGA. In general, light-absorbing 
fluorophores in the RPE, as visualized by AF imaging, had no apparent correspondence 
with the appearance of choriocapillary flow on OCT angiography of CSC. A few sporadic 
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hyper-AF areas corresponded with decreased flow areas, although not all hyper-AF in the 
same images corresponded with decreased flow and vice-versa. The same was true for the 
correspondence between hypo-AF and increased flow, and for other combinations. Areas 
of aberrant choriocapillary flow were generally co-located with locations of current SRF 
accumulation visible on SD-OCT, or with locations where SRF had resolved. The aberrant 
flow patterns appeared similarly heterogeneous in treatment naive patients and treated 
subjects, with no consistent differences in eyes that received micropulse laser treatment or 
photodynamic therapy. 
Correspondence between Hot Spots on ICGA and Aberrant Choriocapillary Flow
We also studied the relationship between decreased choriocapillary flow and hot spots or 
hypofluorescence on ICGA (Figure 4). In most areas with decreased flow on OCT angiography 
we were unable to observe a corresponding, well-defined focus of abnormal fluorescence 
on late phase ICGA (75 out of 117 areas, or 64.1%). The remaining areas with decreased 
flow, however, overlapped largely with hypofuorescent areas on ICGA. Twelve (29.3%) 
out of 41 leakage areas and hot spots on late phase ICGA appeared to be connected with 
areas of decreased choriocapillary flow on OCT angiography, versus 24 (42.9%) out of 56 
hypofluorescent spots on late phase ICGA. The mean distance between hot spots on ICGA 
and matched areas with decreased signal in choriocapillary flow images on OCT angiography 
was 168 µm (SD, 133 µm), or 17 pixels. The mean distance of hypofluorescent spots was 133 
µm (SD, 70 µm), or 13 pixels. Areas of increased flow, however, were often found adjacent 
to leakage hot spots on ICGA. For choriocapillary flow images and corresponding FA/ICGA 
and AF images of all included patients and controls. 
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Table 3. Overlap of image annotations on FA/ICGA and OCT angiography in 11 patients with chronic CSC
FA/ ICGA OCT Angiography Mean JI (SD) Median
Superficial 0.04 (0.1) 0
FA (early phase) Deep 0.06 (0.1) 0.01
Choroid cap 0.25 (0.21) 0.22
FT-OCTA 0.1 (0.19) 0
Superficial 0.03 (0.06) 0
FA (late phase) Deep 0.09 (0.14) 0.02
Choroid cap 0.38 (0.22) 0.41
FT-OCTA 0.11 (0.15) 0.05
Superficial 0.12 (0.2) 0
ICGA (early phase) Deep 0.09 (0.12) 0.04
Choroid cap 0.27 (0.18) 0.24
FT-OCTA 0.1 (0.15) 0.05
Superficial 0.04 (0.06) 0
ICGA (late phase) Deep 0.08 (0.11) 0.05
Choroid cap 0.41 (0.19) 0.41
FT-OCTA 0.14 (0.2) 0.05
Choroid cap: choriocapillaris; CSC: central serous chorioretinopathy; JI: Jaccard index; FA: fluorescein 
angiography; ICGA: indocyanine green angiography; FT-OCTA: full thickness OCT angiogram; OCT: 
optical coherence tomography; SD: standard deviation.
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Discussion
In this study, we compared OCT angiography characteristics of patients with chronic CSC to 
FA and ICGA findings. We found typical changes in the choriocapillary flow pattern of chronic 
CSC patients, which corresponded to areas affected by subretinal fluid accumulation. There 
was moderate inter-observer agreement on changes in choriocapillary flow images of 
CSC patients, and there was moderate spatial correspondence between late FA/ICGA and 
choriocapillary flow images. 
Kitaya et al. (2003) used laser Doppler flowmetry to show that eyes with CSC had reduced 
choroidal blood flow relative to the unaffected fellow eye.18 Using combined FA/ICGA 
imaging, Scheider et al. (1993) also confirmed the reduction in choroidal blood flow in CSC 
and demonstrated that the hypoperfusion persisted after clinical improvement.26 In our study, 
changes of the choriocapillary flow pattern on OCT angiography appeared as focally increased 
and decreased pixel values, indicating coexisting increased and decreased flow, respectively. 
Even though, the appearance of these changes was significantly different from the fairly 
homogeneous appearance of the healthy choriocapillary layer, there was only a moderate 
inter-observer agreement. Obviously, the border between the appearance of healthy and 
affected tissue in OCT angiography may not easily been drawn between observers. This 
phenomenon has been observed earlier in a study that evaluated the agreement among 
highly experienced retinal specialists in grading of FA images for the presence of active 
choroidal neovascularization.27 A multimodal approach in angiographic techniques may help 
to improve the identification of pathological changes. One has to keep in mind, however, 
that OCT angiography measures blood flow dependent on intravascular cell movements, 
while FA/ICGA images the flow of blood plasma, independent of cell movement. Therefore, 
these three techniques give blood flow information that is supplementary to each other.
On OCT angiography, we observed choriocapillary hypoperfusion with hyperperfusion in the 
surrounding area. This is consistent with results of earlier studies, showing focal filling defects 
in the choriocapillaris with dilated and tortuous feeding arterioles and dilated venules.10, 28-
30 These filling defects may be caused by capillary congestion and/or rarefaction.10 Areas 
of irregular choriocapillary texture on OCT angiography partially co-located to areas with 
late staining on ICGA. Also, many hot spots on late-phase ICGA, if present, were in close 
proximity of relative ischemia on OCT angiography within those areas of irregular texture. 
Taken together, these data suggest that reduced blood perfusion in the choriocapillaris may 
be surrounded by reactive hyperperfusion. Hyperperfusion leads to increased hydrostatic 
pressure within the fenestrated choriocapillaris. Together with chronic hypoxic damage, this 
may lead to disintegrity of the continuity of the RPE,31 and to subretinal fluid leakage with 
serous neuroretinal detachment in chronic CSC.32, 33 
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According to our data, the abnormal vascular situation in the choriocapillary layer appeared 
to persist even after resolution of SRF and seemed to be independent of any kind of 
treatment. It is still unclear, why different treatment modalities may lead to successful 
fluid resorption. The mechanism of action of photodynamic therapy has been postulated 
to include short-term choriocapillary hypoperfusion and long-term choroidal vascular 
remodeling with subsequent reduction of vascular hyperpermeability and leakage.19, 34, 35 
On the short term, the hypoperfusion may lead to more ischemic RPE damage. Because 
of the long time period between photodynamic therapy and our study measurements, 
we may have missed any therapeutic effects visible on OCT angiography. It may be useful 
to prospectively follow patients after photodynamic therapy by OCT angiography to learn 
more about the therapeutic mechanism of this treatment. Subthreshold micropulse diode 
laser treatment is applied in an attempt to trigger the regeneration of the RPE and a long-
term metabolic increase at the chorioretinal junction,36 which may increase SRF resorption 
by the RPE.37 Micropulse laser treatment is not thought to affect the choriocapillaris directly. 
The lack of effects on choriocapillary flow in patients after micropulse laser treatment is 
therefore not surprising. 
Our study is mainly limited by the small number of patients and the retrospective and cross-
sectional data acquisition. As a consequence, we have studied a combination of treatment-
naive patients and patients who were previously treated by micropulse laser or photodynamic 
therapy once or multiple times. We do not have pre-treatment data and we did not monitor 
patients over time. To further improve our knowledge of the vascular changes in chronic 
CSC, prospective and longitudinal studies are required to monitor vascular changes during 
the natural course and during different treatment strategies. Although we found no 
consistent effects of chromophores in the RPE on the appearance of choriocapillary flow, 
save for a few sporadic cases, a comprehensive analysis of potential confounders on the 
appearance of OCT angiography signals was out of the scope of this study.  This is important 
in OCT angiography studies of retinal diseases in which layers with high light-absorption 
are affected. Therefore, future studies should include SD-OCT and AF imaging to determine 
potential imaging artifacts. The fields of view on OCT angiography were of considerably 
smaller size than those currently used in ICGA or SD-OCT. Peripheral areas with obvious 
FA/ICGA irregularities were therefore missed. Future studies should aim to include the 
complete posterior pole with all angiographic abnormalities by OCT angiography scanning. 
This could be achieved by a montage of many high-resolution OCT angiography scans or 
by improved OCT hardware-software combinations capable to visualize larger fundus areas 
with high resolution. 
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In conclusion, OCT angiography showed significant textural changes of the choriocapillary 
flow pattern in chronic CSC patients. Our results suggest foci of ischemia surrounded by 
reactive choroidal hyperperfusion as an important factor in the pathogenesis of chronic CSC. 
Prospective OCT angiography studies on chronic CSC are needed to better understand the 
pathogenesis and treatment response of this visually threatening disease.
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Purpose:
To evaluate the outcome of a prospective protocol for the treatment of chronic central 
serous chorioretinopathy (CSC).
Methods:
Interventional prospective case series in 59 eyes (59 patients) with active chronic CSC. All 
patients were first treated with indocyanine green angiography (ICGA)-guided half-dose 
photodynamic therapy (PDT). In case of persistent serous subretinal fluid (SRF) after a follow-
up period of at least 6 weeks, ICGA-guided PDT was repeated. If the SRF persisted after 2 
PDT treatments, additional ICGA-guided high-density subthreshold diode micropulse laser 
(HSML) therapy was performed. Clinical evaluation included best-corrected visual acuity 
(BCVA), fundoscopy, OCT, fundus autofluorescence, fluorescein angiography and ICGA.
Results: 
After a single PDT treatment, complete resolution of SRF was seen in 37 of 59 eyes. Of the 
22 eyes with no complete resolution of SRF, 19 eyes received a second PDT treatment, after 
which 7 eyes of the 19 eyes showed a complete resolution of SRF. Ten eyes underwent 
HSML, of which 1 eye had complete resolution of SRF within 7 weeks. At final follow-up 
a complete resolution of SRF was present in 80% of all eyes. The mean BCVA improved 
from 0.28 logMAR at baseline to 0.16 logMAR at final follow up. Improvement of BCVA was 
highest after the first treatment (-0.12 logMAR, p < 0.001).
Conclusions:
The proposed treatment strategy using half-dose PDT and HSML in active chronic CSC 
resulted in an anatomical success rate of 80%. The first half-dose PDT treatment has the 
highest likelihood of a favorable treatment response on OCT and BCVA increase.
Half-dose PDT followed by diode MP as treatment for chronic CSC: evaluation of a prospective treatment protocol
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Introduction 
Central serous chorioretinopathy (CSC) is characterized by subretinal fluid (SRF) accumulation 
through a dysfunctional outer blood-retinal barrier of the retinal pigment epithelium (RPE),1-
4 causing a serous detachment of the neurosensory retina. Patients with CSC are typically in 
the professionally active age, and men are affected more often than women.1 Besides the 
male sex, several other risks factors have been described, such as the use of corticosteroids, 
Cushing’s disease, stress, and genetic factors.1, 5, 6 More recently, we have identified genetic 
variants implicated in the complement system to be associated with chronic CSC,5 and 
similar findings have been described in a Japanese CSC cohort 6. After the first description of 
CSC by Von Graefe in 1866,7 Gass postulated that not only the RPE, but also the underlying 
choroid plays a pivotal role in the pathogenesis of CSC.8 Multimodal imaging using optical 
coherence tomography (OCT) and indocyanine green angiography (ICGA) has shown that 
dilation, congestion and hyperpermeability of the choriocapillaris and larger choroidal 
vessels is a prominent and possibly primary characteristic of CSC .9, 10 However, the precise 
pathophysiological mechanism remains unclear.
Two main subtypes of CSC can be distinguished. Acute CSC patients present with a rapid 
onset of central vision loss, micropsia and metamorphopsia.2-4 Acute CSC is characterized 
by a focal leakage spot on fluorescein angiography (FA), often with a classic “smokestack 
pattern” of leakage from this small focal “hot spot”, without extensive atrophic RPE 
changes.1, 2, 11, 12 The SRF in acute CSC generally resolves spontaneously within 2-3 months 
with limited visual sequelae.1 Some of these acute CSC patients can have SRF persisting 
for more than 3 months, and can therefore be designated as chronic CSC cases based on 
this time definition. However, many CSC patients without a history of acute CSC present 
with diffuse SRF accumulation and widespread RPE changes that indicate chronic disease.2 
Chronic CSC patients can have one or more hot spots of leakage on FA that are less distinct 
than in acute CSC cases, but widespread hyperfluorescence of an apparently more diffusely 
hyperpermeable RPE barrier without clear hot spots is also common in this chronic subtype 
of CSC.2-4, 11 ICGA characteristically demonstrates hyperfluorescent areas of choroidal 
congestion and hyperpermeability that are more extensive in chronic CSC than in acute CSC. 
In a study by Wang and co-workers,13 a prolonged neurosensory detachment (> 4 months), 
which is often seen in chronic CSC, was shown to be associated with retinal atrophy. 
Therefore, the primary goal of treatment in chronic CSC should be to achieve complete 
resolution of the SRF, preferably within the first 4 months after diagnosis of the disease. 
A broad spectrum of treatment modalities has been used in chronic CSC, such as Argon 
laser treatment of the leaking hot spot on FA, intravitreal injections with anti-vascular 
endothelial growth factor (anti-VEGF) or systemic drug treatments (e.g. spironolactone and 
eplerenone).2, 14-16 Currently, photodynamic therapy (PDT) and high-density subthreshold 
diode micropulse laser treatment (HSML) are among the frequently reported treatment 
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modalities. In HSML a 810 nm diode laser is used delivering repetitive low energy pulses, 
selectively targeting the RPE without inducing a visible laser burn and applied as high 
density grid over the leaking areas.17 Several studies have shown efficacy of both PDT with 
verteporfin and HSML in chronic CSC .18-22 However, few prospective studies on the treatment 
of chronic CSC have been published.22-25 Also, it is unclear if re-treatment or a switch to 
other treatments in previous non-responders can be successful. In this study we evaluate 
a prospective treatment protocol consisting of half-dose PDT as a primary treatment in 
chronic CSC, followed by HSML in non-responders to 2 half-dose PDT treatments. 
Half-dose PDT followed by diode MP as treatment for chronic CSC: evaluation of a prospective treatment protocol
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Material and Methods
Patients
This study represents an interventional prospective case series demonstrating a standardized 
treatment protocol in chronic CSC. The protocol was performed in patients with symptomatic 
active chronic CSC, who were treated according to the protocol between October 2011 and 
April 2013, at the Department of Ophthalmology of the Radboud University Medical Center, 
Nijmegen, the Netherlands. This study followed the guidelines of the Declaration of Helsinki and 
local ethics committee waived approval. 
Active chronic CSC was defined by active leakage of fluid under the retina as evidenced on 
spectral domain (SD)-OCT and further supported by hyperfluorescent area (s) on ICGA or/
and ≥ 1 ill-defined leakage area(s) on FA. Patients with active chronic CSC were considered 
for treatment if they had a decline in best-corrected visual acuity (BCVA) associated with 
subjective vision loss. 
Exclusion criteria included: evidence of other disease that could explain serous SRF such 
as choroidal neovascularization (CNV) or polypoidal choroidal vasculopathy, myopia > 6 
diopters, no hyperfluorescensce on ICGA, (relative) contraindications for half-dose PDT 
treatment (e.g. porphyria, severely disturbed liver function), and (relative) contraindications 
for FA (or ICGA). 
An extensive ophthalmological examination was performed in all patients including 
the following examinations; visual acuity (VA), SD-OCT of the retina and choroid, fundus 
autofluorescence, FA and ICGA (SD-OCT, FA, ICGA; Spectralis HRA+OCT; Heidelberg 
Engineering GmbH, Heidelberg, Germany). If active disease was confirmed by SRF on SD-
OCT and characteristic leakage on FA and ICGA, ICGA-guided half-dose PDT was performed 
(Figure 1).
A control visit was scheduled preferably 6-8 weeks after treatment. Treatment response 
was evaluated based on the SD-OCT scan. A complete response to treatment was defined 
as complete absence of serous SRF on SD-OCT at the first control visit after treatment. In 
case of persistent SRF, a second half-dose PDT treatment was performed that was guided by 
a second ICGA made at the control visit 6-8 weeks after the first half-dose PDT treatment. 
If SRF was still present 6-8 weeks after the second half-dose PDT treatment, ICGA-guided 
HSML treatment was performed if there was no evidence of an alternative diagnosis such as 
CNV or polypoidal choroidal vasculopathy at this time point. 
Interventions
We decided to use half-dose PDT treatment as the first treatment based on reported success 
percentages of 70-100% in the available (retrospective) literature,22, 25-28 as compared to 41-
58% reported for HSML treatment in CSC.27, 29 We preferred to use half-dose PDT because 
this treatment strategy appears to have an outcome that is comparable with half-fluence or 
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half-time PDT, and because reducing the dose may decrease the likelihood of verteporfin-
associated adverse reactions. Both interventions were performed in mydriasis, achieved by 
instillation of a drop of 1.0% tropicamide and 5% phenylephrine in each eye at 3 different 
moments with an interval of 10 minutes. 
Half-dose photodynamic treatment
All patients received 3 mg/m2 verteporfin (Visudyne ®) (half-dose) intravenously, with an 
infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, a contact 
lens (a Volk® PDT lens) was positioned on the affected eye, and the aiming beam of the 
laser was focused on the treatment area. The magnification factor was taken into account in 
the settings of the half-dose PDT machine. The treatment area was chosen based on those 
hyperfluorescent area(s) on mid-phase ICGA that corresponded to SRF accumulation in the 
macula on the OCT scan and hyperfluorescent “hot spots” on the mid-phase FA, with the 
area of the aiming beam corresponding to the area of the subsequent laser spot area. The 
spot size corresponded to the diameter of the hyperfluorescent area on ICGA plus 1mm. 
The treatment was performed with standard 50 J/cm2 fluency, a PDT laser wavelength of 
689 nm, and a standard treatment duration of 83 seconds (Figure 1). The average spot size 
used in this study was 2.4 µm (range 1.3-7.2 µm; 5th percentile: 1.4 µm, median: 2.3 µm, 95th 
percentile: 6.6 µm). 
High-density subthreshold diode micropulse laser treatment
For this intervention a contact lens (an Ocular® Mainster Focal/Grid laser lens) was positioned 
on the affected eye. HSML treatment with an 810 nm diode laser (Iridex, Mountain View, 
United States) was performed over the areas identified on mid-phase ICGA. Multiple 
confluent, adjacent (non-overlapping) laser spots were applied, covering the leakage area 
on mid-phase ICGA. The area to treat was determined based on those hyperfluorescent 
area(s) on ICGA that corresponded to SRF accumulation in the macula on the OCT scan and 
hyperfluorescent “hot spots” on the mid-phase FA (Figure 1).
The following HSML treatment settings were used: a power of ≤ 1800 mW, a duty cycle of 
5%, frequency of 500 Hz, exposure time of 0.2 s per application (100 x [0.1 ms ON-time 
and 1.9 ms OFF-time per single pulse]), spot size: 125 µm and delivered with a high-density 
grid pattern of subthreshold invisible applications over the entire area of leakage, with a 
500 µm minimum distance to the fovea 17. To avoid suprathreshold treatment, a laser test 
spot of 1800 mW was first applied outside the macular area, and 3 seconds of observation 
of the test spot area to exclude a delayed discoloration due to a supratreshold effect. If 
retinal discoloration was seen at a power of 1800 mW (corresponding to suprathreshold 
treatment), the power was reduced with steps of 300 mW until there was no visible reaction. 
This power was then used to perform the ICGA-guided HSML treatment.
Half-dose PDT followed by diode MP as treatment for chronic CSC: evaluation of a prospective treatment protocol
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Clinical evaluation
The onset of complaints, the use of steroids, previous episodes, previous treatments and 
recurrence of disease after first successful treatment were recorded. In addition, all available 
imaging data (SD-OCT, FA, ICGA, and FAF) were collected to investigate the evolution of the 
clinical picture on multimodal imaging. 
The presence of SRF and RPE detachments within the macular area was evaluated using 
SD-OCT. 
In all affected eyes the SD-OCT scan made before each treatment was compared to the 
scan after that treatment, and the SD-OCT scan of the first visit was compared to the last 
available scan.
The central foveal thickness (CFT), defined as the distance between the inner part of the 
internal limiting membrane and the outer part of the external limiting membrane at the 
central fovea, was measured. Also, the height of the SRF accumulation was measured from 
the outer part of the external limiting membrane to the outer part of the RPE layer at the 
central fovea, which we will refer to as the SRF accumulation. If enhanced-depth SD-OCT 
imaging was available, the choroidal thickness was measured from the outer part of the 
hyperreflective RPE layer to the hyperreflective line of the inner surface of the sclera. 
Information of both the study eye and the fellow eye was included. Differences in the 
outcome of these measurements were compared among the patients using a paired t-test.
All FA ICGA, and FAF imaging that was available was evaluated on the following aspects; 
the extent, intensity, and pattern of retinal and choroidal abnormalities by an experienced 
grader. Also, the number of hot spots was registered at baseline, and during follow-up on FA 
and ICGA. Changes in extent, intensity, and pattern of retinal and choroidal abnormalities 
on FA, ICGA, and FAF were evaluated including hot spots on FA and ICGA and focal 
hyperfluorescent spots on ICGA. 
Visual acuity
To assess the overall effect of treatment on VA over time, the VA at first visit before treatment 
was compared to the VA of the first control visit after the first treatment. In addition, the VA of 
the first visit was compared to the VA at the final visit using an independent samples t-test, with a 
p-value < 0.05 considered statistically significant. 
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Figure 1. 
Examples of imaging features on fluorescein angiography (FA) and indocyanine green angiography (ICGA) in 
chronic central serous chorioretinopathy (CSC), and the corresponding treatment areas for photodynamic 
therapy (PDT) and high-density subthreshold micropulse laser treatment (HSML). A-B FA of the right eye of a 
patient showing hyperfluorescent hot spots, indicating leakage superior of the fovea (A). On ICGA an area area 
of hyperfluorescence is seen which corresponds to the hyperfluorescent area on the FA(B). C-F An example of a 
PDT spot (white circle) overlapping the hyperfluorescent area on the ICGA plus 1 mm as described in the protocol 
(C). HSML treatment scheme that would apply to the same eye, in which the central foveal area is excluded for 
treatment (white circle). The hyperfluorescent area on ICGA is treated with numerous, non-overlapping adjacent 
laser spots (white area outlined superior of the fovea) (D).
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Results
Demographics
A total of 59 eyes of 59 patients (46 male, 78%) with a mean follow-up of 39.2 weeks (range: 
8 - 126 weeks) were included in this study. The mean age of the participants was 48 years 
(range: 30-71 years). At the moment of inclusion current use of corticosteroids was reported 
in 7 patients (12%), 3 patients (5%) reported the use of corticosteroids in the past, 44 
patients (75%) did not report any corticosteroid use, and in 5 patients (8%) no information 
on corticosteroid use was available. Fifteen eyes (25%) received previous treatment partially 
at their referring ophthalmologist varying from HSML, Argon laser therapy, intravitreal anti-
vascular endothelial growth factor (anti-VEGF) injections, and oral acetazolamide. In 2 
patients these previous treatments took place 7 and 11 weeks before the first PDT treatment, 
respectively. In the other previously treated eyes, the previous treatment was performed 
more than 3 months before the first PDT treatment. Eleven patients (19%) reported one or 
more acute episode(s) of CSC with spontaneous resolution in the past.
In 5 patients (8%) SRF was found bilaterally at the first visit. An RPE detachment within the 
macular area was seen on SD-OCT in 13 of the study eyes (22%), and in 5 of the fellow eyes. 
Treatment response based on presence of SRF on SD-OCT 
Overall, after 1 half-dose PDT treatment 37 eyes (63%) showed complete resolution of the 
SRF at the first control visit (mean time 8.7 weeks, range: 4 – 18 weeks). Of these 37 eyes, 
2 eyes (5%) had recurrence of SRF within the study period and received further treatment 
according to the protocol. On the last available SD-OCT scan the SRF remained absent in 35 
eyes (95%); the 2 eyes that experienced a recurrence had persistence of SRF on SD-OCT, 
despite additional treatment. 
An overview of the treatment results is given in figure 2 (Figure 2).
Of the 43 eyes (73%) that did not receive any previous treatment, 29 eyes (67%) had 
absence of SRF after the first half-dose PDT treatment. In the group that received previous 
treatments, in 7 (47%) of the 15 eyes no SRF was seen on SD-OCT after the first treatment.
At the last known visit the SRF has disappeared completely on SD-OCT in 47 eyes (80%) (mean 
time 39.1 weeks, range 8 – 126 weeks). In 5 of these 47 eyes (11%) SRF was still present 
at the control visit 6-8 weeks after the last treatment, but a spontaneous improvement 
occurred resulting in complete absence of SRF at the last known visit.
No significant correlations were found between the treatment response and the spot size 
used during half-dose PDT, the use of steroids, the presence of RPE detachments, previous 
treatment and the duration of complaints. 
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Figure 2. 
Overview of the number of treatments per study eye and the treatment result as defined by the absence or 
persistent presence of subretinal fluid on optical coherence tomography 
FU-time; Follow-up-time, HSML; High-density subtreshold micropulse laser, PDT; Photodynamic therapy, SRF; 
Subretinal fluid
Clinical course
Fluorescein angiography, indocyanine green angiography, and fundus autofluorescence
FA, ICGA and FAF were compared before and after each treatment and all changes were scored 
(Table 1). The abnormalities seen on FA were compared to the changes seen on ICGA after 
the first half-dose PDT treatment, and an overlap between the two modalities was found in 
43 eyes (73 %) (i.e. in the 33 eyes with changes on FA the ICGA also showed similar changes, 
and in the 13 eyes without post-treatment changes on FA also no change was seen on ICGA). 
Changes seen on FA after treatment mainly consisted of a decrease in hyperfluorescence, 
conversion of clear focal leakage into staining or more diffuse leakage, and complete 
disappearance of hot spots. In 20 of 30 cases (67%) with a disappearance of the hot spot 
and/or decrease of the hyperfluorescent area as seen on FA, the findings corresponded to 
a complete absence of SRF on SD-OCT. On ICGA a decrease in focal hyperfluorescent zones, 
that may correspond to focal vascular dilations of the choriocapillaris, was observed in 39 
eyes out of 80 eyes/observations (49%) after treatment. In 74% (28 eyes) this decrease in 
hyperfluorescence on ICGA corresponded with a complete resolution of SRF on SD-OCT, and 
a decrease in SRF on SD-OCT was seen in 23% (Figure 3). 
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To compare FAF before and after treatment, accurate imaging was available in 51 eyes. The 
changes that were seen on FAF could mainly be explained by the absence or presence of 
SRF. The presence of SRF as evidenced on SD-OCT led to relative light scatter/blockage of 
autofluorescence. Nineteen of the 51 eyes showed a clear change on FAF imaging after 
treatment, and in 6 of these eyes (32%) a typical punctiform hyperautofluorescent pattern 
was seen in the area of previous SRF accumulation.
Table 1. Percentages of changes seen in multimodal imaging after treatment
First treatment Second treatment Third treatment
FA
58 eyes  
Change; 37 eyes (64%) 
No change; 21 eyes (36%)
17 eyes 
Change; 8 eyes (47%) 
No change; 9 eyes (53%)
2 eyes 
Change; 1 eyes (50%) 
No change ; 1 eyes(50%)
 
ICGA
57 eyes 
Change; 40 eyes (70%) 
No change; 17 eyes (33%)
18 eyes 
Change ; 8 eyes (44%) 
No change; 10eyes (56%)
2 eyes 
Change ; 0 eyes (0%) 
No change ; 2 eyes (100%)
 
FAF
51 eyes 
Change ; 19 eyes (37%) 
No change ; 32 eyes (63%)
19 eyes 
Change ; 5 eyes (26%) 
No change ; 14 eyes (74%)
4 eyes 
Change ; 1 eye (25%) 
No change ; 3 eyes (75%)
FA; Fluorescein angiography, FAF; Fundus autofluorescence, ICG Angiography; indocyanine green 
angiography
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Table 2. Changes measured on spectral domain optical coherence tomography after treatment
Number of eyes Mean difference 95% CI P-value
SRF accumulation 
  
treatment 1
treatment 2
treatment 3
treatment total
 
 
59
 
 
-125.6µm
 
 
-162.5 - -88.8
 
 
< 0.001
19 -75.7 µm -113.1 - -38.3 <0.001
10 -10.1 µm -55.6 – 35.4 0.627
59 -143.0µm -177.3- -108.7 <0.001
CFT 
treatment 1 59 5.4 µm 0.1 – 10.6 0.044
treatment 2 19 -3.1 µm -11.1 – 4.9 0.426
treatment 3 10 4.5 µm -4.9 – 13.9 0.306
treatment total 59 7.3 µm 1.3 – 13.3 0.018 
EDI  
treatment 1
 
29
 
-56.2 µm
 
-85.8- -26.7
 
0.001
treatment 2 17 2.6 µm -32.9 – 38.0 0.879
treatment 3 5 -12.6 µm -60.8 – 35.6 0.508
treatment total 22 -21.9 µm -53.9 – 10.1 0.170
CFT; Central foveal thickness, CI: Confidence Iiterval, EDI; Enhanced depth imaging, SD-OCT; Spectral 
domain optical coherence tomography, SRF; Subretinal fluid
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Figure 3. 
Examples of changes after treatment as seen on fluorescein angiography (FA), indocyanine green angiography 
(ICGA) and spectral-domain optical coherence tomography (SD-OCT) in chronic central serous chorioretinopathy 
(CSC). A-B/E-F/I-J Examples of clear hot spots (indicated by the white arrows) on FA (left image) and ICGA (right 
image) of CSC patients (A/E/I) with a corresponding subretinal fluid (SRF) accumulation on SD-OCT (B/F/J) before 
treatment. C-D/G-H/K-L The same imaging modalities in the same patients after treatment (respectively). C-D 
An illustration of the disappearance of the hot spot in FA and ICGA (C; white arrow), as well as the resolution of 
the SRF on SD-OCT (D). G-H Persistence of the hot spot on FA and ICGA (G; white arrow) after treatment, with an 
absence of SRF on SD-OCT (H). K-L The hot spot as seen before the treatment on FA and ICGA (I), changed into 
diffuse staining on FA and ICGA after treatment (K; white arrow). Also, a clear decline of SRF was seen on SD-OCT 
(L).
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Spectral-domain optical coherence tomography
After the first treatment, the SRF accumulation and the thickness of the choroid showed 
a significant decrease (mean decrease: 125.6 µm; range: 88.8 – 162.5 µm; p <0.001, and 
mean: 56. µm; range: 26.7 – 85.8 µm; p = 0.001, respectively), and the CFT showed a mean 
increase of 5.4 µm (range: 0.1 – 10.46µm; p = 0.044; Table 2). 
Nine fellow eyes that did not have an SRF accumulation on OCT were found to be eligible 
for comparison of the choroidal thickness on the EDI-OCT scan with the affected study eyes. 
For this analysis only the difference between the first EDI-OCT scan and the last available 
EDI-OCT was used. The mean decrease in choroidal thickness was significantly lower in the 
untreated fellow eyes without SRF than in the treated study eyes (-58.7 µm in the study eyes 
versus -14.4 µm in the fellow eyes (p = 0.006)). 
In 9 eyes (15%), of which 8 responded well to the one half-dose PDT treatment with a 
complete resolution of SRF, a gradual anatomical alignment of the outer photoreceptor 
structure was seen on SD-OCT in the months following SRF resolution after treatment 
(Figure 4), which also resulted in VA improvement in 5 of these eyes (50%) at the final 
follow-up visit (approximately 5-6 months after treatment). 
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Figure 4. 
An example of recovery of the photoreceptor layer on the long-term follow-up on Spectral Domain Optical 
Coherence Tomography (SD-OCT) after half-dose photodynamic therapy (PDT). (A) An SD-OCT of a left eye with 
active chronic CSC as evidenced by subretinal fluid. (B) An SD-OCT scan of the same eye taken 9 weeks after half-
dose PDT The treatment resulted complete absence of the subretinal fluid (SRF), but the OCT layers corresponding 
to the outer photoreceptor structures are still irregular (visual acuity: 0.30 LogMAR). (C) An SD-OCT scan of the 
same eye taken 25 weeks after the treatment, without further therapeutic intervention. The SRF is still absent and 
the outer photoreceptor layers have gradually remodeled to a more physiological aspect, which corresponded to a 
visual acuity increase to 0.03 LogMAR.
Development of choroidal neovascularisation 
During follow-up, 3 eyes (5%) of 3 patients (2 female and 1 male, aged; 68, 51 and 40 years) 
in this study cohort developed a CNV. Two of these eyes received 2 half-dose PDT treatments 
and 1 HSML treatment according to the protocol, before the development of the CNV. One 
eye received 2 half-dose PDT treatments before treatment with bevacizumab was started 
after the diagnosis of CNV was established. One patient refused anti-VEGF treatment and 
was lost to follow-up. In one patient anti-VEGF treatment caused an incomplete decrease 
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in SRF, whereas in the other patient an increase in SRF accumulation was seen despite 
treatment with bevacizumab. 
Re-evaluation of the initial imaging before inclusion in the study treatment protocol in these 
3 patients with CNV showed lesions suggestive for a very early stage of a CNV that may already 
have been present and slumbering at that time point. However, the clinical characteristics of 
the lesions at that point in time appeared more compatible with a diagnosis of chronic CSC 
without CNV than with CNV as primary cause of the SRF accumulation.
Visual acuity
Eyes were divided into two groups for specific sub-analysis: group 1 consisting of patients 
with only one half-dose PDT treatment and group 2 containing patients with more than one 
treatment. 
When looking at the overall change in VA after the first half-dose PDT treatment, among 
all eyes a mean decrease of 0.12 LogMAR (95% CI = -0.07 to -0.17, p < 0.0001) was found. 
When dividing the patients into the aforementioned subgroups, we observed that patients 
who received only 1 treatment appeared to have a more pronounced, but not significantly 
different, VA improvement as compared to the group that received multiple treatments 
((-0.14 LogMAR (95% CI = -0.07 to -0.20; p < 0.0001) versus -0.09 LogMAR (95% CI = -0.01 to 
-0.18; p = 0.038), respectively). 
The mean VA at the last visit in group 1 showed a further increase at the final visit (-0.16 
LogMAR (95% CI: -0.10 to -0.23, p <0.001) as compared to the change in VA at the first 
control visit, whereas the mean VA in group 2 did not show a significant change at the final 
visit as compared to the change after the first treatment (-0.08 LogMAR (95% CI: 0.01 to 
-0.18, p = 0.082). 
When comparing the change in VA after the first, second and third treatment, the highest 
increase in VA was seen after the first treatment (Figure 5). 
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Figure 5. 
The mean change of visual acuity (LogMAR) and 95% confidence interval after each treatment (1-3 respectively), 
and the change between the first and the last known measurements of visual acuity (last).
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Discussion 
This study of a prospective treatment protocol for chronic CSC describes a positive treatment 
response using sequential half-dose PDT and HSML treatment. The most significant treatment 
response was seen after the first treatment with half-dose PDT, with a complete resolution 
of SRF in 63% of chronic CSC cases after 1 half-dose PDT treatment. HSML treatment as 
“salvage therapy” in previous non-responders to 2 half-dose PDT treatments had a lower 
treatment response rate, with only 2 of 10 eyes having complete absence of SRF at the final 
follow-up after HSML treatment. 
The success rate of half-dose PDT treatment in our study, defined as an absence of the 
SRF on OCT after treatment, is lower than reported in previous retrospective studies. A 
possible explanation may relate to the fact that 25% of the included patients had previously 
received a treatment (excluding PDT) for chronic CSC before being enrolled in our treatment 
protocol. Also, we observed that a second half-dose PDT treatment, in patients with 
persistent SRF, appeared to have a lower chance of success. It is possible that the subtle 
changes in the choroidal vasculature caused by the first half-dose PDT treatment decreases 
the susceptibility of the choroidal vasculature to further treatment. Sonoda et al. described 
a decrease in luminal area of the choroidal vessels after PDT treatment in patients with 
AMD using non-reduced treatment settings.30 This decreased choroidal luminal volume may 
result in a lower concentration of verteporfin (Visudyne®) at the area to treat, and therefore 
reduce the efficacy of a second half-dose PDT treatment. In addition, changes at the level of 
the RPE have been reported after PDT treatment.31, 32 Pre-existent RPE dysfunction due to the 
chronic CSC itself and/or potential damage to the RPE caused by the previous PDT treatment 
may interfere with the HSML treatment effect, which could result in non-response. Also, the 
titration of a harmless but optimally effective subthreshold HSML treatment effect remains 
uncertain. However, based on previously published studies we believe that the HSML 
treatment settings used in our study are in the upper range of the subthreshold. Selective 
retinal therapy, on the other hand, is a technique introduced by Roider and colleagues,33 in 
which the RPE is selectively treated with short laser pulses (microsecond pulse duration), 
based on the leakage area seen on FA. The advantage of this technique is that response 
of the RPE can be detected during the treatment procedure due to the occurrence of 
microbubbles, and after treatment by laser effects on the RPE on angiography.34 As first-line 
therapy, this technique has shown clinical success in chronic cases, as well as in patients with 
acute CSC.35, 36 However, we did not study the HSML treatment used as a first-line therapy, 
and are therefore unable to compare these results. It is possible that first-line treatment 
of chronic CSC with HSML would be more effective,20 and although no serious side effects 
such a RPE atrophy have been described thus far for selective retinal therapy, we chose the 
HSML treatment in which no anatomical damage is detected, for our study. Additionally, we 
were unable to identify a specific subgroup of chronic CSC patients that may be less likely 
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to respond to half-dose PDT and/or HSML treatment based on the available clinical and 
imaging characteristics. 
Our data show that the highest gain in VA occurs after the first half-dose PDT treatment. 
The second half-dose PDT treatment and HSML treatment showed less effect on VA. Where 
a previous study already outlined the importance of the correlation between the initial VA 
and the final outcome,37 our findings can also guide clinicians in providing further prognostic 
information to the patients. Based on the current findings, ophthalmologists may inform 
their patients that most gain of VA occurs after the first half-dose PDT treatment, and that 
there may be a slow VA gain over up to 6 months due associated with gradual anatomical 
recovery (Figure 4). The gradual VA gain has been described in previous studies. Some 
prognostic factors have been found to be of influence on the final VA outcome. Wang 
et al. described the development of macular atrophy if a subretinal detachment persists 
longer than 4 months .13 Our data did not reveal a clear correlation between the period of 
complaints and the visual outcome, which could be due to the small sample size. Piccolino 
et al. also reported that the preservation of the outer photoreceptor layer is a prognostic 
factor of the VA. 38
We show that the CFT significantly increased after treatment. It is possible that while SRF 
is present, the SRF accumulation stretches the overlying fovea and therefore causes a 
decreased CFT. Prolonged SRF accumulation that separates the neuroretina and RPE and 
precludes their normal symbiotic interaction, as well as the possible foveal stretching, may 
cause irreversible anatomical and functional retinal damage with vision loss. Comparable 
mechanisms have been reported in the Müller cells of rats after mechanically stretching was 
performed.39 Although, our findings were significant, the difference was relatively small (5.4 
µm), and it should be kept in mind that this observation may be caused by the individual 
measurement error.
In this study, 3 patients developed a CNV. PDT can cause hypoperfusion of the 
choriocapillaris,15 which may play a role in the development of CNV in these cases. On 
the other hand, our protocol uses half-dose PDT in which side-effects such as CNV have 
rarely been reported. In addition, a 4-year follow-up study of PDT using full settings in CSC 
has found no evidence of CNV development.40 Re-evaluation of the initial imaging before 
treatment in the 3 patients with CNV in the present study revealed abnormalities that could 
in retrospect be compatible with a subtle, initial stage of CNV. It is unclear if half-dose PDT 
may increase the risk of further growth of a smoldering, small CNV. A certain degree of 
clinical and genetic overlap between age-related macular degeneration and chronic CSC has 
previously been described.5, 41 This diagnostic pitfall should be kept in mind in the case of a 
suboptimal effect of half-dose PDT treatment in chronic CSC patients, or vice versa in non-
response to anti-VEGF in CNV patients. 
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The pathophysiological mechanism of chronic CSC remains unknown, although many theories 
have been postulated. One generally accepted theory postulates that the SRF primary 
derives from fluid leakage in the choroid through a dysfunctional RPE with a disrupted outer 
blood-retinal barrier.3, 42 Multimodal imaging using EDI-OCT and ICGA has shown evidence 
of choroidal dilation, congestion and hyperpermeability of the choriocapillaris in chronic 
CSC.9, 10, 43, 44 The treatment mechanism of PDT is based on this choroidal dysfunction. 
PDT is assumed to induce a remodeling of the choroidal vasculature, supposedly through 
selective vascular occlusion due to damage to choroidal endothelial cells and subsequent 
thrombotic events of the choriocapillaris.45, 46 This change in the choroidal vasculature 
would then result in a reduced choroidal congestion, and less vascular hyperpermeability 
and extravascular leakage.45, 47, 48 Maruko and co-workers have also identified a decrease 
in choroidal thickness after half-dose PDT treatment using EDI-OCT, which supports the 
aforementioned presumed treatment effects on the choroid. 49 PDT is therefore one of the 
most commonly used treatment modalities in chronic CSC.20, 21 Although, it is suggested that 
these changes in choroidal thickness may result from diurnal variation,50 we do not think 
that this phenomenon can fully explain the findings in this study. Especially the fact that a 
significantly greater decrease in choroidal thickness was seen in the study eye as compared 
to the fellow eye, which was examined in the same visit, supports a treatment effect. We 
have found the highest treatment response rate after the first half-dose PDT treatment, 
as well as a significant decrease in choroidal thickness after this treatment, which may 
also indicate that treatment of the choroidal structures as a primary driving force for SRF 
accumulation can treat the SRF as a consequence of this choroidal process. Also, the findings 
on ICGA in our study seemed to correspond better with the findings on SD-OCT than FA. 
Besides the apparently prominent role for choroidal dysfunction in CSC, dysfunction of the 
RPE also seems to play an important role, but it is unclear if there is primary RPE dysfunction 
or that its dysfunction if purely secondary to the choroidal abnormalities.2, 3 To inhibit the 
leakage of SRF, focal argon (suprathreshold) laser treatment of the “hot spots” of RPE leakage 
has been used in CSC. However, despite the fact that argon laser photocoagulation may be 
able to shorten the duration of SRF accumulation, there appears to be no or limited effect 
on VA and disease recurrence rate.49, 51-53 Also, conventional laser therapy cannot be used to 
treat hot spots of leakage near the fovea, because of the risk of central scotoma, long-term 
focal laser scar expansion (atrophic creeping) and/or secondary CNV development. Chronic 
CSC patients often have larger and/or multiple areas of SRF leakage that would make the risk 
of damage of Argon laser treatment even higher. The use of conventional suprathreshold 
laser treatment in chronic CSC patients has therefore lost popularity especially with the 
description of alternative treatments such as PDT, and HSML treatment that seem to have 
a more favorable safety profile.3 Our proposed HSML treatment protocol uses subthreshold 
settings, avoiding the risks of the conventional laser therapy.20, 21 Anti-VEGF treatment has 
also been proposed as therapeutic option. However, Bae and co-workers showed that 
Half-dose PDT followed by diode MP as treatment for chronic CSC: evaluation of a prospective treatment protocol
167
Ch
ap
te
r 
4.
1
in terms of the anatomic outcomes, the effect of ranibizumab injections was inferior to 
low-fluence PDT.54 Therefore, a primarily VEGF-driven process seems less likely, although 
increased VEGF levels could play a significant role in the mechanism of CNV development in 
advanced chronic CSC. Other treatment modalities, including for instance mineralocorticoid 
antagonists such as eplerenone or spironolactone, may also be considered as alternative 
treatment options in chronic CSC,55 although the effectiveness of eplerenone in previously 
treatment-resistant chronic CSC may also be limited.16
In conclusion, this prospective study has demonstrated effective treatment with half-dose 
PDT in chronic CSC. Patients should be informed that the highest chance of success and 
most visual gain is to be expected after the first half-dose PDT treatment. The role of HSML 
treatment in CSC remains unclear, and no results from multicentre randomized controlled 
treatment trials on this topic have been published thus far. We are currently performing 
such a multicenter prospective randomized controlled trial comparing half-dose PDT with 
HSML as primary treatment for chronic CSC 
[EudraCT number 2012-004555-36, NCT01797861; http//clinicaltrials.gov/]. 
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Purpose: 
To investigate if patients who developed chronic central serous chorioretinopathy (CSC) 
in association with corticosteroid treatment respond differently to photodynamic therapy 
(PDT) as compared to patients who have not used steroids.
Methods:
Clinical evaluation included visual acuity (VA), fundoscopy, optical coherence tomography 
(OCT), fluorescein- and indocyanine green angiography. The main outcome measure was a 
complete resolution of subretinal fluid (SRF) on OCT after PDT.
Results: 
One hundred and twenty-three eyes (117 patients), including 35 steroid-associated cases 
(29%), who received PDT treatment with reduced settings for active chronic CSC were 
included. Complete resolution of SRF on OCT was seen in 69% of the steroid-associated 
cases, and in 50% of the controls after PDT treatment (p = 0.062). At the final follow-up 
moment 74% of the cases had a complete resolution of SRF compared to 60% in the control 
group (p = 0.142). The VA at the first visit after therapy showed an increase in both groups 
(mean VA before treatment; cases: 69±14 Early Treatment Diabetic Retinopathy Study 
(ETDRS) letters, controls: 74±13 ETDRS letters, mean VA first visit after treatment; cases: 
76±13 ETDRS letters, controls: 75±13 ETDRS letters). No significant differences were seen in 
response to PDT between the patients who continued corticosteroid treatment and those 
who ceased the use of corticosteroids.
Conclusions:
PDT appears to be equally effective in patients suffering from steroid-associated chronic 
CSC as compared to chronic CSC patients who do not use corticosteroids. Continuation of 
corticosteroids at the time of PDT treatment does not seem to adversely affect PDT response.
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Introduction
Central serous chorioretinopathy (CSC) is a relatively common early-onset eye disease, 
characterized by an accumulation of leaked serous fluid under the retina, causing a 
detachment of the neuroretina. This subretinal fluid (SRF) leakage results from dysfunction 
of the retinal pigment epithelium (RPE), presumably caused by choroidal congestion and 
thickening and hyperpermeability of the choroid.1-4 
Two main subtypes can be distinguished: acute CSC and chronic CSC.1-7 In acute CSC, patients 
manifest with sudden and marked vision loss, and acute CSC is characterized by a focal 
leakage spot seen on fluorescein angiography (FA) that indicates leakage at the level of the 
retinal pigment epithelium (RPE).1-9 This SRF accumulation resolves spontaneously within 3 
months in most acute CSC patients, with near-complete visual recovery.2, 4
Compared to acute CSC patients, chronic CSC patients present at an older age, with a disease 
onset that is generally experienced as less sudden.7 Furthermore, chronic CSC generally 
shows a more diffuse and sometimes multifocal leakage pattern on FA and especially on 
indocyanine green angiography (ICGA), often with more widespread and irregular RPE 
changes associated with various degrees of low-grade leakage as compared to acute CSC.1-
6, 8-11 In contrast to acute CSC, the SRF accumulation in chronic CSC tends to persist for 
more than 3 months, although it can wax and wane multiple times.4-6 Additionally, ICGA 
characteristically demonstrates widespread hyperfluorescent areas of choroidal congestion 
and hyperpermeability, which are more extensive in chronic CSC than in acute CSC.3, 8, 12-14 
These abnormalities mostly overlap with those seen on FA, but can also be present without 
any evidence of leakage on FA in chronic CSC.8
A persistent serous neuroretinal detachment in chronic CSC can cause progressive and 
irreversible photoreceptor damage.3, 15, 16 Therefore, it is common practice to treat these 
patients, although prospective multicenter randomized controlled trials on the optimal 
treatment are largely lacking. Currently, photodynamic laser therapy (PDT) is one of the 
most frequently used treatment modalities in chronic CSC, with reported anatomical 
success rates in retrospective studies ranging from 70-100%.17-20 This is a relatively broad 
range. Therefore, it is of clinical relevance to identify possible factors that could influence 
treatment success.
Although the exact mechanism by which CSC develops is largely unclear, several associations 
and risk factors have been described in the literature, such as male gender, stress, type A 
personality, pregnancy, and the use of corticosteroids.21-23 In addition, genetic risk factors 
have recently been identified in CSC.24-26 In particular the use of corticosteroids, is one of 
the most prominent risk factors known in CSC, although the reported effect sizes vary (odds 
ratio: 2.4 and 10.3).21, 27 Some patients report a clear association between the initiation of 
corticosteroids and the start of CSC-associated visual complaints. This could indicate possible 
differences in the disease mechanisms between steroid users and non-steroid users. The 
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previous or ongoing use of corticosteroids is likewise thought to be a risk factor for ongoing 
disease activity in chronic CSC, and could potentially limit the efficacy of treatment.
In studies on PDT as treatment for chronic CSC the use of corticosteroids is often an exclusion 
criterion; therefore it is unclear if the outcome of PDT in chronic CSC is different compared 
to patients who have no history of current or previous corticosteroid use. 
The aim of this study was to investigate whether the response to PDT is different in 
treatment-naive patients presenting with steroid-associated chronic CSC versus chronic CSC 
patients without a history of steroid use. 
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Methods
Patients
The patients enrolled for this retrospective case-control study were seen at the outpatient 
clinics of the Departments of Ophthalmology of the Radboud University Medical Center 
(Nijmegen, the Netherlands) and the Leiden University Medical Center (Leiden, the 
Netherlands) between January 2004 and February 2015. We retrospectively reviewed 
the medical records of all patients who had been diagnosed with chronic CSC and who 
consequently had been treated with PDT as first-line therapy. The diagnosis of chronic CSC 
was based on characteristic features as seen on multimodal imaging consisting of OCT, FA, 
and ICGA. These features included presence of SRF in the macula on OCT, and irregular 
diffuse and/or multifocal hyperfluorescent areas in the posterior pole, corresponding to 
irregular RPE window defects with or without obvious hot spots of leakage on FA, with one 
or more corresponding hyperfluorescent areas on ICGA (Figure 1).25 Approval for this study 
was obtained at the local institutional review boards, and the study adhered to the tenets 
of the Declaration of Helsinki.
At the visit prior to the PDT, the first evaluation visit after therapy, and at the last available 
follow-up visit, the following parameters were collected; visual acuity (VA) in Early 
Treatment Diabetic Retinopathy Study (ETDRS) letters, start date of visual symptoms, the 
use of corticosteroids (including reason for use and route of administration), presence of 
SRF on OCT, and central retinal thickness (CRT) as measured automatically by the integrated 
software of the Spectralis™ HRA+OCT (Heidelberg Engineering, Heidelberg, Germany). Due 
to a satisfying response to treatment, only the first evaluation visit was available in a part 
of the cases and the controls. If the first evaluation visit after treatment was also the last 
available follow-up visit, the collected information was only used in the analysis for the first 
evaluation visit. An exception was made for the absence of SRF at final follow-up.
Steroid use
Patients were divided into two groups based on their reported use of steroids; patients who 
used corticosteroids within 12 months prior to the development of the chronic CSC (cases), 
and patients who did not have a history of current or prior use of any type of corticosteroids 
(controls). For the first group, only patients in whom a relation between steroid use and the 
onset of CSC symptoms was highly suspected, were included. This probability of a causal 
relationship was assessed by the treating physician at the moment of diagnosis.
For sub-analysis in the cases, a further distinction was made between patients who 
continued steroid use in the period when PDT had been performed and those who ceased 
corticosteroid use before treatment. 
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Figure 1. 
Examples of the typical abnormalities as observed on multimodal imaging techniques (left to right; fundus 
autofluorescence (FAF), early fluorescein angiography (FA), mid-phase indocyanine green angiography (ICGA), and 
optical coherence tomography (OCT)) in 3 patients with chronic central serous chorioretinopathy (CSC).  
The images in the upper 2 rows belong to 2 patients with steroid-associated chronic CSC. (A-D) The right eye of 
a 45-year-old male bodybuilder with frequent steroid injections, illustrating juxtafoveal hyper- autofluorescent 
irregularities of the retinal pigment epithelium (RPE) layer on FAF(A), multifocal leakage on FA and ICGA (B-C), 
and subfoveal subretinal fluid (SRF) on OCT(D). (E-H) The left eye of a 48-year-old male who used topical steroid 
cream for skin problems. The FAF shows hyperautofluorescence inferotemporal of the optic disc (E), and hot spots 
indicating leakage are seen on FA and ICGA accompanied by SRF on OCT (F-H). (I-L) The right eye of 56-years-
old male who did not report the use of steroids. FAF shows central hyperautofluorescence corresponding to 
hyperfluorescent leakage on FA and ICGA (I-K), and a flat SRF accumulation on OCT(L).
Photodynamic therapy
For this study, PDT treatment was performed with reduced settings, either with half-dose or 
half-time as compared to the original settings described for neovascular age-related macular 
degeneration, depending on the preference of the treating physician.28, 29 Before treatment, 
the pupils were dilated (with 1.0% tropicamide and 2.5% phenylephrine). Verteporfin 
(Visudyne ®; 3 mg/m2 (for the half-dose PDT) and 6 mg/m2 (for the half-time PDT)) was 
intravenously administered, with an infusion time of 10 minutes. At 15 minutes after the 
start of the infusion, an anesthetic eye drop was applied (oxybuprocaine 0.4% or equivalent), 
a contact lens (Volk ® PDT lens) was positioned on the affected eye, and a laser beam was 
focused on the area to treat of which the spot size was based on hyperfluorescence as seen 
on mid-phase (approximately 10 minutes) ICGA. The PDT was performed with standard 50 
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J/cm2 fluency, a PDT laser wavelength of 689 nm, and a treatment duration of 83 seconds in 
patients treated with half-dose PDT, and 42 seconds in the half-time PDT.
Definition of the outcomes
Effectiveness of the PDT was based on the anatomical recovery as seen on OCT, defined as a 
complete absence of SRF. Furthermore, we compared the VA and the CRT before and after 
treatment in each patient, and between the (sub)groups. Additionally, we analyzed the period 
of time needed to achieve a complete resolution of SRF between the cases and controls. To 
evaluate the effectiveness of PDT over time, we analyzed the number of recurrences, and also 
the number of additional treatments that each patient received until the end of the study. 
Statistical analysis 
Statistical analyses were performed using IBN SPSS software for Windows version 20. 
For comparisons of continuous numerical data in demographic characteristics and study 
outcome measures we performed a dependent t-test, an independent t-test or a Mann-
Whitney U test as appropriate. Categorical data were analyzed using a Chi-square test. 
Furthermore, two survival analyses were performed and Kaplan-Meier survival plots were 
generated comparing the cases with the controls. The following events were used; ‘complete 
resolution of SRF after 1 PDT treatment’ and ‘complete resolution of SRF at final follow-up’. 
A two-sided P value of less than 0.05 was considered statistically significant.
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Results
Patient characteristics
Demographics
Thirty-five eyes of 33 patients (mean age at time of PDT treatment: 55 ± 11.7 years) with 
corticosteroid-associated chronic CSC, and 88 eyes of 84 patients (mean age at time of PDT 
treatment: 52 ± 11.1 years) who did not report any use of corticosteroids were included 
in this study (Table 1). General characteristics including age, gender, reported duration of 
complaints, elapsed time between treatment and first control visit, baseline VA, and mean 
CRT as measured on OCT at baseline did not differ significantly between the steroid-users 
and the non-steroid users (Table 1).
Among the 33 patients with reported (previous) use of steroids, 9 (27%) patients used 
corticosteroid cream, 9 (27%) patients reported nasal spray containing steroids, 7 (21%) 
patients used oral corticosteroids, 4 (12%) patients used steroids by an inhaler, 1 (3%) patient 
received illegal corticosteroid injections for professional bodybuilding, and the remaining 3 
(9%) patients reported (previous) use of steroids via more than one way of administration. 
The corticosteroid use was continued before, during, and after PDT treatment in 16 (46%) 
of 35 eyes.
Table 1. Patient demographics in cases and controls
 Cases Controls P-value
Eyes (patients) 35 (33) 88 (84) Not applicable
Gender (m/f) 24/ 11 72 / 16 0.109
Age a [range] in years 54.6 [31-80] 52.0 [29-81] 0.285
VA pre-therapy in ETDRS letters (SD) 69 (14) 74 (13) 0.065
CRT before therapy (SD) 381.3μm (111) 374.9μm (116) 0.782
Duration of complaints in weeks b [range] 38.8 [3.1-706.9] 30.3 [3.7-566.0] 0.445
Half-dose PDT / Half-time PDT 30 / 5 82 / 6 0.190
a Age at the time of photodynamic therapy treatment 
b Median number of weeks between the start of the complaints and therapeutic intervention
ETDRS; Early Treatment Diabetic Retinopathy Study, PDT; Photodynamic Therapy, SD; Standard 
Deviation, VA; Visual Acuity
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Optical coherence tomography
At the first control visit after PDT (on average 7.4 ± 2.8 weeks after treatment in the cases, 
and 7.9 ± 2.9 weeks after treatment in the controls) 22 (63%) eyes of the steroid-associated 
chronic CSC patients, and 40 (45%) eyes of the controls showed a complete absence of SRF 
on OCT. Moreover, a clear reduction of SRF was seen in 26% (n=9) of the steroid-associated 
patients, and in 28% (n=25) of the non-steroid associated controls. During follow-up this 
reduction led to a complete absence of SRF in 2 (22%) of these cases, and in 4 (16%) eyes of 
these controls. In 3 (9%) out of 35 steroid-associated eyes with chronic CSC, and 17 (19%) 
out of the 88 eyes of controls with chronic CSC no changes in SRF were observed on OCT at 
the first control visit. One eye with steroid-associated chronic CSC (3%) and 6 (7%) eyes in 
the control group showed an increase in SRF.
When comparing the resolution of SRF using a survival analysis, there was a trend for 
subjects in the corticosteroid-associated chronic CSC group to have a faster full resolution of 
SRF as compared to the controls (Figure 2).
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Figure 2. 
Kaplan-Meier curves showing the cumulative fraction in treated chronic central serous chorioretinopathy patients. 
A. Endpoint: ‘Full resolution of subretinal fluid (SRF) after 1 photodynamic therapy’; median duration before SRF 
fully resolved in cases: 8.9 weeks [95% CI: 6.4-11.3] and controls: 10.0 weeks [95% CI: 5.2-14.8], (p = 0.064) B. 
Endpoint: ‘Complete resolution of SRF at final follow-up’; median duration before SRF fully resolved in cases: 31.7 
weeks [95% CI:18.6-44.8] and controls: 36.8 weeks [95% CI:25.5-48.2], (p = 0.344) 
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A reduction in CRT was seen in both groups at the first and final follow-up after treatment 
(Table 2). There was no significant difference in the mean reduction of CRT between both 
groups at final follow up (steroid users (n=21); 114.1 ± 143.9 µm, non-steroid users (n=46); 
109.4 ± 109.7 µm, p = 0.883, independent t-test).
During follow-up, a recurrence of SRF on OCT was seen in 6 (25%) of the 24 patients with 
steroid-associated chronic CSC, and in 9 (20%) of the 44 patients with non-steroid associated 
chronic CSC who initially showed a good response (absence of SRF on OCT) after PDT. 
At the final visit (on average 48.4 ± 31.4 weeks post-therapy in cases, and 49.6 ± 49.7 
weeks post-therapy in controls) SRF had completely resolved in 26 (74%) out of 35 eyes 
with steroid-associated chronic CSC, of which 5 (19%) eyes had received additional 
treatments that consisted of either a second PDT, conventional laser therapy of the hot 
spot, high-density subthreshold micropulse laser treatment, intravitreal bevacizumab 
or a combination of the aforementioned treatments (mean number of additional 
treatments; 1.8 (range 1 – 3)). In the control group, 53 (60%) eyes had complete absence 
of SRF at final follow-up. Of these eyes 18 (34%) eyes received additional treatment 
consisting of either a second PDT treatment, high-density subthreshold micropulse laser 
treatment, intravitreal bevacizumab, intravitreal aflibercept or a combination of the 
aforementioned treatments (mean number of additional treatments; 1.7 (range 1 – 4)). 
Of the eyes with SRF on OCT at the last available visit (9 (26%) eyes in the steroid-associated 
cases, and 35 (40%) eyes in the controls), 18 eyes received additional treatment (2 (22%) 
eyes in the cases, and 16 (46%) eyes in the controls). 
Patients with suspected neovascularisation
In both groups a subretinal choroidal neovascularisation (CNV) was suspected during follow-
up in 3 eyes (9%) in the steroid-associated chronic CSC group, and 4 eyes (5%) in the controls, 
for which intravitreal anti-vascular growth factor treatment (anti-VEGF) was initiated. One 
of these patients initially responded well to the first PDT treatment with absence of SRF on 
OCT, followed by recurrence of the SRF. After anti-VEGF therapy 2 eyes (29%) had complete 
resolution of SRF, and 5 eyes (71%) had persistent SRF. Re-evaluation of the baseline imaging 
showed small lesions on OCT, FA or ICG that retrospectively could indicate a subtle pre-
existent occult CNV or a small polypoidal choroidal vasculopathy (PCV) at baseline in 4 eyes 
(57%). The mean age of the 7 patients suspected to have a CNV or PCV during follow-up 
was 64 years, which was significantly older as compared to the general group (mean age; 
52 years, , p = 0.006, independent t-test). None of these patients had evidence of drusen on 
ophthalmoscopy, OCT, and FA. 
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Visual acuity
The mean VA increased significantly after PDT treatment in the steroid-associated chronic 
CSC group when comparing the VA pre-PDT (69 ± 14 ETDRS letters) to the VA at the first 
control visit after treatment (76 ± 13 ETDRS letters) (p < 0.001, independent t-test). This 
was also the case in the non-steroid associated patient group (VA before treatment; 74 ± 
13 ETDRS letters, VA after treatment; 75 ± 13 ETDRS letters, p = 0.014, independent t-test). 
At the last available visit the mean VA was comparable between cases (72 ± 18 ETDRS letters 
(n= 21)), and controls (71 ± 14 ETDRS letters (n=45)) (Table 2). Of those patients in the 
case group who showed a full resolution of SRF (n=24), the VA was improved significantly 
after the PDT (VA pre-PDT: 70 ± 15 ETDRS letters; VA post-PDT: 78 ± 13 ETDRS letters, p = 
0.001). This was also the case in control eyes with a full SRF resolution (n=44) after the 
PDT (VA pre-PDT: 72 ± 15 ETDRS letters; VA post-PDT: 78 ± 13 ETDRS letters, p = 0.001). 
No significant differences were found in treatment response on OCT and visual outcome 
when dividing the group of steroid users into a group of patients who continued the use 
of steroids (oral, cutaneous crème, nasal spray, inhaler or a combination) during the study 
period (46% of 35 cases), and a group of patients who stopped the use of steroids during 
therapy (54%) (Table 3). In particular, of the 6 eyes of 5 patients who continued the use of 
oral corticosteroids during the PDT treatment, 4 (67%) eyes showed a complete resolution 
of SRF on OCT after PDT treatment at last available visit. 
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Table 2. Comparison of variables of interest at visit pre- and post-photodynamic therapy in cases and controls 
 Cases Controls P-value 
CRT pre-therapy in µm (SD) 381.1 (111) (n=35) 374.9 (116) (n=88) 0.782
CRT at first follow-upa in µm (SD) 290.9 (121) (n=35) 282.4 (81) (n=88) 0.655
CRT at final follow-upb in µm (SD) 289.4 (114) (n=21) 261.7 (54) (n=46) 0.298
VA pre-therapy in ETDRS letters (SD) 69 (14) (n=35) 74 (13) (n=88) 0.065
VA at first follow-up in ETDRS letters a (SD) 76 (13) (n=35) 75 (13) (n=88) 0.499
VA at final follow-up in ETDRS letters b (SD) 72 (18) (n=21) 71 (14) (n=45) 0.943
a Average number of weeks between therapeutic intervention and first follow-up in the steroid 
group: 7.4 weeks, in the non-steroid group: 7.9 weeks (p= 0.445)
b Average number of weeks between therapeutic intervention and final follow-up in the steroid 
group: 48.4 weeks, in the non-steroid group: 49.6 weeks (p= 0.886)
CRT; Central Retinal Thickness, ETDRS; Early Treatment of Diabetic Retinopathy Study, SD: Standard 
Deviation, VA; Visual Acuity
Table 3.  Comparison of central retinal thickness and visual acuity between patients who continued corticosteroid 
use during photodynamic therapy (PDT) and those who ceased corticosteroid treatment before PDT.
 Steroids were continued 
Steroids were 
ceased P-value
CRT pre-therapy in µm (SD) 405.0 (98) (n=16) 361.0 (119) (n=19) 0.249
CRT at first follow-up a (SD) 286.3 (103) (n=16) 294.7 (137) (n=19) 0.841
CRT at final follow-up b (SD) 227.9 (107) (n=11) 203.1 (125) (n=10) 0.638
VA pre-therapy in ETDRS letters (SD) 66 (14) (n=16) 71 (14) (n=19) 0.285
VA at first follow-up in ETDRS letters a (SD) 74 (14) (n=16) 78 (11) (n=19) 0.272
VA at final follow-up in ETDRS letters b (SD) 69 (23) (n=11) 75 (12) (n=10) 0.434
a Average number of weeks between therapeutic intervention and first follow-up in patients who 
continued corticosteroid treatment : 8.0 weeks, in patients who stopped corticosteroids: 6.9 weeks 
(p=0.265)
b Average number of weeks between therapeutic intervention and final follow-up in patients who 
continued corticosteroid treatment: 23.6 weeks, in patients who stopped corticosteroids: 21.7 
weeks (p=0.801)
CRT;Central Retinal Thickness, ETDRS; Early Treatment of Diabetic Retinopathy Study, SD; Standard 
Deviation, VA; Visual Acuity 
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Discussion
This study suggests that the current or recent use of corticosteroids in chronic CSC does 
not adversely affect the response to PDT. No significant differences were seen between 
the corticosteroid-associated chronic CSC cases and the controls regarding the treatment 
response on OCT and on visual outcome. 
Current literature reports an improvement of retinal anatomy and VA in 70-100% of chronic 
CSC after PDT treatment.17-20, 30, 31 The success rate of PDT treatment, defined as a complete 
absence of SRF on OCT, found in the present study is lower than those reported in previous 
studies. A possible explanation could be that our study evaluated a phenotypically different 
patient group. Previous studies have differentiated acute and chronic CSC  either based on 
the duration of presence of SRF, or based on phenotypic characteristics. However, thus far 
no consensus exists on how to define  chronicity in CSC.1, 32 Where some authors consider 
a duration of presence of SRF up to 2-3 months as typical for acute CSC,3, 8-10, 32 which 
implicates that if the SRF accumulation would exist longer than 3 months one can speak 
of a chronic CSC,  others argue that  CSC becomes chronic after a duration of more than 6 
months.33, 34 Also, division based on the extensity of abnormalities as seen on multimodal 
imaging has been described, and  Wang et al. demonstrated that in case of a subretinal 
detachment of more than 4 months, irreversible atrophy in the macula may already ensue.16 
Therefore, in the current study chronic CSC patients were included not only based on a 
disease duration of more than 3 months, but also on the presence of features indicative 
of chronicity on multimodal imaging: presence of SRF in the macula on OCT, and irregular 
diffuse and/or multifocal hyperfluorescent areas in the posterior pole, corresponding to 
irregular RPE window defects with or without obvious hot spots of leakage on FA, with one 
or more corresponding hyperfluorescent areas on ICGA .25 In contrast to acute CSC, chronic 
CSC patients have (and often present with) more widespread abnormalities on multimodal 
imaging.3, 8, 12-14 Although, the current study  included cases who seemed to have a follow-
up less than 3 months before receiving an intervention, all patients presented phenotypic 
features that confirmed chronicity. It is likely that the short follow-up time was caused by 
lack of information about the exact moment of onset of symptoms.
In our study, no differences were found in efficacy of PDT in chronic CSC patients who ceased 
the corticosteroids in comparison to the patients who had to continue corticosteroids. Lee 
et al. previously found a treatment response with absence of SRF in 100% of the cases, 
using either full-dose or half-time PDT, in a retrospective study of 9 steroid-associated CSC 
patients.35 In this study 5 of the 9 patient discontinued the steroid use, which could be of 
influence on the response.35 The findings in our study are encouraging as they suggest that 
the continuation of corticosteroid treatment, if inevitable for other medical indications, does 
not preclude a favourable response to PDT. It is unclear through which pathophysiological 
mechanisms corticosteroid use is associated with chronic CSC. For instance, it is still 
unknown whether corticosteroids are required to develop chronic CSC in the first place, or 
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if the use of corticosteroids is merely an additional trigger for a subclinical disease state that 
is already present. The use of corticosteroids is postulated to induce platelet aggregation 
and vasoconstriction and suppress vasodilatators (e.g. nitric oxide and prostaglandins).23, 
27, 36 Consequently, this may lead to microthrombus formation, which may alter choroidal 
perfusion and vascular permeability.23, 27, 36 On the other hand, corticosteroids do not have 
the same effect in every patient; Han et al. for example demonstrated that the choroidal 
thickening seen in steroid-induced CSC seems to be more an exceptional rather than a dose-
dependent response, that may be selectively present in vulnerable individuals.37 Choroidal 
congestion and hyperpermeability appear to be present in chronic CSC patients using 
corticosteroids as well as in those who do not. PDT may be an effective treatment in both 
patient subgroups as it is presumed to induce a remodeling of the choroidal vasculature, 
supposedly through selective vascular occlusion due to damage to choroidal endothelial 
cells and subsequent thrombotic events of the choriocapillaris that cause a decrease in 
choroidal thickness, a reduction in choroidal vascular hyperpermeability and leakage 
through the RPE, and a restoration in the fluid balance in the subretinal space.38, 39 PDT using 
standard settings (verteporfin dose of 6 mg/m2, fluency of 50 J/cm2, treatment time of 83 
seconds), has been associated with adverse effects such as choroidal ischaemia, RPE atrophy, 
and CNV formation,4, 17, 40-42 although a 4-year follow-up study in chronic CSC has not found 
any adverse effects using this treatment in 46 eyes with chronic CSC.43 PDT using reduced 
settings has commonly been adopted as this strategy appears to be equally effective and 
potentially safer compared to standard settings.4, 17, 40, 44, 45 However, retrospective evaluation 
of the baseline imaging in our study showed that of 7 patients who were suspected to have 
a CNV or PCV during follow-up, 4 patients had small lesions that were suspect for CNV or 
PCV. These lesions, however, were very subtle and easily overlooked even by experienced 
ophthalmologists. In the remaining 3 patients, who had no suspect lesions at baseline, it 
remains unclear if the PDT with reduced settings may have triggered further growth of 
a possible concealed small CNV. This would indicate that the CNV or the PCV could have 
been primarily associated with CSC-like changes before PDT was performed, as reported 
previously.46, 47 Therefore, chronic CSC patients should be monitored closely for possible 
occult CNV and/or PCV, especially elderly patient with a chronic CSC phenotype, and in case 
of non-response to PDT the initial diagnosis should be re-evaluated.
In conclusion, this study shows that PDT is an effective treatment in patients suffering 
from steroid-associated chronic CSC, and suggests that the efficacy is comparable to PDT in 
patients with chronic CSC who do not use corticosteroids. Although the pathophysiological 
mechanism may not be identical in both patient groups, it is not reflected in the overall 
treatment outcome of PDT. Therefore, PDT can also be offered as a treatment strategy in 
patients who are (or previously have been) on corticosteroid treatment. 
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Background and rationale
Chronic central serous chorioretinopathy
Central serous chorioretinopathy (CSC) is a relatively common early-onset eye disease, 
characterized by an accumulation of leaked serous fluid under the retina, causing a 
detachment of the neuroretina. This subretinal fluid (SRF) leakage results from dysfunction 
of the retinal pigment epithelium (RPE), and the presence of choroidal congestion and 
thickening and hyperpermeability of the choroid, implies an important role for choroidal 
abnormalities as an underlying cause for RPE dysfunction and SRF leakage in CSC.1-4 
Two main subtypes of CSC are generally distinguished: acute and chronic CSC.1-7 Patients 
with acute CSC present with sudden and marked central vision loss, because of SRF leakage 
in the macula due to a focal leak in the RPE that is visible on fluorescein angiography. Acute 
CSC generally has a favorable prognosis because the SRF often disappears spontaneously 
within 2-3 months, with either complete or almost complete recovery of vision. In contrast, 
chronic CSC is typically not self-limiting and SRF persists for more than 3 months. Also, chronic 
CSC patients present at an older age, with a disease onset that is generally experienced as 
less sudden, and bilaterality in chronic CSC is common.8 A history of acute CSC and/or an 
episode of acute vision loss compatible with acute CSC is present only rarely in chronic 
CSC patients,2,8 which also points to a distinction between acute and chronic CSC. Patients 
with the chronic CSC phenotype have more diffuse multifocal leakage on fluorescein and 
indocyanine green (ICG) angiography, as well as irregularly distributed widespread RPE 
changes associated with varying degrees of more indistinct leakage on angiography (Figure 
1). Persistent serous neuroretinal detachments can cause progressive and irreversible 
photoreceptor damage, resulting in a poorer visual prognosis of chronic CSC as compared to 
acute CSC.2,9,10 The etiology of CSC is largely unknown, but the use of corticosteroids is a risk 
factor, and possibly elevated cortisol levels, stress, “type A” personality, and pregnancy are 
also possible risk factors.1, 11-14 The incidence of CSC is approximately 6 times higher in men 
than in women,1 although this male-to-female proportion seems to be less pronounced in 
chronic CSC and steroid-associated CSC. Recently, single nucleotide polymorphisms in the 
Complement Factor H and ARMS2 have been found to be associated with chronic CSC.15,16
PLACE trial: a study protocol for a randomized controlled trial
195
Ch
ap
te
r 
4.
3
Figure 1 
Multimodal imaging in chronic central serous chorioretinopathy. Examples of fluorescein angiography (FA), 
indocyanine green (ICG) angiography and spectral-domain optical coherence tomography (SD-OCT) in chronic 
central serous chorioretinopathy (chronic CSC). (A-C) Right eye of a patient with chronic CSC with more widespread 
leakage on FA (A) corresponding with hyperfluorescent areas on ICG angiography (B) and SRF on SD-OCT (C)
A prolonged neuroretinal detachment in the macula leads to progressive and permanent 
central visual loss due to photoreceptor atrophy. In addition, Piccolino et al. described 
the occurrence of not only SRF, but also intraretinal fluid accumulations, posterior cystoid 
degeneration, in prolonged neuroretinal detachments in severe chronic CSC cases.17  Nicolo 
et al. have shown that this posterior cystoid degeneration is associated with a poorer 
response to photodynamic therapy (PDT),17,18 A loss of visual acuity with image distortion, 
loss of colour and contrast vision may have a significant impact on a patient’s personal 
and professional life. Early diagnosis and treatment is important to try to improve the 
visual outcome and quality of life, as long-term follow-up studies have shown that the 
natural course of chronic CSC often results in permanent visual loss.3,9,10,19-25 Therefore, 
several treatment options have emerged in an attempt to accelerate the resolution of SRF 
accumulation, and to improve the visual outcome in patients with chronic CSC. Treatment 
within 4 months after the onset of the disease has been advocated by several authors, 
based on the observation that permanent visual loss may result from prolonged duration of 
disease.2,3 Photoreceptor atrophy in the fovea may occur, even after successful reattachment 
of the retina, after a duration of symptoms of approximately 4 months.9 To date there is no 
international consensus on the optimal treatment protocol of chronic CSC.
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Photodynamic therapy in chronic central serous chorioretinopathy
A number of retrospective studies suggests that in 70-100% of CSC patients treatment with 
PDT, using the photosensitizing drug verteporfin (Visudyne®), is effective in reducing SRF, 
with an improvement of retinal anatomy, visual acuity,18,26-30 as well as retinal sensitivity.31-35 
PDT treatment has been developed originally as treatment for neovascular age-related 
macular degeneration, on which there are extensive data available.36, 37 There are several 
other retinal diseases for which PDT with verteporfin is successfully used as an off-label 
treatment, such as choroidal hemangioma and polypoidal choroidal vasculopathy.37 
PDT with Visudyne® (verteporfin for injection) is a two-stage procedure which first requires 
the intravenous administration of verteporfin, followed by the administration of non-
thermal red light into the affected eye. Verteporfin is transported in the plasma primarily by 
lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, 
short-lived singlet oxygen and reactive oxygen radicals are generated. Verteporfin appears 
to accumulate preferentially in abnormal neovascularization (which is not present in chronic 
CSC), but also in the choroidal vasculature. The latter mechanism is of special interest in the 
treatment of chronic CSC, because CSC primarily affects the choroidal circulation, resulting 
in multifocal areas of choroidal vascular hyperpermeability that may finally result in the 
accumulation of SRF. The therapeutic effect of PDT in chronic CSC is thought to result from 
short-term choriocapillaris hypoperfusion and long-term choroidal vascular remodelling, 
leading to reduction in choroidal congestion, vascular hyperpermeability, and extravascular 
leakage.38-40 
As mentioned previously, there is no international consensus on the optimal treatment 
protocol of chronic CSC. Nevertheless, PDT has emerged as the treatment of choice in 
many centres worldwide, based on the high rate of anatomic success, the increase of visual 
acuity, improvement in retinal sensitivity, and an excellent safety profile reported in many 
retrospective studies.3, 41-43 The PDT strategies that are generally used are either with half 
the dose of verteporfin and full fluency (energy) of laser treatment, half the fluency level 
and the full dose of verteporfin, or half the treatment time using the full dose of verteporfin 
and full fluency, as compared to the original protocol that was used for neovascular age-
related macular degeneration. These PDT strategies that use either half-dose of half-fluency 
treatment have been developed because a combination of the dosage and fluency that was 
originally used for the treatment of neovascular age-related macular degeneration showed 
a potentially higher risk of developing choroidal ischemia and retinal atrophic changes.36, 
44-46 The half-dose or half-fluency PDT strategies, however, have been shown to be safe and 
effective in relatively large retrospective studies and one non-controlled non-randomized 
prospective study by Chan et al. in chronic CSC patients with sufficient follow-up periods.3, 
27, 29, 41
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Therefore, tailoring the therapy to obtain the maximal treatment effect with minimal toxicity 
is essential in treating patients with CSC. By reducing the dose of verteporfin, studies have 
demonstrated that the potential retinal damage caused by PDT can be minimized while the 
photodynamic effects in inducing choroidal vasculature changes required for treating CSC 
remain sufficient.2,3,18,26-30,41, 47 None of the patients treated with this half-dose PDT protocol 
experienced any systemic adverse event (AE) associated with verteporfin infusion.27 In 
several relatively large retrospective studies on half-dose PDT in CSC, none of the patients 
had any subjective or objective drop in vision immediately after PDT, nor at subsequent 
follow-up visits.18, 26-30 This “safety-enhanced” protocol with half-dose verteporfin appeared 
to be one of the safest and effective treatment options in patients with active chronic 
CSC.23,41 In conclusion, a relatively large body of well-documented retrospective studies 
indicates that half-dose PDT is able to yield positive functional and anatomic outcomes 
while at the same time reducing the potential AEs associated with conventional PDT with 
full-dose verteporfin. 
High-density subthreshold micropulse laser therapy (HSML) as an alternative treatment in 
chronic central serous chorioretinopathy
There are several retrospective studies that indicate that HSML therapy may be effective in 
41-58% of CSC patients.18,48 HSML treatment using a 810 nm wavelength is an established 
treatment option for a broad range of retinal diseases.49 In this treatment, no photosensitizing 
drug is needed. This relatively new laser treatment modality may prevent damage to 
the neural retina that occurs in conventional (non-PDT) laser techniques by raising the 
temperature of the RPE below the protein-denaturation-threshold so that the thermal wave 
that reaches the neural retina is insufficient to cause neither damage nor a clinically visible 
end-point (opacified retina). It is different from subthreshold continuous wave in that more 
energy can be delivered to the RPE without neuroretinal damage using multiple short pulses. 
In contrast, in the continuous wave mode of conventional laser therapy, the laser energy is 
delivered with a single pulse with a duration of exposure of 0.1-0.5 s, most of the energy is 
absorbed by the RPE and the heat energy is transferred to the neurosensory retina leading 
to transient retinal swelling (visible end-point). As a result, conventional laser application in 
the macula may cause damage to the neuroretina and RPE, leading to central scotomas and 
possibly loss of visual acuity. Previous studies have shown that conventional laser treatment 
in CSC, in contrast to HSML treatment and half-dose PDT treatment, does not improve visual 
acuity, may cause photoreceptor damage, and may induce choroidal neovascularisation.3 
Recently, studies using a relatively new 577 nm wavelength micropulse laser in subthreshold 
mode have also shown possible efficacy in the treatment of chronic CSC.50,51
Outline of proposed clinical trial
The PLACE study is a superiority study, because retrospective studies suggest that the rate 
of anatomical and functional success of PDT treatment might be higher than the success of 
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HSML treatment. Therefore, half-dose PDT treatment arm is challenged against a treatment 
arm of HSML treatment. 
In this study, we want to define treatment success not only on the basis of structural 
parameters (anatomic success, e.g. absence of SRF after treatment), but also based on 
functional vision-related endpoints, which are most important from a patient’s perspective. 
These functional vision-related endpoints will include best-corrected visual acuity (BCVA), 
retinal sensitivity on microperimetry and score on a validated visual function questionnaire 
(the NEI-VFQ-25 questionnaire).52,53 
With the results of this study we hope to establish a strong scientific foundation for further 
research on the optimal treatment of patients with chronic CSC to improve the visual 
outcome and quality of life of this relatively frequently occurring eye disease. 
Objectives
Primary objective
To investigate whether treatment of chronic CSC patients with macular SRF on optical 
coherence tomography (OCT) with half-dose PDT results in more eyes with absence of SRF 
on OCT as compared to HSML treatment.
Secondary objectives
To investigate the clinical outcome comparing half-dose PDT treatment with HSML 
treatment in patients with SRF due to active leakage in chronic CSC, based on evaluation of 
BCVA, retinal sensitivity on microperimetry, and subjective success score on the NEI-VFQ-25 
questionnaire. 
PLACE trial: a study protocol for a randomized controlled trial
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Methods/Design
Summary of trial design
This study is a multicenter, prospective, randomized, controlled, open-label study that will 
compare the efficacy and safety of two treatments in patients with chronic CSC. The first 
group of patients will receive half-dose PDT treatment. The second group of patients with 
receive 810 nm HSML treatment. Each patient will receive at least one treatment, but may 
be eligible to receive a second treatment during follow-up (Figure 2), which will be the same 
type of treatment as the first treatment: either half-dose PDT treatment or HSML treatment.
Potential eligible patients will be identified in one of five specialist ophthalmology trial sites, 
each led by one of the principal investigators (PIs).
Fundus photographs, fluorescein angiograms, ICG angiograms and OCT images collected at 
the screening visit will be sent to a central reading center (CRC). The CRC will review these 
images to confirm subject eligibility based on the characteristics specified in the inclusion 
and exclusion criteria. Once eligibility has been confirmed by the CRC, all other inclusion 
and exclusion criteria have been met at the baseline visit, and informed consent has been 
obtained, patients will be enrolled in the trial.
There are nine examinations that will be performed at the baseline assessment, 6-8 weeks 
after treatment (at evaluation visit 1, and - if applicable, if a second treatment is required 
- at evaluation visit 2), and at the final visit (7-8 months after start of the treatment). 
The 6 anatomical assessments include ophthalmoscopy, fundus photography, OCT, 
autofluorescence imaging, fluorescein angiography, and ICG angiography. The 3 functional 
assessments include visual acuity measurement, microperimetry, and a questionnaire on 
vision-related functioning. 
Enrolled patients will be randomized at a 1:1 ratio to receive either half-dose PDT treatment 
or HSML treatment. 
The total number of visits per patient is 5 (in case of 1 required treatment) or 7 (in case 
of 2 required treatments). The duration of participant participation within the study is 7-8 
months (Figure 2).
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Overview of assessments in the trial:
1. Ophthalmoscopy
This examination will be performed by one of the ophthalmologists to confirm the diagnosis. 
To perform ophthalmoscopy the pupils will have to be dilated with 1.0% tropicamide and 2. 
% phenylephrine. 
2. Fundus photography
The fundus photography will be taken with a Topcon TRC-50 series fundus camera. The 
photographs will be taken with a 50º-field centred on the area of the macula.
3. Optical coherence tomography (OCT) imaging
Patients will be examined by non-invasive OCT imaging. OCT shows the different layers of 
the retina and is the imaging modality of choice to visualize subretinal and intraretinal fluid, 
for instance in chronic CSC. This examination is performed in mydriasis (dilated pupils). OCT 
imaging will be carried out with a Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, 
Germany).
4. Fundus autofluorescence imaging
Fundus autofluorescence is a non-invasive imaging technique that is able to register changes 
of autofluorescence intensity in the retina, for instance due to accumulation of lipofuscin 
in the RPE. Fundus autofluorescence imaging will be carried out with a Spectralis HRA+OCT 
(Heidelberg Engineering, Heidelberg, Germany).
5 & 6. Fluorescein and indocyanine green (ICG) angiography
To perform fluorescein and ICG angiography, intravenous injection of fluorescein and ICG 
is required. During the angiography procedure, both (fluorescein and ICG) dyes may be 
injected at the same time or separately. Fluorescein reveals the retinal vasculature and may 
show areas of fluid leakage through the RPE, whereas the ICG dye images the choroidal 
vasculature. The visualization of both the retinal vasculature and RPE permeability (by 
fluorescein angiography) and choroidal vasculature (by ICG angiography) is essential to 
image the areas of abnormal anatomy and leakage that may guide treatment. Images of 
the study eye are taken at set times: 0-1 minutes (several images covering the arterial and 
venous filling phases), 3 minutes, 6 minutes, 10 minutes, 15 minutes, and 20 minutes. 
Images of the non-study eye will be taken at 1 minute, 6 minutes, and 20 minutes. All images 
will be acquired with Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, Germany).
PLACE trial: a study protocol for a randomized controlled trial
201
Ch
ap
te
r 
4.
3
7. Best-corrected visual acuity (BCVA)
BCVA will be assessed for both eyes at all evaluation visits. To measure BCVA, early treatment 
diabetic retinopathy study (ETDRS) visual acuity testing charts will be used at a distance of 
4 meters. 
8. Microperimetry
All patients will be examined by non-invasive microperimetry. This technique is able to 
measure retinal sensitivity to light, and follow-up pre- and post-treatment changes in 
retinal sensitivity at predetermined loci in the macula. By using a reliable eye tracking 
system, this microperimetry system is able to exactly locate the areas of retina that have 
been tested previously, in order to ensure testing of identically the same area at follow-up. 
Microperimetry according to a standard protocol take 5-8 minutes for each eye, and will be 
performed with non-dilated pupils. 
9. Questionnaires 
Each participant will be asked to complete a quality of life questionnaire based on 
national eye institute visual function questionnaire (NEI-VFQ-25),53 and the Cohen stress 
questionnaire.52,54 NEI-VFQ-25 is a reliable and validated 25-item version of the 51-item 
national eye institute visual function questionnaire.55 The questionnaire is especially useful 
in settings such as clinical trials, where interview length is an important consideration. The 
Cohen stress questionnaire is a validated questionnaire indicating the stress level patients 
have been exposed to during the month before disease onset. 
There will be standard operating procedures (SOPs) available to all investigators involved in 
the trial as well as in the trial master file for each of the described examinations.
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Figure 2. 
Study flow chart
PLACE trial: a study protocol for a randomized controlled trial
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Primary and secondary endpoints
Primary endpoint
The primary endpoint of this study is to assess if there is a difference between the efficacy 
of half-dose PDT treatment versus HSML treatment in patients with chronic CSC. The 
assessment of this efficacy will be based on the anatomical effect on OCT: absence of SRF 
versus persistent SRF, 6-8 weeks after treatment. After all, the absence or presence of fluid 
under the retina on the OCT scan is a direct reflection of the activity of the disease in these 
patients.
Secondary endpoints
As secondary endpoints, we will mainly look at 3 parameters that reflect the patient’s vision-
related functioning. These three parameters are: a standardized measurement of BCVA 
according to the ETDRS standards, a standardized measurement of sensitivity of the macula 
with microperimetry, and standardized assessment of the patient’s vision-related quality of 
life using a validated questionnaire, the NEI-VFQ-25.
The secondary endpoints that will be assessed as a reflection of functional improvement 
after treatment include: 
 - Number of second treatments needed in each treatment arm
 -  Mean change from baseline in ETDRS BCVA in the study eye at 6-8 weeks after 
treatment visit 1 and at 7-8 months after treatment visit 1, among the two 
treatment modalities
 -  Mean change from evaluation visit 1 in ETDRS BCVA in the study eye at final 
evaluation (7-8 months after treatment visit 1), among those who required one 
treatment and those who required a second treatment, and among the two 
treatment modalities overall
 -  Mean change from baseline in retinal sensitivity on microperimetry in the study 
eye at 6-8 weeks after treatment visit 1 and at 7-8 months after treatment visit 1 
among the two treatment modalities
 -  Mean change from baseline in the NEI-VFQ-25 questionnaire at 6-8 weeks 
after treatment visit 1 and at 7-8 months after treatment visit 1 among the two 
treatment modalities 
 -  An absence of SRF on evaluation with OCT scanning as compared to HSML 
treatment at 7-8 months follow-up after successful treatment (after treatment 
visit 1; “success” defined as an absence of SRF on OCT at 6-8 weeks after 
treatment)
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Trial participants
Overall description of trial participants
This study will enrol subjects with chronic CSC with active leakage of fluid under the retina 
as evidenced on OCT scanning and further supported by findings on fluorescein angiography 
and ICG angiography, in at least one eye. If both eyes are eligible, then the eye with the 
longer duration of disease will be used as the study eye, except in cases where the disease 
is present for more than 18 months. In the latter case, which is an exclusion criterion, the 
other eye will be eligible for inclusion if the disease is active for less than 18 months. If the 
non-study eye also has active disease, the choice to treat and the type of treatment in this 
eye may be chosen freely at the discretion of the responsible ophthalmologist. 
Before enrolment, each subject must meet all of the following inclusion criteria and none of 
the exclusion criteria, and agree to comply with the study requirements including completion 
of all of the study visits.
Inclusion criteria
 -  Male and female patients ≥ 18 years of age who are able to give written 
informed consent
 - Active chronic CSC
 -  Subjective visual loss > 6 weeks, interpreted as onset of active disease
 -  SRF that includes the fovea on OCT scanning at baseline examination. 
Note: SRF does not have to include fovea on OCT to be eligible for treatment 
at control visit 1, as long as there is persistent SRF in the macula, which is 
interpreted as persistently active disease.
 -  Hyperfluorescent areas on ICG angiography
 -  ≥1 ill-defined hyperfluorescent leakage areas on fluorescein angiography with 
RPE window defect(s) that are compatible with chronic CSC
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Exclusion criteria
The participant may not enter the study if any of the following apply:
 - Any previous treatments for active CSC in the study eye
 -  Current treatment with corticosteroids (topical or systemic), corticosteroid use 
within 3 months before possible start of trial treatment, or anticipated start of 
corticosteroid treatment within the first 7-8 months from the start of the trial 
period 
 - Evidence of other diagnosis that can explain serous SRF or visual loss
 - BCVA < 20/200 (Snellen equivalent)
 -  Profound chorioretinal atrophy in central macular area on ophthalmoscopy  
and OCT
 - Myopia > 6D
 - Visual loss and/or serous detachment on OCT < 6 weeks
 -  Continuous and/or progressive visual loss > 18 months or serous detachment on 
OCT > 18 months
 - No hyperfluorescence on ICG angiography
 - Intraretinal edema on OCT
 -  (relative) contraindications for PDT treatment (pregnancy, porphyria, severely 
disturbed liver function). Pregnancy will not be routinely tested in female 
patients, but the possibility of pregnancy will be discussed during eligibility 
screening
 -  (relative) Contraindications for fluorescein angiography or ICG angiography 
(known allergies especially against shellfish, previous reactions)
 -  Soft drusen in treated eye or fellow eye, signs of choroidal neovascularization on 
ophthalmoscopy and/or fluorescein angiography/ICG angiography
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Study procedures 
Screening and eligibility assessment
Identification of potential participants
Potential participants with chronic CSC will be identified in the participating trial sites, 
after being referred to the department by the general practitioner (GP) or referring 
ophthalmologists from other hospitals. Before screening, a visual acuity measurement, dilated 
ophthalmoscopy, fundus photography, OCT of the retina and choroid, autofluorescence 
imaging, and fluorescein and ICG angiography will already have been performed in most 
patients as part of standard clinical care. These examinations constitute most of the baseline 
examinations, and therefore do not have to be repeated if screening and randomisation is 
performed within 2 weeks after these examinations. Screening and baseline examinations/
enrolment are performed on the same day if possible. The maximum duration allowed 
between screening and randomisation is 2 weeks. 
In addition to the examinations mentioned previously, the following information will be 
collected from patients who have been consented, at the baseline assessment, at control 
visit 1 and - if applicable - control visit 2, and at the follow-up visit at 7-8 months after 
treatment visit 1.
 -  Demographic details: the date of birth, gender, race, smoking and drinking habits 
will be recorded on case report forms (CRFs). 
 -  Medical history: details of any history of disease or surgical interventions will be 
recorded on CRFs.
 -  Concomitant medication: all over-the-counter or prescribed medication, vitamins, 
and/or herbal supplements will be recorded on CRFs.
Informed consent
The study will be discussed with the subject. The patient information sheet will be given to 
the patient at the screening visit, and the patient will be asked to contact us if he/she is willing 
to take part. A subject wishing to participate must give written informed consent prior to 
any study-related procedures or change in treatment. The participant must personally sign 
and date the latest approved version of the informed consent form before any study-specific 
procedures are performed. Written and verbal versions of the participant information and 
informed consent will be presented to the participants, detailing the exact nature of the 
study, the implications and constraints of the protocol, the known side effects, and any risks 
involved in taking part. It will be clearly stated that the participant is free to withdraw from 
the study at any time for any reason without prejudice to future care, and with no obligation 
to give the reason for withdrawal.
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The participant will be allowed as much time as wished to consider the information, and the 
opportunity to question the investigator, their GP or other independent parties to decide 
whether they will participate in the study. Written informed consent will then be obtained 
by means of participant dated signature and dated signature of the person who presented 
and obtained the informed consent. The person who obtained the consent must be suitably 
qualified and experienced, and have been authorised to do so by the chief/principal 
investigator. A copy of the signed informed consent will be given to the participants. The 
original signed form will be retained at the study site, and an additional copy will remain in 
the patient notes.
Randomisation 
Subject numbers will be assigned sequentially as each subject enters the study. 
The subjects will be assigned study treatment by a web based random numbers generator 
using block randomisation without minimization. This application will be specially designed 
for this study by the Department of Epidemiology, Biostatistics and Health Technology 
Assessment of the Radboud University Nijmegen Medical Center (Nijmegen, the 
Netherlands). Randomisation will be performed at the same visit as the baseline visit. The 
randomisation schedule is designed by a statistician, and the randomisation codes are kept 
in the CRF and in the digital database of the Clinical Research Center Nijmegen (www.CRCN.
nl).
Interventions
Half-dose PDT treatment
For this intervention the patients need dilated pupils (with 1.0% tropicamide and 2.5% 
phenylephrine). All patients will get an intravenous infusion of 3 mg/m2 verteporfin (Visudyne 
®) (half-dose) is over 10 minutes. At exactly 15 minutes after the start of the infusion, an 
anaesthetic eye drop is given (oxybuprocaine 0.4% or equivalent), a contact lens (a Volk® 
PDT lens) is positioned on the affected eye, and the aiming beam of the laser is focused on 
the treatment area. The magnification factor is taken into account in the settings of the PDT 
machine. The area of treatment is chosen, with the area of the aiming beam corresponding 
to the area of the subsequent laser spot area. The area that has to be treated is determined 
based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG 
angiography that correspond(s) to SRF accumulation in the macula on the OCT scan and 
hyperfluorescent “hot spots” on the mid-phase (approximately 3 minutes) fluorescein 
angiogram. The spot size will be defined based on the diameter of the hyperfluorescent 
area on ICG angiography plus 1mm (Figure 3). The edge of treatment spot has to be at least 
200 µm away from the optic disc rim. The PDT treatment is performed with standard 50 J/
cm2 fluency, a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 
seconds. Care must be taken to treat at exactly 15 minutes after the start of the infusion, to 
maximize the localization of the effect of treatment to the choroid and minimize possible 
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damage to the adjacent retinal structures. The PDT treatment must take place at least 45 
minutes after ICG angiography has been performed.
HSML treatment
For this intervention the patients need dilated pupils (with 1.0% tropicamide and 2.5% 
phenylephrine). An anaesthetic eye drop is given (oxybuprocaine 0.4% or equivalent), and 
a contact glass (for instance a Volk® area centralis lens) is positioned on the affected eye. 
HSML treatment with an 810 nm diode laser will be performed of the areas identified on 
mid-phase ICG angiography. Multiple confluent, adjacent (non-overlapping) laser spots 
will be applied, covering the leakage area on mid-phase ICG angiography. The number of 
spots and number of zones treated depends on the extent of the leakage area(s) on mid-
phase ICG. The area that has to be treated is determined based on those hyperfluorescent 
area(s) on mid-phase (approximately 10 minutes) ICG angiography that correspond(s) to 
SRF accumulation in the macula on the OCT scan and hyperfluorescent “hot spots” on the 
mid-phase (3 minutes) fluorescein angiogram (Figure 3). The treatment will consist of small 
adjacent laser spots covering the designated area keeping a distance of 500 µm from the 
foveal centre (corresponding to a laser-free circular zone of 1000 µm diameter centred on 
the fovea).
The following HSML treatment settings will be used: a power of 1800 mW*, a duty cycle 
of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, a spot size of 125 µm, with a 
minimal distance of the spot from the fovea of 500 µm.48,56
* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment 
has to be seen in the retina. In virtually all patients, a power of 1800 mW will not produce a 
visible discoloration of the retina after application of a laser spot with the aforementioned 
settings. If retinal discoloration is seen at a power of 1800 mW (corresponding to 
suprathreshold treatment), for instance in patients with darkly pigmented fundi, the power 
will be reduced with steps of 300 mW until there is no visible reaction. The first laser “test” 
spot will always be applied just outside the macular area.
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Figure 3.
Examples of areas treated in photodynamic therapy and micropulse laser treatment. Examples of imaging 
features on fluorescein angiography (FA) and indocyanine green angiography (ICG) angiography in chronic central 
serous chorioretinopathy (chronic CSC), and the corresponding treatment areas for photodynamic therapy 
(PDT) and high-density subthreshold micropulse laser treatment (HSML). A-B FA of the right eye of a patient 
showing hyperfluorescent “hot spots,” indicating leakage inferior of the fovea (A). On ICG angiography, an area 
of hyperfluorescence, which corresponds to the hyperfluorescent area on the FA, is seen (B). C-F An example of 
a PDT spot (white circle) overlapping the hyperfluorescent area on the ICG angiography plus 1 mm as described 
in the protocol (C). HSML treatment scheme that would apply to the same eye, in which only the central foveal 
area is excluded for treatment (white circle). The hyperfluorescent area on the ICGA is treated with numerous, 
nonoverlapping adjacent laser spots (white area) (D)
Retreatment criteria and considerations
At evaluation visit 1, at 6-8 weeks after treatment visit 1, an OCT scan of the retina will be 
performed, among other imaging examinations. If there still is SRF present in the macular 
area, a second treatment according to the protocol will be performed within 3 weeks after 
this evaluation visit 1. 
This second treatment (either half-dose PDT or HSML treatment) will again be guided by the 
hyperfluorescent area(s) on ICG angiography that correspond(s) to SRF accumulation in the 
macula on the OCT scan and hyperfluorescent “hot spots” on the mid-phase (approximately 
3 minutes) fluorescein angiogram. 
In cases where there is no more SRF under the fovea but there is persistent fluid within the 
macular area encircled by the optic disc and temporal retinal vascular arcade, retreatment 
will be performed. The rationale behind this second treatment is that the persistent fluid 
may be interpreted as an incomplete treatment response, because SRF accumulation 
indicates ongoing disease activity due to choroidal vascular hyperpermeability and fluid 
leakage through the RPE. 
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Note: if a patient did not require retreatment at evaluation visit 1 (= 6-8 weeks after treatment 
visit 1) according to the protocol, but returns with visual symptoms in the period between 
evaluation visit 1 and the follow-up visit at 7-8 months, a regular clinical examination should 
be performed that includes at least a measurement of visual acuity, ophthalmoscopy, and 
OCT scan to determine whether SRF has reoccurred. If there is evidence of recurrence of SRF 
on OCT (and therefore disease activity), these findings should be noted in the CRF. In these 
cases, additional evaluations compatible with evaluation visit 2 should be performed, and 
the patient should be planned for treatment visit 2 (max. 2-3 weeks after evaluation visit 2). 
Further considerations adhere to the retreatment criteria described above. 
However, no treatment is allowed if the patient has already been treated twice (either with 
two half-dose PDT treatments or two HSML treatments) according to the trial protocol 
between evaluation visit 1/2 and follow-up visit (7-8 months after treatment visit 1). There 
are no data on the usefulness of more than 2 half-dose PDT treatments in the same patient 
with persistent chronic CSC. Some authors argue that more than 2 PDT treatments in 
the same eye may increase the risk of complications such as choroidal ischemia and the 
formation of choroidal neovascularization. In the case of HSML treatment, there also are 
no reports to suggest that more than 2 treatments may be useful. That is why a maximum 
amount of two of the same treatments is allowed within the trial period. After completion of 
the trial (at follow-up visit, 7-8 months after treatment visit 1), treatment may be considered 
and the treatment modality may be chosen at the discretion of the treating ophthalmologist.
Definition of end of trial
The end of trial is the date on which the last included participant has received the last 
follow-up visit (7-8 months after treatment 1). 
Discontinuation and withdrawal of participants from study treatment
Each participant has the right to withdraw from the study at any time. In addition, the 
investigator may discontinue a participant from the study at any time if the investigator 
considers it necessary for any reason including: 
 -  Ineligibility (either arising during the study or retrospective having been 
overlooked at screening)
 - Significant protocol deviation
 - Significant non-compliance with study requirements
 -  An AE which requires discontinuation of the study medication or results in 
inability to continue to comply with study procedures
 - Consent withdrawn
 -  Lost to follow-up 
PLACE trial: a study protocol for a randomized controlled trial
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 -  Pregnancy before evaluation visit 1 or 2 (which is a relative contraindication for 
angiography). Pregnancy will not be routinely tested in female patients, but the 
possibility of pregnancy will be discussed during eligibility screening. 
Patients suffering from a vision-threatening AE will also be withdrawn from the study. 
Withdrawal from the study will result in exclusion of the data from analysis from those 
participants, except if adherence to the protocol and follow-up examinations were sufficient 
to allow inclusion in the analysis. The reason for withdrawal will be recorded in the CRF. 
If the participant is withdrawn due to an AE, the investigator will make arrangements for 
follow-up visits or telephone calls until the AE has resolved or stabilised. 
Sample size calculations showed the need of 78 participants per treating arm to find 
significant values. In case of a withdrawal a replacing subject will be included. This could 
cause a delay of the end of the trial but is not relevant for the outcomes. All subjects 
withdrawn from this study will return to normal consultation at their ophthalmologist of 
choice. 
Safety reporting
Adverse event reporting period
The reporting period during which AEs must be reported is the period from enrolment to 
the end of the study period (24 months). All unresolved AEs must be followed by the trial 
monitor in contact with the chief investigator and principal investigators until the events 
are resolved, the patient is lost to follow-up, or the AE is otherwise explained. At the last 
scheduled study visit, the trial nurse will instruct each patient to report any subsequent 
event(s) that the patient, or the patient’s personal physician, believes might reasonably be 
related to prior study treatment. Such events should be reported to the (previous) treating 
ophthalmologist at the department of ophthalmology of the trial site after the trial has 
ended. Patients who withdraw early from the study will be contacted by trial staff 30 days 
after their last visit, if the patient gives permission to do so, to ascertain whether any AEs 
have occurred.
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Definition of adverse events/reactions
An adverse event (AE) or adverse experience is:
Any untoward medical occurrence in a patient or clinical investigation participants 
administered a medicinal product, which does not necessarily have to have a causal 
relationship with this treatment (the study medication).
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom or disease temporally associated with the use of the study 
medication, whether or not considered related to the study medication.
In the case of an adverse reaction (AR), a causal relationship between a study medication 
and an AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out.
All cases judged by either the reporting medically qualified professional or the sponsor 
as having a reasonable suspected causal relationship to the study medication qualify as 
adverse reactions. 
All untoward and unintended responses to a medicinal product related to any dose.
ARs could include for instance: nausea, hypertension, lower back pain, headache, arthralgia, 
intravenous injection site reactions (in the case of PDT), cough, pharyngitis, pneumonia, 
fever and flu-like symptoms, hypersensitivity and allergy reactions, vaso-vagal reactions, 
atrial fibrillation, angina, and sunburn after sunlight exposure in the first two days after PDT 
treatment.
Procedures for recording adverse events/reactions
All AEs occurring during the study observed by the investigator or reported by the 
participant, whether or not attributed to study medication, will be recorded on the CRF. The 
following information will be recorded: description, date of onset and end date, severity, 
assessment of relatedness to study medication, other suspect drug or device and action 
taken. Follow-up information should be provided as necessary. AEs considered related to 
the study medication as judged by a medically qualified investigator or the sponsor will be 
followed until resolution or the event is considered stable. AEs considered related to the 
study procedure as judged by a qualified investigator or the sponsor will be followed until 
resolution or the event is considered stable. All related AEs that result in a participant’s 
withdrawal from the study or are present at the end of the study, should be followed up if 
the patient gives consent to do so, until a satisfactory resolution occurs.
It will be left to the investigator’s clinical judgment whether or not an AE is of sufficient severity 
to require the participant’s removal from the trial. A participant may also voluntarily withdraw 
from treatment due to what he or she perceives as an intolerable AE. If either of these occurs, 
the participant must undergo an end of study assessment and be given appropriate care under 
medical supervision until symptoms cease or the condition becomes stable.
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The relationship of AEs to the study medication will be assessed by a medically qualified 
investigator and if necessary discussed with the chief investigator. Any pregnancy occurring 
during the clinical study and the outcome of the pregnancy fathered by trial participants, 
should be recorded and followed up for congenital abnormality or birth defect.
Definitions of serious adverse events/reactions
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:
 - Results in death,
 -  Is life-threatening, note: the term "life-threatening" in the definition of "serious" 
refers to an event in which the participant was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused 
death if it were more severe.
 -  Requires inpatient hospitalisation or prolongation of existing hospitalisation,
 -  Results in persistent or significant disability/incapacity, or is a congenital 
anomaly/birth defect.
 -  Other important medical events. Note: other events that may not result in 
death, are not life threatening, or do not require hospitalisation, may be 
considered a SAE when, based upon appropriate medical judgement, the event 
may jeopardise the patient and may require medical or surgical intervention to 
prevent one of the outcomes listed above. In this trial, these events are mainly 
vision-related.
Vision-threatening adverse events/reactions
An AE is considered to be vision-threatening and is a reportable SAE if it meets one or more 
of the following criteria:
 -  It caused a decrease in visual acuity of >30 letters (compared with the last 
assessment of visual acuity prior to the most recent treatment) within the follow-
up period of 7-8 months.
 -  It required surgical intervention 
 -  In the investigator’s opinion, it may require medical intervention to prevent 
permanent loss of vision. Causes for such vision-related AEs could include for 
instance: RPE tears, subretinal haemorrhage, choroidal neovascularization.
A serious adverse reaction (SAR) is an adverse event (expected or unexpected) that is both 
serious and, in the opinion of the reporting investigator, believed with reasonable probability 
to be due to one of the study treatments, based on the information provided.
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A suspected unexpected serious adverse reaction (SUSAR) is a serious adverse reaction, the 
nature or severity of which is not consistent with the applicable product information (e.g. 
Investigator’s brochure for an unapproved investigational product or summary of product 
characteristics for an approved product).
Reporting procedures for serious adverse events
The data monitoring committee (DMC) will undertake to review all SAEs for the study. The 
DMC may hold electronic meetings. The DMC will meet at intervals and consider:
 
 -  Occurrence and nature of adverse events 
 -  Whether additional information on adverse events is required 
 -  Consider taking appropriate action where necessary to halt trials 
 -  Act / advise on incidents occurring between meetings that require rapid 
assessment (e.g. SUSARs)
All SAEs will be reported to the DMC within one working day of discovery or notification of the 
event. All SAE information will be recorded on an SAE form, which will be sent electronically 
to members of the DMC. Additional information received for a case (follow-up or corrections 
to the original case) will be detailed on a new SAE form. After receiving the SAE report within 
one working day, the medical monitor will review possible SAEs weekly, and the DMC has 
a meeting every 3 months to review the SAEs, if present. The chief investigator will also 
report all SUSARs to the competent authorities (TOL / CCMO in the Netherlands, Bfarm 
in Germany, and ANSM (Agence Nationale de Sécurité du Médicament et des Produits de 
Santé) in France, the ethics committees concerned, and the host NHS trust in the UK. Fatal or 
life-threatening SUSARs will be reported within 7 days and all other SUSARs within 15 days. 
The chief investigator will also inform all investigators concerned of relevant information 
about SUSARs that could adversely affect the safety of participants. 
Trial safety group / data monitoring committee 
The DMC will conduct a review of all SAEs for the study reported every 3 months and 
cumulatively, if present. The aims of this review include:
 -  To pick up any trends, such as increases in unexpected/expected events, and take 
appropriate action
 -  To seek additional advice or information from investigators where required
 -  To evaluate the risk of the trial continuing and take appropriate action where 
necessary
 -  To act or advise, through the chairman or other medical monitors, on incidents 
occurring between meetings that require rapid assessment
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This committee, which is based in the coordinating centre in Nijmegen, will receive SAEs 
within one working day, and will analyse the available safety data and study data in a 
meeting every 3 months, if present.
Statistics 
Description of statistical methods
Univariate analysis:
Analysis for the primary endpoint
The purpose of this study is to identify the difference between the efficacy of the two 
treatment modalities based on the anatomical effect on OCT scan (absence of SRF versus still 
SRF visible). As we expect one treatment to be superior to the other, this study is designed 
to be a superiority study. Statistical analysis on the primary parameter will be performed 
by analyzing the relative risk by using a cross-table comparing evaluation at 6-8 weeks after 
treatment with baseline. 
Multivariate analysis:
Analysis for the secondary endpoints
For the secondary endpoints, the following analyses will be performed: 
 -  Compare anatomic results based on OCT scan (absence of SRF versus persistent 
SRF) at evaluation point 1 compared to baseline
 -  Number of subsequent treatments needed in each treatment arm
 -  Compare mean change from baseline in ETDRS BCVA in the study eye at 6-8 weeks 
after treatment and at the end evaluation, among the two treatment modalities. 
 -  Compare mean change from evaluation point 1 in ETDRS BCVA in the study eye 
at final evaluation among those with subsequent and those without subsequent 
treatment among the two treatment modalities
 -  Compare mean change from baseline in retinal sensitivity in the study eye at 6-8 
weeks after treatment among the two treatment modalities.
 -  Compare mean change from baseline in the NEI-VFQ-25 questionnaire at 6-8 
weeks after treatment among the two treatment modalities. 
The first two analyses will be performed by the use of a cross-table. Furthermore, the 
continuous secondary variables will be analyzed using an ANCOVA model with baseline 
as and treatment as factor. For categorical secondary endpoints, a chi-square test will be 
performed. In addition a logistic model with baseline as covariate and treatment as factor 
will be performed. The change from baseline in the NEI-VFQ-25 questionnaire results will be 
summarized descriptively. 
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Interim analysis
A formal interim analysis will be performed when 78 participants received the first evaluation 
6-8 weeks after treatment. Statistical analysis on the primary parameter will be performed 
by analyzing the relative risk by using a cross-table comparing evaluation at 6-8 weeks after 
treatment with baseline.
Number of participants 
Total number of patients: 156 patients (see table “distribution of subjects per site”)
Justification of sample size: 
For HSML, an anatomic success rate of approximately 50%, defined as no SRF on OCT, 
after 6-8 weeks may be estimated based on retrospective studies.48,57 For half-dose PDT 
approximately 80% anatomic success may be estimated.18,26-35 taking such a difference of 
30% in treatment success into account, a power calculation indicates that one would need 
40 patients per treatment arm (power: 80%, α: 0.05). However, when we also correct for 
factors such as positive publication bias and our own empiric treatment experience, we 
expect to find a difference in treatment success rate of approximately 22% in favour of half-
dose PDT. If we take one interim analysis into account according to the O’Brien-Fleming 
method, 78 patients per treatment arm would be required (power: 80%, α: 0.05).
PLACE trial: a study protocol for a randomized controlled trial
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Distribution of subjects per site
Netherlands (Nijmegen/Leiden) Oxford (UK)/ Cologne  
(Germany)/Paris (France)
Group 1* 50 subjects 28 subjects
Group 2* 50 subjects 28 subjects
*group 1 (78 patients): half-dose PDT with Visudyne®
*group 2 (78 patients): HSML
The level of statistical significance
 For the primary endpoint, the overall null hypothesis is:
 H
0
 : probabilities of success are the same in both treatment arms (π
1 
= π
2
)
    versus
 H
1
 : probabilities of success are different in the treatment arms (π
1 
≠ π
2
)
For statistical testing the significance level will be 0.05 unless specified otherwise. 
Criteria for the termination of the trial.
The DMC will perform a review of the study data every 3 months. The study may be 
terminated prematurely on the recommendation of the DMC. Reasons for premature 
termination of the trial may include: 
 
 -  Early solid statistical evidence that the investigational medicinal product (IMP) is 
significantly better than the comparator. 
 
 - Early evidence that one or both treatments are harmful.
Ethics
Declaration of Helsinki
The chief investigator will ensure that this study is conducted in accordance with the 
principles of the 2008 declaration of Helsinki. 
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ICH guidelines for good clinical practice
The investigator will ensure that this study is conducted in full conformity with relevant 
regulations and with the ICH guidelines for good clinical practice (CPMP/ICH/135/95) July 
1996.
Approvals
The protocol, informed consent form, participant information sheet, and any proposed 
advertising material was submitted and written approval was obtained at the appropriate 
research ethics committees (REC) (see list below), regulatory authorities, and host 
institution(s). This trial has been internationally registered at Clinicaltrials.gov (NCT01797861; 
http://clinicaltrials.gov/). List of research ethical committees that have approved the study 
protocol at the different sites:
1. Commissie Mensgebonden Onderzoek (CMO) Regio Arnhem-Nijmegen approved the 
protocol for;
- Radboud University Medical Center, Nijmegen, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
2. Ethik Kommission Universität zu Köln approved the protocol for:
- University Hospital Cologne, Cologne, Germany
3.  Health Research Authority National Research Ethics Service (NRES) Committee South 
Central – Oxford A approved the protocol for:
- Oxford Eye Hospital, Oxford, United Kingdom
4.  Comité de Protection des Personnes Ile de France V approved the protocol for:
- University Paris Est Creteil, Paris, France
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Discussion
To establish the optimal treatment for chronic CSC, a eye disease associated with potentially 
severe visual disability, a multicenter prospective randomized controlled trial is mandatory 
but currently lacking. The proposed study is the first multicenter prospective randomized 
controlled trial that compares half-dose PDT with HSML treatment with regard to their 
ability to reduce SRF accumulation in chronic CSC, and their ability to improve the quality of 
vision. We have chosen for half-dose PDT treatment instead of half-fluency PDT treatment, 
a reduction of the dose of verteporfin rather than the fluency of the laser treatment 
appears preferable because dose reduction may reduce possible systemic side effects of 
PDT treatment, such as lower back pain and photosensitivity of the skin in the first days after 
treatment,58 while having an efficacy comparable to half-fluency PDT.59,60 
HSML treatment has been chosen as the treatment of choice in the control arm for a number 
of reasons. First, sham (no treatment) was studied by Chan and co-workers in the acute 
form of CSC, who showed a large difference in anatomic and functional outcome (complete 
resolution of SRF) between the half-dose PDT and placebo group.61 As it is well-established 
that prolonged leakage of SRF under the macula due to chronic CSC may lead to permanent 
visual loss, it is not desirable to include comparison with sham in our study.8-10,20,25,61-66 
HSML treatment of CSC has been shown to be effective and safe in 41-58% of patients in 
smaller, retrospective studies.18,48,57 The safety and efficacy of HSML treatment has also been 
reported in various other retinal diseases.49 In contrast, it has been shown that conventional 
laser treatment of focal leakage point on fluorescein angiography in CSC does not result 
in a better visual outcome.3,41 Also, conventional laser treatment in CSC has a higher risk 
of complications than HSML and half-dose PDT, including vision loss, scotoma, decreased 
color vision, decreased contrast sensitivity, and choroidal neovascularisation.2,41,67 The 810 
nm HSML laser modality was chosen instead of the 577 nm wavelength, because at the 
time of the start of the study relatively little had been published on the safety and efficacy 
of 577 nm HSML, and experimental studies between 810 nm and 532 nm micropulse laser 
strategies have not shown obvious differences in histological effect.68
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CHAPTER 4.4
The use of eplerenone in therapy-
resistant chronic central serous chorioreti nopathy.
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An inappropriate activation of the mineralocorticoid receptor, found in the vasculature 
(endothelial and smooth muscle cells), has been recently suggested to underlie the 
pathogenesis of CSC.1,2 This study also suggested a reduction of subretinal fluid (SRF) in 2 
patients by systemic use of eplerenone, a selective mineralocorticoid receptor antagonist, 
implying that eplerenone could even be a promising alternative treatment. 
Here we report the treatment outcome with oral eplerenone in 5 patients suffering from 
chronic CSC, who experienced persistent SRF on spectral-domain optical coherence 
tomography (OCT) for at least 9 months, and responded insufficiently to previous treatments. 
Oral administration of eplerenone 25 mg/day was started at baseline. At the start of week 
2, eplerenone was increased to 50 mg/day, and completely stopped at the end of week 5, 
according to the previously described protocol.1
A fixed follow-up protocol was used with visits scheduled at baseline, 1 week, 3 weeks, 5 
weeks and a final examination after 10 weeks. 
The five patients (3 males) had a mean age of 55 years (range 41-64 years), and two patients 
had bilateral active chronic CSC. None of the patients had a history of steroid use. 
A full reduction of SRF on OCT was seen in patient 1 (Figure 1A). In this patient, there was 
only a minor increase in visual acuity (VA), which is most likely the result of the prolonged 
detachment of the neurosensory retina, causing irreversible damage to the photoreceptors.4 
Patient 2 initially had a decrease of SRF but then relapsed after cessation of the eplerenone-
treatment (Figure 1B). Patient 3 showed a decrease of subfoveal SRF, but showed an 
increase of SRF inferior of the fovea (Figure 1C). Patient 4 had no change in SRF, nor a clear 
effect on VA (Figure 1D). Patient 5 had bilateral active disease, in which one eye first had a 
decrease of SRF which then returned to baseline-level, whereas an increase of SRF occurred 
in the other eye (Figure 1E). 
The use of eplerenone did not influence the hyperfluorescent pattern, typical for chronic 
CSC, seen in all patients on fluorescein angiography and indocyanine green angiography. 
None of the patients showed a change in subfoveal choroidal thickness on enhanced-depth-
imaging-OCT during the course of the study, and systemic parameters remained within 
normal range in all patients.
Curative therapeutic options for chronic CSR are scarce and the current leading options 
consist of PDT, conventional laser treatment, and micropulse laser treatment, with 
anatomical success rates ranging from 60 up to 100%.5 A lack of response to these treatment 
modalities is not uncommon. Zhao and colleagues described that an overstimulation of 
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the mineralocorticoid receptor in a rat model caused dilation of the choroidal vasculature 
and choroidal thickening,1 similar to clinical observations in chronic CSC. The same group 
recently presented promising results in 13 patients with CSC, showing a full reduction of SRF 
in 25% of the patients at 1 month and 67% at 3 months after use of eplerenone.5
However, the current pilot study indicates that eplerenone has a beneficial effect only in a 
minority of patients with long-standing treatment-resistant chronic CSC. The precise role 
of an inappropriate activation of the mineralocorticoid receptor in chronic CSC, therefore, 
remains controversial. 
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Figure 1. 
Enhanced depth optical coherence tomography (OCT) imaging of the most illustrative eye and corresponding 
visual acuity (VA) (logMAR) of the five patients. (A) The left eye of patient 1 demonstrated a complete reduction of 
subretinal fluid (SRF) at 5 weeks, which was maintained after 10 weeks and accompanied by a slight increase in VA. 
(B) The left eye of patient 2 with central SRF at baseline showed a reduction of SRF at week 5, an increase above 
baseline at week 10 (after stopping eplerenone), and an increase in VA. (C) The right eye of patient 3 showed an 
almost complete reduction in subfoveal SRF, which appeared stable over time, the VA was also stable. (D) In patient 
4, the SRF remained unchanged at follow-up, with a mild decline in VA. (E) The left eye of patient 5 showed an 
increase in SRF at 5 and 10 weeks as compared with baseline, accompanied by a decrease in VA. In all patients, the 
choroidal thickness did not show a significant change over time.
The use of eplerenone in therapy-resistant chronic CSC
231
Ch
ap
te
r 
4.
4
Referencesa
1.  Zhao M, Celerier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human 
ocular chorioretinopathy. J Clin Invest 2012;122(7):2672-9.
2.  Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: Recent findings and new 
physiopathology hypothesis. Prog Retin Eye Res 2015;48:82-118
3. Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am 
J Ophthalmol 2002;133(6):787-93.
4. Quin G, Liew G, Ho IV, et al. Diagnosis and interventions for central serous chorioretinopathy: 
review and update. Clin Experiment Ophthalmol 2013;41(2):187-200.
5. Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of 
chronic central serous chorioretinopathy: a pilot study. Retina 2013;33(10):2096-102.

CHAPTER 5
General discussion
Chapter 5
234
General discussion
Many studies on chronic central serous chorioretinopathy (CSC) have been undertaken in 
the past decades. However, the precise pathogenesis and the optimal therapeutic approach 
for patients with CSC still remain largely obscure. The main purpose of this thesis was to 
investigate and assess whether genetic factors play a role in chronic CSC, to delineate the 
clinical characteristics and prognosis, and to analyse possible treatment options in chronic 
CSC. In this general discussion the major findings of this thesis are reviewed and placed into 
a broader perspective, evaluating the clinical relevance and future implications.
5.1 Epidemiology of chronic central serous chorioretinopathy
With a reported incidence of at least 9.9 cases per 100.000 men and 1.7 per 100.000 women,1 
CSC is considered the fourth most common macular disease.2 The higher male to female ratio 
is more evident in the acute form as compared to the chronic form, but still strikingly present in 
chronic CSC. Also, the mean age at presentation appears to be higher in chronic CSC patients.3 
There is limited information about the precise incidence of CSC among different ethnic 
groups. Tsai et al. reported a incidence of 21 cases per 100.000 men, and 15 cases per 
100.000 women in a Taiwanese population,4 which is consistent with the suspected higher 
frequency in Asians as compared to other ethnic groups. In addition, some studies suggest 
an increased frequency among Caucasians and Hispanics as compared to African Americans. 
3, 5 These findings suggest variations of the CSC incidence among various ethnic groups.3, 
5 Also, acute CSC with bilateral and multifocal leakage is reported more frequently in the 
Asian population than in other ethnic groups.3, 6 
Risk factors  
Chronic CSC is a multifactorial disease. Although the precise pathogenesis is uncertain, 
several risk factors have been described in association with CSC. The most commonly 
reported risk factors include the male gender and the use of corticosteroids.3, 7
Thus far it is unclear why the incidence of CSC in much higher in men. An explanation may 
lie in the hormonal differences between men and women. Higher levels of testosterone are 
present in men as compared to women.8 A decline in the levels of testosterone in males 
is seen in the advanced adulthood.8 Vice versa, a small increase of the testosterone levels 
occurs in the female population after entering the menopause.9 Interestingly, these changes 
appear to be in line with the differences in age at onset between the genders: male CSC 
patients tend to be younger at onset than female CSC patients.3 Besides the differences in 
testosterone levels between the genders, higher levels of testosterone have been reported 
in individuals with type A personality,10 an additional risk factor associated with CSC (Table 
1, Chapter 1). A person with a type A personality exhibits a simple preponderance of the 
following personality traits; a competitive drive, a sense of urgency, an aggressive nature, 
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and a hostile temperament.11 Also, androgen receptors and messenger RNA for 5-alpha-
reductase, the enzyme responsible for the conversion of testosterone to the more potent 
dihydrotestosterone, are found in the human retinal pigment epithelium (RPE).12 This, and 
recent studies suggesting a positive effect of the use of 5-alpha reductase inhibitors in CSC 
patients,13 support the thought of a possible involvement of testosterone as a risk factor to 
develop CSC.
Not only testosterone is an interesting candidate to be of influence in the pathogenesis 
of CSC. Endogenous as well as exogenous steroids are also strongly associated with CSC. 
For example, CSC has been described in patients with Cushing’s disease, a disorder that is 
characterized by hypercortisolism.14-18 Also, the use of corticosteroids via various application 
forms has been reported to be a major risk factor of CSC, with reported odd ratios up to 37.1 
to develop CSC when using corticosteroids.7, 19-22
Theoretically, one may expect to find increased levels of testosterone and/or cortisol in 
patients suffering from CSC. However, the relatively small studies that have been conducted 
on this subject thus far show indifferent results. Where 24h urine samples have shown 
elevated cortisol levels in chronic CSC patients,23, 24 these results were not observed in single 
serum measurements during set times.25, 26 These discrepancies could be explained by 
hormonal fluctuations between individuals during the day. In addition, testosterone levels 
appear to be within the normal range in patients with chronic CSC.25 Although no clear 
change in serum levels of testosterone and/or cortisol has been found, it is possible that 
more acute changes, rather than a chronic elevation, influence and trigger the underlying 
disease mechanism. This may explain the patients that present with separate attacks either 
provoked by episodes of corticosteroid therapy or periods of stress. It is also possible that 
chronic CSC patients are more sensitive and have an impaired response at the level of the 
choroid and/or RPE to normal serum levels of cortisol and/or testosterone. 
5.2 Clinical presentation
In general, two forms of CSC can be identified: acute CSC and chronic CSC. This distinction 
is often based on the period of time during which subretinal fluid (SRF) is present. In 
the case of long-standing SRF accumulation, the nomenclature changes from acute to 
chronic. In this definition, no consensus exists about the duration of the presence of the 
SRF accumulation that differentiates acute from chronic CSC.2, 27, 28 Arbitrarily, this period 
is set somewhere between 3 and 6 months in most publications.3 The second method of 
differentiation between acute and chronic CSC, which was also used in this thesis, is based 
on the presence and extent of anatomical changes on multimodal imaging including optical 
coherence tomography (OCT), fundus autofluorescence (FAF), fluorescein angiography 
(FA), and indocyanine green angiography (ICGA). Acute CSC is characterized by a focal 
leakage spot on FA, beneath a macular neurosensory retinal detachment.2, 28, 29 This so 
called ‘hot spot’ indicates leakage at the level of the RPE.5, 27, 28 Chronic CSC shows more 
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diffuse RPE changes, with single or multifocal areas of leakage on FA and ICGA.2, 27, 28 In 
chronic CSC, the SRF on OCT is often more shallow as compared to acute CSC, in addition 
the SRF tends to persist, although it can wax and wane multiple times.30, 31 Additionally, ICGA 
characteristically demonstrates widespread hyperfluorescent areas of choroidal congestion 
and hyperpermeability which are more extensive in chronic CSC than in acute CSC.2, 28, 32-34
However, debate exists about the accuracy of the differentiation into acute and chronic 
CSC, and some argue that these represent two separate disease entities. It is unclear if 
uncomplicated acute CSC can eventually evolve into chronic CSC with diffuse RPE changes. 
Support for this connection is found in case reports and case series.3, 35 Larger studies are 
necessary to evaluate both CSC entities and possible their possible association. Despite the 
fact that a certain overlap exists in clinical presentation, the prognosis and clinical course 
appear to differ considerably.
Most patients with the acute form of CSC generally recover spontaneously and tend to have 
a good visual prognosis.3, 36, 37 In contrast, we have shown that chronic CSC is generally a 
progressive chorioretinopathy with a negative impact on the visual outcome (Chapter 3.1). 
The progressive nature of chronic CSC is also reflected on multimodal imaging. A gradually 
progressive decrease in central foveal thickness was seen on optical coherence tomography 
(OCT). Also, on follow-up the FA often showed an increase of hyperfluorescent atrophic RPE 
changes and an increased number of hot spots of leakage in many patients. Our data show 
a marked decrease in reported vision-related quality of life in this chronic CSC cohort when 
compared to healthy individuals (Chapter 3.1). 
Chronic CSC typically presents with SRF on OCT, with areas of leakage on FA and ICGA. 
Multimodal imaging using these diagnostic tools has enabled a faster and more accurate 
diagnosis. However, a striking resemblance in phenotype may exist between chronic CSC 
and other retinal diseases, such as neovascular age-related macular degeneration (AMD) 
(Chapter 1). Establishing the right diagnosis is important to provide patients with an 
accurate prognosis and an optimal treatment if required. Re-evaluation of the initial imaging 
at inclusion is important in patients who developed an obvious choroidal neovascularization 
(CNV) at follow-up in one of our studies, showed lesions suggestive for a very early stage of 
CNV that may have already been present and slumbering at the time of first examination 
(Chapter 4.1). Clinical characteristics that were in retrospect suggestive of small, early CNV 
were a shallow RPE detachment, more diffuse (instead of focal hot spot) leakage on FA, and 
a hyperfluorescent branching network on ICGA. In contrast to chronic CSC, which is treated 
with half-dose PDT, CNV is primarily treated with anti-VEGF injections.38 Therefore, in case of 
non-response to treatment, the physician should always reconsider the diagnosis, whether 
it is CNV simulating chronic CSC or vice versa. 
The imaging methods FA and ICGA provide dynamic 2-dimensional information about the 
retinal and choroidal vasculature, the OCT is able to provide 3-dimensional information. 
The non-invasive character of OCT as compared to FA and ICGA is a big advantage of this 
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technique. However, OCT, FA, and ICGA visualize different aspects of the disease and are 
thus complementary in the clinical assessment of CSC. For instance, FA can show the extent 
of RPE changes and the number of hot spots of leakage through a dysfunctional RPE outer 
blood-retinal barrier.39 ICGA is able to visualize choroidal changes such as diffuse choroidal 
hyperfluorescent leakage that is typical of chronic CSC.28, 32, 40 These choroidal changes on 
ICGA correlate with choroidal thickening and other abnormalities on enhanced depth OCT 
imaging.41-44 In addition, FA and ICGA can better visualize lesions suspect for CNV and/or 
polypoidal choroidal vasculopathy (PCV). 
In chronic CSC, OCT is mainly used to monitor the SRF accumulation. Interestingly, 
multimodal imaging characteristics are not only pivotal to establish a correct diagnosis, 
but may also be of prognostic value, for instance with regard to the likelihood of response 
to treatment. Differences in the optical density ratio of the SRF accumulation in serous 
neuroretinal detachment were recently demonstrated to be a valuable tool to differentiate 
chronic CSC from PCV, again two entities that may be strikingly similar and may have 
partly overlapping pathophysiology.45-47 In longstanding serous neuroretinal detachments, 
subretinal hyperreflective material on SD-OCT in chronic CSC can appear and may become 
increasingly prominent.48 In Chapter 3.2, we used a semi-automated OCT analysis technique 
to show that differences in these OCT characteristics seem to be present between patients 
who respond well to half-dose PDT treatment, and patients who have a poor response to 
half-dose PDT treatment. The skewedness, a measure for the symmetry of the histogram of 
pixel intensity values, showed a trend to be higher in patients who responded better to half-
dose PDT as compared to patients who had poor response to PDT treatment. The median 
pixel intensity of the SRF accumulation was lower in the group with complete absence of 
SRF after treatment. Subretinal debris, such as accumulation of shed photoreceptor outer 
segments that are less efficiently phagocytised by a dysfunctional RPE, gives rise to a higher 
pixel intensity in OCT. Our findings suggest that chronic CSC patients with a higher pixel 
intensity in the SRF on OCT are less likely to achieve complete SRF resolution after half-dose 
PDT. A possible explanation may be that the higher intensity is a reflection of longstanding 
and more inactive disease that may be less sensitive to treatment.
Besides retinal OCT scanning, we investigated the novel OCT-based application of OCT 
angiography (OCTA), also known as split-spectrum amplitude decorrelation angiography. This 
technique detects movements of blood cells in the retinal and choroidal vessels, and is thus 
able to visualize retinal and choroidal vasculature and neovascular changes non-invasively.49 
OCTA enables the visualization of the inner plexus of retinal vessels, which is also seen in the 
early phase of FA. Additionally, OCTA can visualize the deeper retinal plexus because specific 
vascular layers can be selected in the depth resolved OCT volume and because the presence 
of overlying vessels does not mask the underlying vessels.50 It therefore complements the 
current diagnostic methods, and can be of use in the differentiation between small CNV and/
or PCV, that can present with a typical branching vascular network on OCTA, and chronic 
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CSC in which no neovascular network is present. Also, OCTA offers the opportunity to non-
invasively expand our knowledge of the physiology of the retina in health and disease. 
We showed that OCTA is also able demonstrate typical changes in the choriocapillary flow 
pattern, showing choriocapillary hypoperfusion and hyperperfusion of the area in CSC that 
corresponded to areas affected by SRF accumulation, which was not always clearly visible 
using the invasive techniques of FA and ICGA (Chapter 3.3). This is consistent with results 
of earlier studies using FA, ICGA and conventional OCT, showing focal filling defects in the 
choriocapillaris with dilated and tortuous feeding arterioles and dilated venules.10, 28-30 Areas 
of irregular choriocapillary texture on OCTA partially co-located to areas with late staining 
on ICGA. Hot spots of choroidal hyperpermeability and leakage visible on ICGA were in close 
proximity to abnormalities interpreted as relative choriocapillary ischemia on OCTA. These 
results suggest that focal choriocapillary ischemia with surrounding hyperperfusion may lead 
to SRF leakage in chronic CSC. This is an interesting finding, supporting one of the suggested 
hypotheses on CSC pathophysiological mechanisms: in this hypothesis, it is postulated that due 
to choroidal/choriocapillary vasoconstriction and capillary occlusion, a reduction in vascular 
bed occurs. The combination of a higher resistance and increased blood viscosity, which 
may for instance result from relative endogeneous hypercortisolism, can result in sectorial 
hypoperfusion and an increased endoluminal pressure in the surrounding tissue. Together 
with chronic hypoxic damage, a breakdown in the continuity of the RPE outer blood-retinal-
barrier may occur,31 leading to SRF leakage with a serous neuroretinal detachment in CSC.32, 33 
5.3 Genetic findings 
Familial occurrence of CSC,51, 52 as well as interracial differences in the prevalence of chronic 
CSC suggest a role for genetic factors in CSC.3-5 
In one of the first genetic studies ever in CSC, we have found several genetic factors that are 
associated with chronic CSC. First of all, we have found an association with a variant in the 
age-related macular susceptibility 2 (ARMS2) gene (Chapter 2.1). Specific polymorphisms in 
the ARMS2 gene are well known to be associated with AMD. 53, 54 Interestingly, the reported 
association of  the ARMS2 SNP (rs10490924) with AMD appears to have an opposite 
effect compared to the effect that we found in chronic CSC. Where the ARMS2 variant is 
risk-conferring for AMD, we found that it is protective for chronic CSC.  Based on specific 
phenotypic characteristics we stratified patients into different groups ranging from typical 
chronic CSC patients with bilateral disease, typical chronic CSC patients with unilateral 
involvement, to atypical chronic CSC patients that show overlap with or are similar to a form 
of AMD (Chapter 2.1). Intriguingly, differences between these groups are not only present 
on a phenotypic level, but can also be found at a genetic level. When comparing the first 
two groups, no significant difference in minor allele frequency of the tested SNP was found. 
However, when comparing the typical CSC subgroups with the more atypical patients, a 
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significant difference in allele frequency in the ARMS2 SNP was demonstrated. The atypical 
subgroup consisted of patients in which the phenotype showed considerable overlap with 
other macular diseases such as AMD. Interestingly, the minor allele frequencies found in this 
group were similar to those normally observed in AMD, with the same direction of effect 
seen in AMD as opposed to typical CSC.
In addition, this ARMS2 SNP has been previously associated to the subtype of PCV with a 
branching vascular network.55, 56 However, no significant association was found with the form 
of PCV without a branching network. Especially clinical features of PCV without a branching 
network show a large overlap with the CSC phenotype,47, 57, 58 and it is not uncommon for PCV 
patients to report an episode of CSC in their medical history. 59 The presence of a branching 
vascular network, possibly indicating an early CNV, on the other hand, shows more overlap 
with the neovascular subtype of AMD, illustrating the phenotypical overlap between these 
macular diseases. Therefore, Miki et al. hypothesized that there may be a functional role 
of ARMS2 at the level of the RPE and/or choroid that may contribute to the formation of 
branching network vessels in PCV and/or CNV in AMD.55 Indeed, recent studies have shown 
that the ARMS2 protein interacts with components of the extracellular matrix, and is strongly 
expressed in the regions around the capillaries and intercapillary pillars of the choroid.60 
Associations found with other SNPs in our study on genetic risk factors in chronic CSC also 
pointed towards the involvement of the extracellular matrix, although significance was 
lost after correcting for multiple testing (Chapter 2.1). The extracellular matrix provides 
structural and biochemical support to surrounding cells in human tissue. Changes in this 
matrix in the choroidal vessels and Bruch’s membrane could lead to either more rigidity 
of these structures, or an increased elasticity as compared with the healthy population. 
In the situation of an increased rigidity of the vessels, an increase in choroidal vascular 
resistance could occur, inducing an increase in local vascular blood pressure. On the other 
hand, an increased elasticity could result in a local impairment of the vascular pressure wave 
propagation that usually supports the flow of blood through the vessels. This could eventually 
lead to congestion of blood in the choroidal vasculature. Either way, decompensation at the 
level of the choroid may occur, and possibly lead to fluid leakage. The choroid is significantly 
thickened in CSC patients as compared to controls on enhanced depth OCT, and areas of 
choroidal congestion and hyperpermeability have been described on ICGA. Therefore, 
choroidal congestion appears to be a plausible mechanism causing the fluid leakage. 
Besides the rs10490924 ARMS2 SNP, we also found that the CFH rs1061170 / Y402H SNP 
is significantly associated with chronic CSC. Again, as with ARMS2, an opposite effect was 
found for this association as compared to AMD.53 A study in a Japanese cohort and a Greek 
population also identified associations between CSC and common complement factor H 
(CFH) polymorphisms.61, 62 CFH plays an important role as an inhibitor of the complement 
system, which is an essential part of the innate immune system.63 It complements the ability 
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of antibodies and phagocytic cells to clear pathogens such as bacteria from the human 
body. The complement system consists of a number of proteins that are normally found 
in the blood as inactive precursors. Activation of these precursors is necessary to create an 
appropriate immune response, which is normally directed against the invading pathogens. 
Disturbances in the complement system can lead to an underactivation, resulting in an 
increased susceptibility to pathogens, or to a harmful overactivation, which can inadvertently 
damage self-cells. Activation of the complement system proceeds through one of three 
possible pathways; the classical pathway, the lectin pathway or the alternative pathway. 
Each of these pathways eventually initiates a cascade in which the complement system 
becomes activated, activating the C3 convertase, followed by C5 convertase activation, 
leading to terminal pathway activity (Figure 1). 
Figure1. 
Schematic illustration of the activation and function of C3 as a central player in the complement system.
The complement activity is strongly regulated by several inhibitory proteins. For AMD it is 
suggested that the alternative pathway plays the most important role in the pathogenesis. 
CFH is a potent inhibitor of the alternative pathway of the complement system by acting on 
3 different steps. CFH not only influences the decay of C3 convertase, but is also competitive 
toward factor B and is a cofactor to allow cleavage of C3b into an inactive form. In AMD, 
changes in the CFH protein appear to result in an overactive complement system, with 
proven elevated serum levels of complement. The overactivity of the complement system in 
AMD results in inflammation at the level of the Bruch’s membrane and RPE. Furthermore, 
an altered alternative complement pathway activity, extravasation of complement-related 
proteins, and deposition of terminal complement membrane attack complexes, may all lead 
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to RPE damage and dysfunction. Damage of the RPE outer blood-retinal barrier could thus 
result for instance from (a combination of) complement dysfunction, abnormalities in the 
underlying extracellular matrix, and a dysfunctional, hyperpermeable thickened choroid. 
When the RPE outer blood-retinal barrier is disrupted focally or more diffusely, this opens 
the gates to possible subretinal leakage, resulting the classical clinical picture of a serous 
neuroretinal detachment. Also, CFH binds and interacts with adrenomedulin, which has 
been shown to induce vasodilatation of the choroid, increase microvascular permeability, 
and affect the choroidal blood flow. However, our findings in Chapter 2.1 show opposite 
effects in the association of several CFH SNPs in the chronic CSC population as compared to 
AMD. To date no clinical information regarding the serum levels of the complement system 
exist in chronic CSC. Therefore, it is unclear if and how the CFH SNPs affect the activity of the 
complement system. It might therefore be possible that an impaired complement system 
rather than an overactive one as in AMD underlies CSC. 
Our identification of CFH SNPs in association with chronic CSC is not the only lead that 
points towards an involvement of the complement system. Interestingly, we also found an 
association with genetic variations of the complement 4 (C4) gene (Chapter 2.2). Different 
from CFH, C4 acts through the classical and lectin pathways. The C4 gene encodes the C4 
protein, of which two variants have been described (C4A and C4B), differing in only four amino 
acids.64 The gene lies within the RP-C4-CYP21-TNX (RCCX) locus situated within the major 
histocompatibility complex region III (MHCIII) on chromosome 6 of the human genome.65 
The MHC region contains an elevated level of genomic copy number (GCN) variations that 
are presumably present to increase the immunological diversity.66 These duplications and 
deletions have led to the formation of haplotypes containing variable copies of the RCCX 
module in the human population.66, 67 Haplotypes containing two or more duplications of 
the RCCX locus show extensive variability in their gene build-up, generally with complete 
duplications of the C4 gene.67, 68 Our study showed that C4B genomic copy numbers were 
significantly lower in chronic CSC patients compared to healthy controls. Carrying no copies 
of C4B conferred significant risk of chronic CSC, whereas three copies of C4B significantly 
decreased the risk of chronic CSC (Chapter 2.2). Associations of C4B copy number variations 
with several ocular diseases and autoimmune disorders (e.g. Vogt-Koyanagi-Harada disease 
and Behçet’s disease), have been described in previous studies. In Vogt-Koyanagi-Harada 
disease, a T-cell-mediated auto-immune response against melanocytes occurs, resulting in 
a diffuse choroiditis. On OCT patients can present with an ocular phenotype consisting of 
an SRF accumulation in the fundus, and a thickened choroid. Furthermore, FA classically 
demonstrates widespread, pinpoint areas of leakage throughout the fundus.69 Hou et al. 
described a decreased expression of serum C4 and a decreased frequency of high C4 gene 
copy number in patients with Vogt-Koyanagi-Harada disease. Although we did not see the 
same effect concerning the C4 gene copy numbers in the chronic CSC patients, it may be 
possible that serum C4 is also abnormal in CSC. In addition, several studies have reported a 
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positive linear correlation between serum C4 and C4 genomic copy number, which suggests 
that a lower number of C4B copies in chronic CSC leads to lower systemic C4B levels. It should 
be noted, however, that although the phenotypes of chronic CSC and Vogt-Koyanagi-Harada 
disease show a certain phenotypical overlap, the treatment of Vogt-Koyanagi-Harada disease 
consists of long term use of high-dose corticosteroids in contrast to CSC which is aggravated 
by corticosteroids, suggesting another pathophysiological pathway. 
In addition to the aforementioned associations, Banlaki et al. discovered an association 
between the genomic copy number of C4B and cortisol release after adrenocorticotropic 
hormone (ACTH) stimulation. This link to the hypothalamic-pituitary-adrenal (HPA)-axis is of 
increased interest as chronic CSC has been associated with stress, endogenous hypercortisolism 
and the use of corticosteroids. Stress on its own has a strong influence on the HPA-axis and 
increases ACTH release. Banlaki et al. found that low copy numbers of C4B were associated 
with hyperactivity of the HPA-axis. Patients with a low C4B genomic copy number responded 
with a higher cortisol response after ACTH stimulation. To date, various small studies have 
evaluated the cortisol levels in chronic CSC patients, thusfar without finding a clear indication 
for a chronic elevated cortisol level. Although a possible association of the cortisol levels and 
chronic CSC is at present uncertain, it is possible that patients with chronic CSC generally have 
normal cortisol levels, but respond differently to stimulation of the HPA axis. The low C4B copy 
numbers observed in our chronic CSC patients may support this hypothesis.
It is unknown how increased levels of cortisol can link to SRF accumulation. Interestingly, 
Zhao et al. have introduced an idea of a possible involvement of the glucocorticoid receptor 
(GR) and the mineralocorticoid receptor (MR). The MR is typically expressed in kidney cells, 
but is also present in the retina and in the choroidal vessels.70 Based on the association of CSC 
with corticosteroids, it was postulated that inappropriate/excessive occupancy of the MR by 
glucocorticoids may occur in the choroid of CSC patients. A rat model was used to investigate 
the short-term effects of MR activation in choroidal vasculature after intravitreous injection 
of corticosteroids. They found that the injection of corticosteroids resulted in a thickening 
of the choroid within 24 hours. In addition, an injection of aldosterone, a classic MR ligand, 
also induced choroid thickening and vasodilatation of the choriocapillaris and choroidal 
vessels. It appears that a mechanism involving the K+ channel KCa2.3 is involved in the MR-
induced choroidal thickening promoted by aldosterone.71 The clinical information gathered 
from human studies support the idea that CSC starts with abnormalities at the level of the 
choroid. Therefore, the findings in this rat model may translate well to the human model, 
and local MR activation by endogenous or exogenous glucocorticoids may be involved in the 
underlying disease mechanism. These findings have also resulted in clinical studies that are 
described in the section 5.4 Treatment of chronic central serous chorioretinopathy.
  In another study, a connection between corticosteroids and the Cadherin 5 gene was 
found to be associated with CSC in male patients.72 Cadherin 5 is the major cell-cell adhesion 
molecule in the vascular endothelium. Functional studies illustrated that prednisolone in 
cultured endothelial cells and human organ cultures, and triamcinolone in mice in vivo, 
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significantly reduced the expression of Cadherin 5 mRNA. It is suggested that this results in 
an increased vascular permeability in vivo, possibly explaining the vascular changes as seen 
in the choroid of CSC patients.72 However, the latter described association was only found 
in male patients of the study cohort, and no correction for multiple testing was performed, 
indicating that the relevance of these findings should be further investigated. 
5.4 Treatment of chronic central serous chorioretinopathy
Studies suggest that the persistance of serous SRF longer than four months may finally 
result in permanent atrophic damage of the neuroretina.2 These findings, and the 
progressive nature of chronic CSC and its negative impact on the vision-related quality of 
life that we describe in Chapter 3.1, emphasizes the need for an effective treatment in this 
patient group. The primary aim of treatment in CSC is to restore visual acuity and image 
quality, and to eliminate metamorphopsia. With serous SRF accumulation in the macula 
being the principal vision-threatening feature, treatment should aim to achieve a complete 
resolution of macular SRF, thus inducing a re-attachment of the neurosensory retina. A 
wide range of different treatments have been used in CSC patients over the past decades, 
with various results (Table 1). Unfortunately, virtually all of these therapeutic options have 
been described in a retrospective study setting in clinically variable CSC patients (ranging 
from acute to chronic CSC). Therefore, there is still much controversy regarding the optimal 
treatment strategy in CSC.
Table 1. An overview of therapeutic interventions described in central serous chorioretinopathy 
Conventional thermal laser treatment Argon laser 37, 73-75
Photodynamic therapy (PDT) Standard settings PDT76
Half-dose PDT77 
Half-fluency PDT78, 79 
Half-time PDT80 
High-density subthreshold micropulse 
laser treatment and selective retina 
therapy laser
Wavelength: 810 nm81
Wavelength: 577 nm82
Wavelength: 527 nm83
Anti-vascular endothelial growth factor 
treatment
Ranibizumab84  
Bevacizumab85
Aflibercept 86
Systemic treatment Carbonic anhydrase inhibitors87
Beta-blockers88
Treatment against H. pylori infection89, 90
Glucocorticoidreceptor antagonists91
Anti-platelets92
Antimetobolites93
5α-reductase inhibitors13
Aldosterone/mineralocorticoid receptor antagonists70, 71
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One of the most frequently used treatment options in the past has been conventional laser 
photocoagulation treatment of the hot spots of leakage based on FA.37, 73-75 This approach 
is largely based on the idea that the primary problem in chronic CSC occurs on the level 
of the RPE, as suggested by the focal of diffuse leakage seen on FA. Conventional laser 
photocoagulation, often using an Argon laser, has been shown to have a positive effect on 
the hastening the resolution of the SRF accumulation, especially in the acute CSC phenotype 
with obvious focal leakage.37 However, due to the localized thermal damage, side effects 
such as (para)central scotoma and iatrogenic CNV can occur, particularly if performed in 
the juxtafoveal area.3, 94, 95 A way to bypass these side effects, was made possible by the 
introduction of the High-density subthreshold micropulse laser (HSML) and selective retina 
therapy. In HSML, a laser is used to deliver a high-density pattern of repetitive multiple 
short low energy pulses, selectively targeting the RPE without inducing a visible laser burn.96 
HSML laser can either be used to only treat the hot spots of leakage seen on FA, or to apply 
high-density laser treatment on all hyperfluorescent areas in the posterior pole seen on 
ICGA. Both 810nm and 577 nm HSML treatment has been described in acute and chronic 
CSC. A study using a HSML treatment with a wavelength of 810 nm evaluated the macular 
thickness as a primary outcome. Eleven eyes of ten symptomatic CSC patients, that had SRF 
for at least three months, were included. They found a reduction of the maximum macular 
thickness in 72.7% of the cases after treatment.81 Scholz et al. used HSML treatment with 
a 577 nm wavelength. In this study 38 eyes of 38 CSC patients were included. A response 
to treatment at the final follow-up (5 months after treatment) was seen in 74% of the 
eyes, defined as a reduction of SRF (50%) or a complete absence of SRF (24%). The authors 
also note that although a confluent treatment was performed, several patients needed a 
repetition of the treatment.82 Finally, selective retina therapy with a wavelength of 527 nm 
demonstrated a positive effect especially in acute CSC patients up to 100% reduction of SRF 
on OCT, but less promising results in patients with chronic CSC.83, 97 
  Another laser-based treatment, photodynamic therapy (PDT), is probably the 
most commonly used treatment for chronic CSC at present. PDT was originally developed 
to treat neovascular AMD,98, 99 and is used as an off-label treatment in CSC. In PDT the 
photosensitive drug verteporfin (Visudyne®) is administered intravenously and activated in 
the eye by a laser light with a wavelength ranging between 689-693 nm. The activation 
of verteporfin results in a cascade of events finally causing endothelial vascular damage 
and vessel occlusion in the choriocapillaris/choroid.3, 100 There is an ongoing debate on 
whether to perform FA-guided or ICGA-guided PDT treatment.  Multimodal imaging has 
demonstrated that abnormalities are often more pronounced and more extensive in the 
choroid of CSC patients as compared to the RPE, indicating that the choroid is the primarily 
affected structure in CSC, many consider ICGA-guided treatment the method of choice.77, 
101-103 The exact mechanism through which PDT treatment influences the choroid is not 
fully known, but it is thought to mainly target the choroid. A possible explanation is that 
PDT results in selective local choroidal damage, which causes short-term choriocapillaris 
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hypoperfusion and long-term choroidal restructuring. This remodelling is thought to reduce 
choroidal congestion, hyperpermeability, and extravascular leakage.3, 104, 105 Two follow-up 
studies, with 4 and 5 years of follow-up respectively, have shown that the use the original 
settings (6 mg/m2 of verteporfin with a laser fluency of 50 j/cm2) in CSC patient appears to 
be effective and safe.76, 106 In the study with 4-years of follow-up a complete resolution of 
SRF was achieved in 93% of the subjects, and a significant improvement of visual acuity was 
seen. No systemic or ocular side effects were registered.76 However, rare but serious side 
effects such as choriocapillary non-perfusion and atrophy, secondary CNV, RPE atrophy and 
subsequent visual loss have been described with these full settings.3, 101 Because of these 
reported side effects, and since the aim of treatment for CSC is not neovascular vessel closure 
but rather a decrease in leakage and hyperpermeability from existing choroidal vessels with 
subsequent resorption of fluid,101 reduced settings have been introduced in the treatment of 
CSC patients. Reduction of the settings can be induced either by using half the normal dose 
of verteporfine (3 mg/m2: half-dose PDT); by reducing the fluency to 25 J/cm2 - half-fluency 
PDT - or by limiting the treatment time to 42 seconds: half-time PDT. A recent meta-analysis 
reported that the use of half-dose PDT resulted in a significant improvement of visual acuity, 
and kept central macular thickness significantly lower as compared to a placebo group.107 
Also, the proportion of eyes with a complete resolution of SRF was 18.4 fold higher in the 
half-dose PDT group as compared to the placebo group based on the combined data from 
mostly retrospective studies.107-110 The use of half-fluency PDT also results in a significant 
improvement of the visual acuity. Complete resorption of the SRF has been reported in 
81-100% of chronic CSC patients.78, 79, 101, 111 Interestingly, one study found that half-fluence 
PDT resulted in less choriocapillaris nonperfusion (seen on ICGA), as compared to standard-
fluence PDT (0% versus 44%).79 The success rate of half-dose PDT treatment in our study, 
in which we used a strict definition of ‘success’ as a complete absence of SRF on OCT 
after a single half-dose PDT treatment, was 63%, which is lower than reported in previous 
retrospective studies on PDT in chronic CSC. A possible explanation may relate to the fact 
that 25% of the included patients had previously received a treatment (excluding PDT) for 
chronic CSC before being enrolled in our treatment protocol. It is currently unknown if there 
is a difference in success rate between half-dose, half-fluency, or half-time PDT treatment for 
CSC. In a study by Nicolo et al., a higher success rate with a complete resolution of SRF after 
12 months was found for half-dose as compared to half-fluency PDT (100% vs 84%),112 but 
other studies did not find a significant difference between half-dose PDT and half-fluency or 
half-time PDT.113, 114 Therefore, it may be preferable at present to use half-dose PDT to treat 
CSC, to reduce the likelihood of verteporfin-associated side effects, as we did in the PLACE 
trial (Chapter 4.3) in which half-dose PDT is compared to HSML treatment in chronic CSC. 
There are several other chorioretinal diseases besides CSC for which PDT with verteporfin is 
successfully used as an off-label treatment, such as choroidal haemangioma and PCV.98
  Besides laser interventions, several systemic treatment options have been 
suggested for CSC (Table 1). Unfortunately, most of the published studies that investigated 
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other systemic treatments included relatively small sample sizes and were retrospective, 
with a resulting poor quality of scientific evidence.31 A recently introduced and possible 
promising approach involves the use of oral treatment with MR antagonists. This approach 
is based on the previously described finding that an overstimulation of the MR in a rat model 
causes dilatation of the choroidal vasculature and choroidal thickening, similar to clinical 
observations in chronic CSC.71 The use of spironolactone, a competitive MR antagonist, 
has been reported in a case series of 18 patients. The use of 50 mg daily for up to three 
months resulted in a decrease in SRF (119 µm) and reduced central foveal thickness was 
found (118 µm), accompanied by an increase of visual acuity from 0.32 at baseline to 0.20 
after 3 months.115 Also, the use of oral eplerenone, a selective MR antagonist, during a 
treatment period of 1-3 months was investigated in 13 patients with CSC of at least 4-month 
duration. A complete resolution of SRF was seen in 25% of the patients after 1 month of 
eplerenone treatment, and 67% at 3 months after use of eplerenone, which is lower than 
most success rates reported for PDT.70 The same group that introduced the thought of the 
use of eplerenone, recently presented novel retrospective results in 54 eyes.116 The eyes had 
either persistent SRF that lasted longer than 4 months, or recurrent SRF that lasted longer 
than 2 months, compatible with the diagnosis of chronic CSC. A complete resolution of SRF 
was seen in 38% and 50% of the eyes at 3 and 6 months, respectively. In these studies it 
was not clearly described into which category persistent or recurrent CSC these eyes could 
be categorized, but is unclear if this classification would have any consequence.116 Large 
multicenter prospective, randomizes, controlled trials evaluating the use of eplerenone and 
spironolactone are currently lacking. Therefore, in this thesis we only tested eplerenone 
in a pilot setting in chronic CSC patients who were previously treatment-resistant to other 
therapies (Chapter 4.4). In this patient population beneficial effects were only noticed in a 
minority of the patients.
Corticosteroids and PDT treatment
A strong association exists between the use of corticosteroids and chronic CSC.7 It is generally 
advised to stop corticosteroids in CSC patients if medically possible, although it is unknown 
what the likelihood is that cessation of corticosteroids can lead to a resolution of CSC. The 
question arises as to whether patients with clear corticosteroid-associated chronic CSC 
respond in the same way to PDT treatment as patients without any history of corticosteroid 
use. If different, it could not only influence the clinical practice in these patients, but can 
also give rise to new insights into the pathogenesis. The retrospective study we performed 
however, showed no differences in response to PDT treatment in patients with chronic CSC 
that was or was not associated with corticosteroid use (Chapter 4.2). The findings in our 
study are encouraging as they suggest that the continuation of corticosteroid treatment, 
if inevitable for other medical indications, does not exclude a favorable response to PDT. 
However, it should be emphasized that cessation of corticosteroid use, if possible, can also 
lead to full resolution of SRF, and should always be endeavoured before further treatment 
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is initiated. Our findings may also suggest a similar pathophysiological mechanism between 
chronic CSC patients using corticosteroids and patients who have no reported history of 
corticosteroid use. It is more likely that the corticosteroids provoke chronic CSC in patients, 
for instance by exceeding a certain vulnerability threshold. The same mechanism could exist 
in patients without any reported use of corticosteroids. In these cases a systemic rise of 
endogenous ‘steroids’ such as cortisol may be the cause of exceeding a similar threshold, 
although more research is definitely needed to test this hypothesis. 
Prospective treatment approach using half-dose PDT and HSML
In this thesis we reviewed a treatment protocol using up to two half-dose PDT treatments 
in chronic CSC, followed by HSML if there was no complete resolution of SRF after previous 
PDT treatment. The success rates of the PDT treatment in this study cohort were found to 
be lower as compared to previous studies on PDT in chronic CSC (Chapter 4.1). Previous 
studies have described success rates that generally fall between 81% and 100%.78, 101, 117-119 
Four studies included patients with symptomatic CSC for at least 6 months. In 3 studies 
evaluation took place 1 month after half-dose PDT treatment, one study reporting complete 
resolution of SRF on OCT in 100% versus 85% and 87% of cases in the other studies117-119 
One study had a second evaluation moment at final follow-up (14.2 ± 5.8 months): at this 
time point absence of SRF on OCT in the macula was seen in as much as 92% of the study 
eyes. Another study looked at the results after one half-dose PDT treatment and found a 
complete resolution of SRF on OCT in 86% of all eyes.78 During follow-up, recurrence of 
SRF on OCT was reported in 14% of the eyes, in which case the eyes were retreated with 
half-dose PDT. At the end of the follow-up (minimum of 12 months and a maximum of 40 
months) all eyes had absence of SRF on OCT.78 Our study found treatment success, defined 
as an absence of the SRF on OCT after treatment in 63% of cases after 1 half-dose PDT 
treatment. However, the retrospective character of most of the current studies on half-
dose PDT make a one-to-one comparison difficult. Not only are there differences in the 
follow-up time, but there may also be a positive publication bias for studies which found 
higher success rates. In addition, it is possible that these differences can be explained by 
different definitions of chronic CSC. The definition of the chronic CSC phenotype, as used in 
this thesis, is not yet universally accepted. Many studies still distinguish acute from chronic 
CSC based on the period in which SRF is present. In our study, however, we defined active 
chronic CSC by active leakage of fluid under the retina as evidenced on spectral domain OCT 
and further supported by hyperfluorescent area (s) on ICGA or/and ≥ 1 ill-defined leakage 
area(s) on FA. Therefore, it is possible that other groups have included milder phenotypes 
that are more prone to show spontaneous resolution of the SRF accumulation or are more 
likely to show a favorable treatment response to PDT. In addition, 25% of the included 
patients in our study had previously received a treatment (excluding PDT) for chronic CSC 
before being enrolled in our treatment protocol, which indicates that we included relatively 
severe chronic CSC cases. We observed that a second half-dose PDT treatment, in patients 
with persistent SRF after the first PDT treatment, resulted in a complete resolution in 67% 
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of these patients. Only 20% of the eyes that received 2 half-dose PDT treatments prior to 
HSML treatment responded with complete resolution of SRF on OCT after HSML treatment. 
As we did not study HSML as primary treatment we are unable to compare our results to the 
current literature on HSML treatment in CSC patients.
The PLACE trial: a prospective, multicenter randomized controlled treatment trial for chronic 
central serous chorioretinopathy 
A recent meta-analysis of 25 studies with a total of 1098 participants concluded that of the 
interventions for CSC studied to date, PDT or HSML treatment appear the most promising 
to study in prospective randomized controlled trials.120 Although current literature appears 
to be in favor of PDT treatment as compared to HSML treatment, no large multicenter 
prospective randomized controlled treatment trials have thus far been performed that 
compare PDT to HSML treatment. Furthermore, besides this lack of prospective studies, 
there are no long-term studies (>12 months) recording visual function, recurrence rate, 
benefit of possible re-treatments, and the rate of adverse events after single or multiple 
treatments.3 In this thesis we introduce the PLACE-trial (Photodynamic therapy versus 
micropulse laser treatment in chronic central serous chorioretinopathy) (Chapter 4.3). 
In this multicenter prospective randomized controlled treatment trial (clinicaltrials.gov 
identifier: NCT01797861; EUDRACT number 2012-004555-36), half-dose PDT and HSML are 
compared as treatments for chronic CSC. Since half-dose PDT appears to be more promising 
for chronic CSC according to current, largely retrospective literature, a superiority design 
was chosen for this study protocol. Currently, this investigator-initiated trial is conducted in 
5 different tertiary university clinics, in 4 different European countries (Radboud University 
Medical Center, Nijmegen, the Netherlands; Leiden University Medical Center, Leiden, the 
Netherlands; University Eye Clinic of Cologne, Cologne, Germany; Oxford University Eye 
hospital, Oxford, United Kingdom; University Eye Clinic of Créteil, University of Paris Est 
Créteil, Paris, France). A total of 156 chronic CSC patients, with active leakage of fluid under 
the retina as evidenced on OCT scanning and further supported by findings on FA and ICGA, 
in at least one eye, will be recruited. Extensive phenotyping based on multimodal imaging 
including fundus photography, OCT of the retina and choroid, autofluorescence imaging, FA 
and ICGA will be performed. With this extensive phenotyping a more homogeneous chronic 
CSC study group can be included in this treatment trial. After inclusion the patients will be 
randomized into the two treatment arms: half-dose PDT or HSML treatment. A complete 
ophthalmological examination with visual acuity measurement, microperimetry, vision-
related quality of life (NEI VFQ-25) and stress questionnaires, will be performed at baseline; 
6-8 weeks after first treatment; 6-8 weeks after a second treatment (if necessary); and at the 
final follow-up visit at 7-8 months after first treatment. The primary endpoint of this study is 
to assess if there is a difference between the efficacy, based on the absence or persistence 
of SRF on OCT, of half-dose PDT treatment versus HSML treatment in patients with chronic 
CSC. In addition, we have added a number of functional secondary outcome parameters.
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The results of this study will not only provide information about whether half-dose PDT 
is indeed superior to HSML treatment on an anatomical level, but also with regard to 
functional parameters including visual acuity, microperimetry, and vision-related quality of 
life. In addition, the extensive multimodal imaging performed will enables us to look for 
phenotypical features that may predict response to treatment. In addition, the influence of 
treatment on the anatomy of the ocular tissue may be evaluated. Finally, this prospective 
study protocol generates a unique, well-comparable dataset providing information regarding 
epidemiological factors, and long-term clinical outcome (both anatomical and functional) in 
chronic CSC. 
5.5 Final remarks and future perspectives
In conclusion, the findings reported in this thesis illustrate that genetic factors may provide 
important clues towards a better understanding of the etiology of chronic CSC. We have 
shown that genetic factors are involved in the susceptibility to the disease, despite the fact 
that environmental factors such a corticosteroids also appear to play an important role 
in CSC. New methods to discover additional genetic risk factors, such as a genome-wide 
association study or whole exome/genome sequencing, and functional studies to determine 
the effect of the genetic findings are necessary to further investigate the network of genetic 
factors and molecular pathways involved in CSC. Such approaches may not only lead to 
further new insights into the pathophysiology of chronic CSC, but may also identify new 
preventive and therapeutic targets. For example, complement modulation treatment, which 
is already being studied for geographic AMD,121-123 may prove to be an interesting treatment 
option for CSC. 
  We have also demonstrated the importance of detailed phenotyping to obtain 
reliable results, not only for study purposes, but also for clinical practice. A pilot classification 
to differentiate between typical and more atypical cases of chronic CSC was introduced. 
Interestingly, differences found between these phenotypic groups also translated into 
differences on a genetic level. The phenotype thought to be atypical for chronic CSC, 
showed more overlap with AMD not only on a phenotypic level, but also on a genetic level. 
Therefore, further research should be initiated to study the similarities and differences 
between chronic CSC and AMD.
  To date, no uniformity regarding the treatment of chronic CSC exists due to the 
lack of well-designed prospective randomized controlled trials. In contrast to acute CSC, 
for which an initial watch and wait policy may be appropriate, chronic CSC patients should 
receive adequate treatment. A broad spectrum of treatment modalities is being or has been 
used in chronic CSC, with variable success. A recent meta-analysis concluded that currently 
the most promising treatment modalities are PDT and HSML treatment.120 To determine 
if and which of these two therapeutic approaches may be superior, we designed the first 
prospective randomized controlled trial for chronic CSC that compares half-dose PDT with 
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HSML treatment. The results of these studies will potentially lead to the establishment of a 
best-practice treatment guideline to treat chronic CSC. 
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Summary
Chronic central serous chorioretinopathy (CSC) is a disease of the eye with leakage of fluid 
under the central part of the retina, the macula. The fluid is derived from the choroid 
underlying the retinal pigment epithelium (RPE). Because of the subretinal fluid collection 
under the macula, patients can experience complaints of metamorfopsia and blurred vision. 
Chronic CSC often occurs in men who are relatively young and still professionally active. 
Other risk factors that have been associated with CSC are the use of corticosteroids and 
stress. Although chronic CSC is one of the most common maculopathies, little is known 
about the pathofysiology, the clinical characteristics and the optimal therapy.
The aim of this thesis is to gather more information about the genetic background, the 
clinical characteristics and the most effective treatment options of this disease. This could 
lead to new insights in the pathofysiological mechanisms of the disease. In addition, it may 
aid to more accurate information of patients regarding the clinical course, prognosis, and 
the optimal treatment approach for chronic CSC.
In Chapter 1 a general introduction about the anatomy of the eye, and specifically the retina, 
is given. Also, the different imaging modalities to investigate the retina are discussed. Also, 
the different imaging modalities to investigate the retina are discussed. Furthermore, the 
clinical characteristics, the current ideas about the pathophysiology, and treatment options 
are introduced.
Chapter 2.1 describes one of the first genetic studies performed in a large chronic CSC 
patient cohort. In this study, genetic variants that are known to be associated with age-
related macular degeneration (AMD), were investigated. Despite notable clinical differences, 
chronic CSC and AMD also share some clinical similarities prompting this genetic exploratory 
study. All chronic CSC patients were divided in three subgroups (ranging from very typical 
chronic CSC to atypical, AMD-like CSC) based on the phenotypical presentation on 
multimodal imaging. DNA collected from 292 chronic CSC patients, 1147 AMD patients, and 
1311 healthy controls was analyzed for a range of single nucleotide polymorphisms (SNPs). 
Besides an already known genetic variant in the Complement factor H (CFH) gene, a new 
association was found with a varient in the ARMS2 gene. Interestingly, the genetic variants 
that conferred risk for chronic CSC were protective for AMD, and vice versa. Also, significant 
differences in the genetic variants were found between the three phenotypic subgroups, 
illustrating the importance of correct clinical classification.
  In Chapter 2.2 the possible role of the complement system, an essential player in 
the innate immune system, in chronic CSC was further investigated. The complement 4 (C4) 
gene, a gene that plays an important role in the classic and lectine pathway of the complement 
system, was studied. We found a significant association between the copy number of the 
C4B gene and chronic CSC. Individuals who carry no copies of C4B have an increased risk of 
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chronic CSC, whereas carrying three copies of C4B appeared to be protective. These genetic 
findings suggest that the complement system may play a pathophysiological role in chronic 
CSC.
In Chapter 3.1 the clinical course of chronic CSC was investigated in a follow-up study in 
52 eyes of 26 patients. Also, the impact of chronic CSC on the vision-related quality of life 
was analysed. The results show that chronic CSC is a progressive disease in many patients, 
causing a decrease in visual acuity, accompanied by a lower reported vision-related quality 
of life. In deciding whether or not to treat chronic CSC, the progressive nature of CSC should 
be taken into account.
  Chapter 3.2 demonstrates that optical coherence tomography may not only be 
used to monitor the subretinal fluid in chronic CSC, but may aid in the prediction of the 
treatment response. The OCT characteristics of the subretinal fluid pocket of 48 eyes of 
treatment naive chronic CSC patients were analysed using a semi-automated computer 
program. All patients were subsequently treated with half-dose photodynamic therapy 
(PDT), and the treatment response was recorded. Variations within the OCT characteristics 
of the subretinal fluid appearance seem to be of predictive value for the treatment response 
to half-dose PDT.
  In Chapter 3.3 the new technique of OCT angiography was used to illustrate 
abnormalities in the flow patterns at the level of the choriocapillaris in chronic CSC patients. 
These irregularities corresponded to abnormalities that were seen on indocyanine green 
angiography. The abnormalities on OCT angiography in chronic CSC consisted of local areas 
of reduced flow surrounded by hyperperfusion. This may lead to focal ischemia of the 
choriocapillaris with hyperperfusion, eventually leading to leakage of serous fluid into the 
subretinal space. 
Chapter 4 describes multiple studies on the treatment of chronic CSC.
Chapter 4.1 presents the results of a prospective treatment protocol that was conducted 
in a period of 18 months. In this protocol, chronic CSC patients were first treated with half-
dose PDT, followed by a second half-dose PDT treatment in the case of persistent serous 
subretinal fluid. In case of persistent fluid leakage despite these two PDT treatments, a 
high-density subthreshold micropulse laser treatment was performed. This protocol led to 
a positive treatment result, defined as a complete resolution of subretinal fluid, in 80% of 
the cases, in which the visual acuity also increased after treatment. The first half-dose PDT 
treatment had the highest likelihood of a favorable treatment response and an increase in 
visual acuity. The use of corticosteroids is known to be associated with chronic CSC, but it 
is unknown if corticosteroid use as an exogenous factor influences the response of chronic 
CSC to treatment with PDT. 
In Chapter 4.2 we investigated if patients suffering from corticosteroid-associated chronic 
CSC respond differently to half-dose PDT treatment as compared to chronic CSC patients 
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without previous or current corticosteroid use. Possible differences between these patients 
groups could indicate different pathophysiological pathways. The study found no significant 
difference between both groups when looking at the percentage of complete resorption of 
the serous subretinal fluid fluid after PDT treatment. Continuation of corticosteroids at the 
time of PDT treatment also did not seem to adversely affect response to PDT. Therefore, PDT 
treatment appears to be a viable and effective treatment option also in patients with chronic 
CSC associated with corticosteroid use. There is no consensus on the optimal treatment for 
CSC, and a broad range of therapies have been applied without a well-designed prospective 
randomized study design.
  In Chapter 4.3 the protocol of the first multicenter prospective randomized 
controlled treatment trial in chronic CSC, comparing half-dose PDT with high-density 
subthreshold micropulse laser treatment is described. In this unique investigator-initiated 
treatment trial, 156 chronic CSC patients will be recruited for randomized treatment. All 
patients will be examined extensively using multimodal imaging, as well as additional tests 
such as microperimetry and questionnaires. After inclusion, patients will be randomized into 
one of the two treatment arms, resulting in two equal treatment groups of which the visual, 
anatomical and functional treatment results will be compared. The aim of this study is to 
shed more light on the preferred treatment for chronic CSC patients, by comparing these 
two modalities that appear the most hopeful according to current literature. The results 
of this study may also aid in reaching an international consensus regarding the optimal 
therapeutic approach in chronic CSC, something that is currently lacking.
  Finally, in Chapter 4.4 we describe the use of eplerenone, an orally administered 
mineralocorticoid receptor antagonist, in patients with long-standing treatment-resistant 
chronic CSC. Five patients were included in this pilot study, who used eplerenone for 5 
weeks. In contrast to the positive response reported in recent literature, this pilot study 
showed a positive effect with complete resolution of the serous fluid pocket only in one 
patient. This indicates that eplerenone may have a beneficial effect only in a minority of 
patients with long-standing treatment-resistant chronic CSC.
Chapter 5 is a general discussion of the main finding of this thesis, in which the study results 
are put into a broader perspective. An overview of the etiology and known risk factors is 
given, followed by discussion of the possible implications of the genetic associations that 
were identified. In addition, the different treatment modalities described in the current 
literature are discussed and compared to the results found in this thesis. Finally, future 
studies are proposed that may aid in unravelling the still mysterious entity of chronic CSC.
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Samenvatting
Chronische centrale sereuze chorioretinopathie (CSC) is een aandoening van het oog 
waarbij lekkage van vocht onder het centrale deel van de retina, de macula, optreedt. Dit 
vocht is het gevolg van vochtlekkage vanuit het onderliggende vaatvlies, de choroidea, door 
een dysfunctioneel retinaal pigment epitheel. Door dit subretinale vocht kunnen patiënten 
last hebben van vervorming van het beeld en minder scherp zien. Chronische CSC komt 
met name voor bij mannen van middelbare leeftijd. Andere beschreven risico’s voor CSC 
zijn het gebruik van corticosteroïden en stress. Hoewel chronische CSC één van de meest 
voorkomende maculopathieën is, is nog lang niet alles bekend over het ziektemechanisme, 
de klinische kenmerken en de optimale behandeling. 
Het doel van dit proefschrift is daarom meer kennis te verkrijgen over de genetische 
achtergrond en mogelijke geassocieerde ziektemechanismen, de klinische kenmerken en 
meest effectieve behandeling van deze veelvoorkomende oogaandoening. Een beter inzicht 
in deze aspectenkan zo bijdragen aan een betere voorlichting voor patiënten over het 
klinische beloop en de prognose, en aan een betere behandeling van chronische CSC gericht 
op het ziektemechanisme. 
In Hoofdstuk 1 wordt een algemene introductie gegeven over de anatomie van het oog, in 
het bijzonder van de retina, en de verschillende onderzoekstechnieken die gebruikt worden 
om de structuur van het netvlies te onderzoeken. Tevens worden de klinische kenmerken, 
de huidige ideeën over de ziektemechanismen en de behandelwijzen van CSC besproken.
Hoofdstuk 2.1. beschrijft één van de eerste genetische studies in een groot cohort van 
chronische CSC patiënten. Omdat chronische CSC en leeftijdsgebonden maculadegeneratie 
(LMD) klinisch erg op elkaar kunnen lijken, werden genetische varianten onderzocht 
waarvan al uitgebreid bekend is dat zij een rol spelen bij LMD. Er werd vervolgens gekeken 
naar het verband tussen de klinische kenmerken en de gevonden genetische associaties. 
De chronische CSC patiënten werden hiervoor op basis van de typische kenmerken op 
de klinische beeldvorming ingedeeld in 3 groepen. Voor deze studie werd het genetische 
materiaal uit het bloed van 292 chronische CSC patiënten, 1147 patiënten met LMD en 
1311 gezonde controles met elkaar vergeleken. Naast een reeds bekende genetische variant 
in het Complement factor H (CFH) gen, werden ook associaties gevonden met een variant 
in het ARMS2 gen. De genetische varianten waarvan bekend is dat ze een beschermend 
effect hebben voor LMD bleken risicoverhogend te zijn voor chronische CSC en vice 
versa. Daarnaast verschilden de 3 chronische CSC patiënten groepen significant voor deze 
genetische varianten, waarmee de noodzaak van juiste fenotypering wordt benadrukt. 
  In Hoofdstuk 2.2 is nader onderzoek verricht naar een mogelijke betrokkenheid 
van het complement systeem, een onderdeel van het aangeboren immuunsysteem bij 
de pathogenese van chronische CSC. Er werd gekeken naar het complement 4 (C4) gen, 
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dat zowel een belangrijke rol speelt in de klassieke route als in de lectine route van het 
complement systeem. Uit de analyses kwam naar voren dat het aantal kopieën van C4B 
significant geassocieerd is met chronische CSC. Personen die geen kopieën van C4B dragen 
hebben een verhoogd risico op chronische CSC, terwijl personen met 3 kopieën van C4B 
juist minder risico lijken te hebben op het ontwikkelen van chronische CSC. Deze genetische 
bevindingen suggereren dat, net zoals bij LMD, het complementsysteem betrokken is bij het 
ontstaan van chronische CSC.
In Hoofdstuk 3.1 is gekeken naar het klinisch beloop en de prognose van chronische CSC 
in een follow-up studie van 52 ogen van 36 patiënten met chronische CSC. Daarnaast werd 
gekeken naar de impact die de ziekte heeft op de visus-gerelateerde kwaliteit van leven. 
De resultaten laten zien dat chronische CSC een progressieve oogziekte is die geassocieerd 
is met een langzame achteruitgang van de visus, resulterend in een verminderde visus-
gerelateerde kwaliteit van leven. Het is belangrijk dat de oogarts deze bevindingen 
meeneemt in de overwegingen of een patiënt behandeld zou moeten worden of niet.
  Hoofdstuk 3.2 laat zien dat optische coherentie tomografie (OCT) bij chronische 
CSC niet alleen ingezet kan worden als diagnostisch middel om het subretinale vocht 
vast te stellen en te vervolgen, maar mogelijk ook kan helpen om de behandelrespons 
te voorspellen. De OCT karakteristieken van de sereuze vochtblaas in de ogen van 48 
chronische CSC patiënten die nog geen behandeling hadden gehad, werden met een semi-
geautomatiseerd programma geanalyseerd. Vervolgens werden deze patiënten behandeld 
met een halve-dosis fotodynamische therapie (PDT) en werd gekeken hoe zij op deze 
behandeling reageerden. Variaties in de OCT karakteristieken van de sereuze vochtblaas 
bleken een voorspellende waarde te hebben voor de behandelrespons op PDT.
  Naast de reguliere OCT-scan werd ook een nieuwe techniek, de angio-OCT, getest 
in patiënten met chronische CSC. In Hoofdstuk 3.3 wordt beschreven dat met behulp 
van deze nieuwe techniek afwijkingen in de bloedstroom van de choriocapillaris kunnen 
worden aangetoond bij chronische CSC patiënten. Deze afwijkingen komen overeen met 
afwijkingen die gezien kunnen worden met indocyanine-groen angiografie. De afwijkingen 
bestaan uit focale gebieden met een verlaagde stroomsnelheid, omgeven door een gebied 
met hyperperfusie. Dit kan mogelijk duiden op focale ischemie van de choriocapillaris met 
hyperperfusie die vervolgens kan leiden tot de typische lekkage van sereus vocht onder het 
netvlies in CSC patiënten.
Hoofdstuk 4 beschrijft verschillende studies naar de behandelmogelijkheden van chronische 
CSC. In Hoofdstuk 4.1 worden de resultaten besproken van een prospectief behandelprotocol 
dat gedurende anderhalf jaar werd uitgevoerd. In dit protocol werden patiënten eerst 
behandeld met halve-dosis PDT. Indien nodig werd deze behandeling nogmaals herhaald. 
Bij uitblijven van behandelsucces na 2 halve-dosis PDT behandelingen werd een micropulse 
laser behandeling toegepast. Dit protocol leidde in 80% van de gevallen tot een goed 
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resultaat, waarbij ook een verbetering van de visus werd gezien. Vastgesteld werd echter 
ook dat de eerste halve-dosis PDT behandeling de hoogste kans bood op een goede reactie 
en daarmee de beste verbetering in visus opleverde. 
  Het gebruik van corticosteroïden is sterk geassocieerd met het krijgen van 
chronische CSC, maar omgekeerd gebruiken lang niet alle chronische CSC patiënten 
corticosteroïden. Daarom wordt in Hoofdstuk 4.2 ingegaan op de vraag of patiënten met 
corticosteroïdgeassocieerde chronische CSC, anders reageren op een PDT behandeling dan 
patiënten die geen corticosteroïden gebruiken. Verschillen hierin zouden kunnen duiden op 
een ander ziektemechanisme in beide groepen. In onze studie vonden we geen significant 
verschil tussen beide groepen als we keken naar het percentage patiënten waarbij de 
sereuze vochtblaas volledig was verdwenen na de behandeling. Hierbij leek het in de door 
ons onderzochte patiëntengroep ook niet uit te maken of men de corticosteroïden tijdens 
de behandeling nog doorgebruikte, of dat men de corticosteroiden stopte. In patiënten 
die corticosteroïden hebben gebruikt en/of deze niet kunnen stoppen vanwege medische 
noodzaak blijkt dat PDT een effectieve behandeling is ondanks deze veronderstelde 
externe risicofactor. Deze resultaten zijn ook een aanwijzing dat chronische CSC in deze 
patiëntengroepen door een soortgelijk ziektemechanisme word veroorzaakt. 
  In Hoofdstuk 4.3 beschrijven wij het protocol van de eerste multicenter prospectieve 
randomized controlled trial die halve-dosis PDT direct vergelijkt met micropulse laser 
therapie voor chronische CSC. In deze unieke door onderzoekers geïnitieerde behandel-
trial zullen 156 chronische CSC patiënten geïncludeerd worden. Alle patiënten worden 
met uitgebreide beeldvorming en aanvullend onderzoek in kaart gebracht en krijgen met 
behulp van een randomisering-programma een behandeling toegewezen. Uiteindelijk 
zullen er twee even grote behandelgroepen ontstaan waarbij de behandelresultaten met 
elkaar vergeleken zullen worden. Met deze zogenaamde PLACE-studie wordt getracht 
meer inzicht te krijgen in de effectiviteit van halve-dosis PDT en micropulse laser therapie, 
de behandelmethoden die tot op heden het meest effectief lijken voor behandeling van 
chronische CSC. Het streven is dat de studie zal bijdragen aan de ontwikkeling van een tot 
op heden ontbrekende internationale consensus en behandelrichtlijn voor chronische CSC. 
  Tot slot wordt in Hoofdstuk 4.4 de toepassing beschreven van een nieuw medicijn 
bij chronische CSC patiënten die eerder niet reageerden op behandelingen zoals PDT en 
micropulse laser. Aan deze pilot studie deden 5 patiënten mee, die gedurende 5 weken 
het middel eplerenon innamen. In tegenstelling tot sommige positieve resultaten die 
beschreven zijn in andere kleine studies, werd er in deze pilot-studie slechts bij één van 
de patiënten een volledige afname van de sereuze vochtblaas gezien. Dit suggereert dat 
eplerenon, ondanks dat het goed verdragen wordt, van beperkt nut is voor patiënten die 
eerder ook niet reageerden op andere behandelingen.
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De belangrijkste bevindingen van dit proefschrift worden in Hoofdstuk 5 samengevat en in 
een breder perspectief bediscussieerd. Na een samenvatting van de etiologie en de bekende 
risicofactoren, komt de mogelijke rol van de nieuwe genetische bevindingen aan de orde. 
Tevens worden de verschillende behandelmogelijkheden uit de recente literatuur besproken 
en vergeleken met de resultaten uit dit proefschrift. Tot slot worden mogelijke toekomstige 
studies besproken die verder inzicht kunnen geven op het na anderhalve eeuw nog altijd 
mysterieuze ziektebeeld chronische CSC.     
Summary / Samenvatting
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Daar zit je dan met enkele duizenden woorden op papier, woorden die in de afgelopen 4 
jaar op zijn plek zijn gevallen. Niet alleen door de mensen die direct betrokken zijn geweest 
bij mijn onderzoek, maar ook zeker door alle mensen die me vanaf buiten hebben gesteund 
en mee zijn gegaan in dit avontuur. De enige woorden die dan nog missen, zijn misschien 
wel de belangrijkste woorden van dit geheel: de woorden van dank. Ook al kun je sommige 
dingen niet volledig met woorden omvatten en zijn woorden niet helemaal ‘mijn ding’, wil ik 
toch proberen één ieder die mij zover heeft laten komen te bedanken. 
Prof. dr. C.B. Hoyng, beste Carel, toen ik begon met mijn project was serosa eigenlijk een 
ondergeschoven stiefbroertje van de AMD. Hoe dan ook, het was steeds duidelijk dat 
als puntje bij paaltje komt, ik altijd van je op aan kan. Bedankt voor de stabiliteit en de 
mogelijkheden die jij hebt weten te scheppen voor het onderzoek naar CSC. Het is mooi om 
ook jouw ogen af en toe te zien glunderen als het om CSC gaat.  
Prof. dr. J.E.E. Keunen, beste Jan, met jou begon mijn avontuur in Nijmegen. De veilige 
basis die je vanaf het begin af aan uitstraalde gaf mij een gerust gevoel om zonder 
twijfel de stap naar Nijmegen te maken. Door jou draaide mijn onderzoek niet alleen om 
‘significante resultaten’, maar ook om de patiënten achter deze resultaten. Dank voor 
jouw relativeringsvermogen en persoonlijke interesse, gecombineerd met de gevarieerde 
intermezzo’s tijdens mijn onderzoeksperiode.
Prof. dr. A.I. den Hollander, beste Anneke, de rust die jij zelfs in het heetst van de strijd 
kunt uitstralen doet mij keer op keer versteld staan en bewonder ik zeer. Ook al stond jij 
tijdens mijn promotie traject niet direct op de voorgrond, het was al snel duidelijk dat jij 
alles nauwlettend in de gaten hield achter de schermen. Daar waar wij als clinici vaak in 
rondjes bleven draaien, wist jij ons met je kritische blik weer op het rechte pad te zetten. 
Vooral in de afsluitende fase heb ik je sturende en begeleidende kant steeds meer mogen 
ervaren en ik had deze niet kunnen en willen missen, waarvoor veel dank.        
Prof. dr. C.J.F. Boon, beste Camiel, ik ben meer dan vereerd met het feit jij mijn ‘kwartet’ 
compleet hebt gemaakt. Ondanks dat wij elkaar fysiek weinig in hetzelfde ziekenhuis 
hebben getroffen, wist ik dat je altijd met raad en daad voor me klaarstond, niet alleen als 
‘begeleider’maar ook als ‘persoon’. Geen mail te veel, geen tijdstip te bont en geen afstand 
te ver. Dank voor jouw tomeloze inzet, inspiratie, kennis en bemoedigende woorden die ik 
vooral in de laatste periode erg nodig heb gehad om dit werk zo neer te zetten als het nu 
voor ons ligt. Het is mooi om te zien dat alle uren van grading, randomiseren en reviseren 
geleid hebben tot vele mooie projecten. 
Als iemand het mysterie achter de ‘serosa’ kan ontrafelen dan ben jij het! 
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Dr. K. Brasse, lieber Karl, ohne deine Ausdauer wäre ich vielleicht nie überzeugt für die 
Augenheilkunde, ich danke dir für die lehrreiche und vor allem angenehme Zeit in deiner 
Praxis.
 
Drs. J.K.Mohr-Karsenberg, beste Jacqueline jouw voorwerk heeft mij op weg gebracht. Ik vind 
het jammer dat ik je maar heel even als assistent heb mogen meemaken. Desalniettemin, 
was je altijd even enthousiast en geïnteresseerd op de momenten dat wij elkaar tegen 
kwamen, wat me motiveerde ons onderzoek tot een goed eind te brengen.
Beste Lex, bedankt voor al je monnikenwerk en coördinatie met ons project hier en in 
Oxford.
Lieve mensen van de administratie, zonder jullie hulp in de planning en jullie vele bezoekjes 
aan de promovendi kamer, zouden vele patiënten de weg naar en op de poli niet gevonden 
hebben voor mijn onderzoek en zou mijn ‘privé’ archief niet hebben kunnen bestaan. 
Bedankt voor het puzzelen en alle zoektochten naar statussen. 
Lieve mensen van de verpleegpost, ik moet toegeven dat als ik even niet wist/weet hoe ik 
iets voor elkaar moet krijgen, ik vaak gewoon even bij jullie langs loop, want oplossingen 
vinden is jullie tweede natuur (daarnaast is het natuurlijk altijd gewoon erg leuk om even 
langs te lopen). Bedankt voor de ‘extraatjes’ en tussentijdse bloedafnames ook al was/is er 
niet altijd evenveel tijd voor.
Beste dames van trial, lieve Maria en Anne, bedankt voor al de planning en het administratieve 
werk.
Beste optometristen, door jullie beschikken we vandaag de dag over enorme hoeveelheid 
en variatie aan imaging van patiënten, iets wat voor mijn onderzoek van essentieel belang is 
geweest. Ik weet dat ik jullie vaker dan eens heb opgezadeld met nog ‘even wat aanvullende 
scans’, bedankt voor jullie flexibiliteit! 
Asha, jou wil ik speciaal bedanken. Zonder jouw overgave voor de studie, was alle energie 
die wij in de PLACE hebben gestoken voor niets geweest!    
Beste Berna, Francis, Laura, Mara en ten tijde van mijn promotie Bart, Karlijn en Charlotte 
het is fijn dat jullie onze staf zo goed in de gaten houden en hun agenda’s plannen. Ik weet 
dat ik menigeen horendol heb weten te maken met last-minute meetings in agenda’s die 
per definitie al 100% overboekt zijn. Toch lukt het jullie steeds weer een plekje voor ons te 
creëren. Bedankt voor alle flexibiliteit en ook voor de interesse in ons allen. Een praatje met 
jullie maakte het tussentijds koffie halen des te leuker en meer ontspannen. 
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Beste Bjorn, Eiko, Bert en Frederieke, bedankt voor de uren die jullie in het serosa project 
hebben gestoken, zonder jullie structuur en ideeën was het een rommeltje geworden.
Drs. J.M. Groenewoud, beste Hans, jij was voor mij de ‘Araschnia levana’ als het om de 
statistiek gaat. ‘Geen resultaat’ komt niet voor in jouw vocabulair, ook al waren sommige 
resultaten voor ons soms erg bedroevend, jij wist er altijd een positieve draai aan te geven. 
Bedankt voor je rust, chocolade en vooral voor je statistische analyse op de momenten dat 
ik ze soms allemaal niet meer op een rijtje had.  
Tijdens mijn promotie traject heb ik de kans gekregen mee te werken aan het opzetten van 
een unieke trial: de PLACE-trial. Dit proces was niet alleen erg leerzaam (soms leek het een 
ware hordenloop), maar ging ook samen met het leren kennen en samenwerken met unieke 
personen uit verschillende landen. 
Oxford; Dear prof. dr. R.E. Maclaren and dr. S. Downes, Dear Robert and Susan, thank you 
for the opportunity to bring the PLACE-trial to Oxford. Thank you, dear Alexina Fantato and 
dear Daniel Buttress for all the organising work behind the scenes. Also many thanks to all 
the members of the research team involved in the PLACE trial.
Paris; Cher prof. dr. E.H. Souied et dr. G. Querques, j’aimerais adresser ma gratitude pour le 
service que vous m’avez rendu en accueillant le trial PLACE dans votre clinique. Chère dr. 
Blanco-Garavito, chère Rocio, merci pour votre enthousiasme et votre zèle (et pour votre 
avis d’aligot ;)). Merci à tous ceux qui nous ont aidé lors du trial à Paris
Köln; Sehr geehrter Herr Prof. Dr. Fauser, lieber Sascha, die PLACE-Studie war nicht unsere 
erste Zusammenarbeit zwischen Köln und Nijmegen. Deswegen fühlt es sich bei euch schon 
fast so an, als würde man nach Hause kommen. Herzlichen Dank für die vielen interessanten 
Besprechungen und die großartige Mitarbeit an der PLACE-Studie. Sehr geehrte Frau 
Franken, Liebe Katharina, sehr geehrte Frau Neumann, Frau Prinz und Frau Dr. Scholz, liebe 
Paula, und allen anderen, die bei der Studie mitgeholfen haben, herzlichen Dank für Ihre/
eure Mühe, Flexibilität und Einsatz für dieses Projekt! 
Leiden; Beste dr. Dijkman, beste Greet, bedankt voor het mogelijk maken van de studie 
in Leiden. Beste dames van het trial centrum in Leiden, bedankt voor jullie hulp bij het 
opzetten en het coördineren van de studie in Leiden, zonder jullie zaten we nu nog bij de 
METC. Tot slot dank al alle optometristen en verpleegkundigen die zich voor de PLACE studie 
in de nodige bochten hebben weten te wringen. 
Roos, Elon en Danial, mede door jullie heeft het onderzoek naar CSC een grote toekomst. 
Beste Elon, de energie waarmee jij het onderzoek bent ingedoken en de snelheid waarmee 
je doordendert is af en toe beangstigend, maar ook zeer bewonderenswaardig. Ik denk dat 
er geen betere opvolger van het project en vooral ook de PLACE-trial had kunnen zijn dan 
jij. Samen met Danial (en waarschijnlijk zullen er nog vele promovendi volgen) houdt jij de 
zaak onder controle in het ‘Leidse’. Vol spanning zal ik jullie onderzoeken blijven volgen! 
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Lieve Roos, door jou zit er weer leven in het onderzoek naar de genetische achtergrond van 
CSC. Op sommige vlakken kun je niet meer verschillen dan wij, soms wat onhandig maar 
vooral ook soms erg fijn. Ik denk dat we elkaar daarmee goed aanvullen, niet alleen op de 
werkvloer maar ook in ons gedeelde huis. Bedankt voor je altijd vrolijke aanwezigheid, ook 
als ik me soms liever even afsluit, waarmee je me helpt herinneren aan de essentiële dingen 
in het leven!
Dank aan mijn mede promovendi op de kamer die POG-en, WOG-en en SOG-en aangenaam 
en zeer makkelijk maakten. Ramon bedankt voor je muzikale begeleiding. Michel bedankt 
voor je andere kijk op dingen en dank dat jij zonder er ooit over te klagen altijd voor ons 
de algemene telefoon op nam. Yara en Freekje bedankt voor jullie kennis, gezelligheid (ook 
’s avonds bij de pubquiz) en informatie over alle online sales. Constantin thank you for 
thinking out of the box! Nicole bedankt voor je ‘twentse’ nuchterheid, door jou voelde het 
bijna als thuis. Freerk bij jou weet ik nog niet zo goed of ik je moet bedanken voor alle RSI of 
misschien toch vervloeken, de toekomst zal het leren. Hoe dan ook bedankt voor de gezellige 
momenten, graden naast jou was nooit saai! Nathalie bedankt voor je vrolijke aanwezigheid 
na een goede kop koffie en Stanley bedankt voor het delen van jouw technische kennis, ik 
had soms graag wat van jouw vermogen je af te sluiten meegekregen. Niet alleen op de 
kamer was het gezellig, daarom ook dank aan de overige (oude en nieuwe) promovendi die 
de researchmeetings gevarieerd en gezellig maakten: Mark, Bart, Laura, Maartje (160km!), 
Shazia, Mahesh, Karlijn, Eveline, Sanne, Vivian en Dyon. 
Beste AIOS, beste Samuël, Linda, Ann-Laure, Paulien, Carla, John, Dzenita, Anita, Stefan, 
Ramon, Frank, Jelina, Ellen, Nicole, Yara, Artin, Anna, Nathalie, Mustapha en Martijn, bedankt 
voor het gespreide bedje dat voor mij als jongste klaar stond, dat samen met het afronden van 
mijn promotie voelt als voldoende ontgroening. Op naar nog een mooie tijd samen 
Lieve familie, lieve vrienden en vriendinnen, ondanks dat promoveren een team-effort is, 
maakt het je soms zeker niet socialer. Dank aan iedereen die me steeds weer uit mijn sociale 
isolement heeft weten te trekken op het moment dat ik zelf de tijd en energie niet meer kon 
opbrengen mezelf te zijn en op alle plekken tegelijk te zijn. Wees gewaarschuwd.. dit was de 
stilte voor de storm!
(P.S. ik houd nog steeds niet van bellen ;)) 
 
Lieve Soof, zo verschillend maar toch ook zo gelijk, ik hoop nog veel van de wereld samen 
met jou te zien en te beleven!
Lieve Eef, de stabiele factor ben je tijdens onze studententijd altijd al geweest en blijf je nog 
altijd voor mij. Fijn dat je er bent!
Lieve Lot, het is zo leuk dat ‘MYLO’ ook in Nijmegen voortbestaat.
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Lieve Marianne, ik ken niemand die zo lief en zorgzaam is voor anderen als jij, je bent een 
schatje!
Lieve Anneloes, thanks for stalking me!
Lief Kippie, wat vliegt de tijd en wat schiet afspreken er toch soms bij in, toch is het fijn dat 
wij ‘zusjes’ zijn!
Lieve Nonche, bedankt voor de altijd gezellige avondjes, je interesse en je energie.
Lieve Jelina, dank je voor de adoptie en de fijne avondjes op de rode bank.
Liebe Kathrin und Esther, ohne euch ist Urlaub in Frankreich kein richtiger Urlaub!
Lieve ‘Hoogstraatjers’, beste Iliana, Wiets en Kas, bedankt voor het altijd luisterende oor, de 
altijd open deur en vooral de gezelligheid. Beter een goede buur dan een verre vriend, laten 
we er nog vele pannenkoeken op eten! 
Lief Kick-spin-fit-team, of misschien hadden we het beter Kick-spin-fit-gin-tonic-green-ice-
tea-team kunnen noemen, zonder jullie had ik een hoop gezellige momenten in Nijmegen 
gemist. Bedankt voor jullie ‘atletische’ inzet binnen en buiten de sportschool. 
Lieve vogels, ik ben zo blij dat jullie er zijn en zonder jullie waren de afgelopen jaren een 
stuk minder leuk en een stuk stressvoller geweest. Met jullie maak je alles mee (ook al heb 
ik daar vooral het afgelopen jaar te veel van moeten missen..)! Een vogel hoort op de berg! 
Lieve paranimfen, lieve Hanna Mai en lieve Ellen, ik ben blij dat jullie tijdens mijn promotie 
aan mijn zijde zullen staan.
Lieve Mai, een peptalk staat jou op het lijf geschreven en gelukkig lijd jij net als ik aan 
chronisch tijdgebrek. Ik ben blij dat je mijn vriendinnetje bent! 
Mai, rodijn en rosijn zijn zonder jou toch vele malen minder fijn! 
Lieve Ellen, altijd positief, begaan en in voor een sportieve activiteit. Bedankt voor het 
luisteren en het meedenken als dingen niet zo lopen als gepland. Ondanks dat we elkaar 
pas enkele jaartjes geleden hebben leren kennen, voelt het al als een eeuwigheid, ik ben 
blij dat ik je ken!
El, samen halen we de top!
Broerlief, zoals jij is er geen (en dat weet jij stiekem ook maar al te goed….). Ondanks dat we 
elkaar soms liever achter het behang plakken dan gewoon lief tegen elkaar te zijn, ben ik blij 
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dat jij er altijd voor me bent. Ik denk dat we trots kunnen zijn op elkaar, op wie we zijn en 
waar we staan en wie weet worden ook wij ooit volwassen!
Lieve mam en pap, als iemand mij als jong meisje had verteld dat ik in de voetstappen van 
papa zou treden, had ik ze denk ik voor gek verklaard (eigenzinnig als ik toen al was en 
nog steeds een beetje ben). Blijkbaar hebben de vele uren in de praktijk, het spelen met 
de apparatuur (want wat was het leuk om een Goldmann keer op keer te doen) en het 
meespieken bij kleine operaties toch de nodige vruchten afgeworpen. Jullie hebben voor 
Holger en mij altijd een stabiele basis weten te creëren, ook al ging dit soms ten koste van 
jullie zelf. Jullie hebben mij geleerd zelf keuzes te maken en ook om te gaan met de (soms 
minder leuke) consequenties van deze keuzes. De geborgenheid, het vertrouwen en de 
wetenschap dat jullie er op ieder moment voor ons zijn, hebben mij enorm gesteund in mijn 
onderzoeksperiode. Mama bedankt voor je analytische en kritische blik en zorgzame liefde. 
Papa bedankt voor je eindeloze geduld en ongecompliceerde liefde. 
Tot slot, in de geneeskunde bestaat er zonder patiënten en proefpersonen geen onderzoek. 
Ik wil alle patiënten en proefpersonen bedanken voor hun deelname aan ons onderzoek. 
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Curriculum vitae
Myrte Breukink was born on January 1st, 1986 in Enschede, the Netherlands. She completed 
her secondary school (VWO-certificate, Nature and Health) at ‘De Driemark’ in Winterswijk 
and commenced her medical study at the University of Groningen, successfully completing 
this in 2011. During her medical training she became interested in science and she did 
research on the complement system and genetics in patients who received a lungtransplant 
(under the supervision of dr. M.A.J. Seelen and prof. dr. W.J. van Son). Her interest in research 
and foreign countries was combined in her final year of her medical training in which she 
took part in research at the Canniesburn Plastic Surgery Unit, Glasgow, Scotland. Here she 
became more and more enthousiastic about the fine (micro) surgery.  From April 2011 untill 
June 2012 she worked as a resident in ophthalmology at the ‘Augenärtzliche Praxis Dr. Brasse’ 
and the ‘Augenklinik Ahaus’, Germany. In this period her interest in ophthalmology grew, 
leading to an application for a PhD position in the Radboudumc, Nijmegen, that resulted 
in this thesis. After a research period of 3 years she recommenced her specialisation in 
ophthalmology in August 2015 at the Radboudumc under the supervision of prof. dr. J.E.E. 
Keunen and prof. dr. B.J.Klevering.
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STELLINGEN 
BEHORENDE BIJ HET PROEFSCHRIFT:
Chronic central serous chorioreti nopathy
Studies on the clinical and geneti c characteristi cs
 
1.  De visuswinst is vaak het hoogst na de eerste halve dosering fotodynamische 
therapie behandeling bij pati ënten met chronische centrale sereuze 
chorioreti nopathie. 
2.   Chronische centrale sereuze chorioreti nopathie gaat gepaard met een 
verminderde visus-gerelateerde kwaliteit van leven. 
3.    Geneti sche varianten in ARMS2 en CFH zijn geassocieerd met chronische 
centrale sereuze chorioreti nopathie. 
4.   Met behulp van adequate fenotypering vindt men signiﬁ cante verschillen in 
allel frequenti es tussen chronische centrale sereuze chorioreti nopathie en 
leeft ijdsgebonden maculadegenerati e.
5.   Focale ischemie van de choriocapillaris ligt mogelijk ten grondslag aan lekkage 
van subreti naal sereus vocht bij chronische centrale sereuze chorioreti nopathie.
6.  Chronische centrale sereuze chorioreti nopathie verbreedt je horizon. 
7.  There is only one PLACE to be! 
8.   De baten voor de pati ënt zijn mede afh ankelijk van de onbaatzuchti gheid van 
de onderzoeker.
9.   Promoveren is in Nederland het langste traject om 1 lett er verandering door 
te voeren.
10.  Ontlokt een stelling twijfel, dan treft  de stelling doel.
Myrte B. Breukink, Nijmegen, 27 januari 2017
